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Background and aim: A subgroup of coeliac disease patients have IBS (irritable bowel 
syndrome)-like symptoms despite following a gluten free diet (GFD). We wanted to compare 
the microbiota in these patients with an IBS and a healthy population, and look at changes 
during a low FODMAP (fermentable oligo-, di-, monosaccharides and polyols) diet versus a 
stricter GFD. We also wanted to look at the effect of diet on symptom relief in these patients. 
Methods: 40 celiac disease patients with IBS-like symptoms confirmed by the Rome III-criteria 
and IBS-SSS (symptom severity scale)>75 were compared to Norwegian IBS and healthy 
cohorts, and randomized into two groups. Group A followed a stricter GFD, whilst patients in 
group B reduced FODMAPs in their GFD. Both groups followed their diet for six weeks. Faecal 
samples were collected at baseline and 6 weeks and IBS-SSS at baseline, 3 and 6 weeks. 
Hydrogen breath test was performed at baseline and after six weeks. The faecal samples were 
analysed by Genetic Analysis for bacteria and Dysbiosis Index (DI) 1-5, where DI>2 is 
considered clinically relevant. Statistics: T-test, Mann-Whitney U, RM one way ANOVA, 
Fisher’s linear discriminant analysis. 
Results: FODMAPs were reduced from 11.5 to 1.6g/day (p=0.0001) in group B, and IBS-SSS 
score improved in both group A (p=0.0022) and group B (p=<0.0001). 45% of the patients had 
dysbiosis at baseline, compared to 73% in IBS (p=0.0091) and 16% in healthy controls 
(p=0.0007), with a mean score of 2.5±1.1 versus 3.0±1.0 and 1.7±0.7, respectively. Several 
bacterial genera were significantly altered at baseline compared to healthy controls, including 
Bacillus and Prevotella. In group A (18F/2M, age 39±15), dysbiosis stayed constant on diet, 
but more patients had severe dysbiosis (DI>3), 15% vs. 25% (p=0.85). In group B (15F/5M, 
age 44±12), fewer patients had dysbiosis after diet, 60% vs. 50% (p=0.79). There was a 
statistically significant reduction in the genus Bacteroides after the LFD compared to the stricter 
GFD (p=0.024). Responders to low FODMAP diet (IBS-SSS score reduction >100) had a 
distinctive microbiota pattern with less Lactobacilli and Firmicutes (Clostridia), and more 
Atopobium at baseline. There were no reduction in the AUC for hydrogen after six weeks on a 
low FODMAP diet (p=0.926). 
Conclusion: Celiac disease patients with IBS-like symptoms had less severe dysbiosis than 
an IBS-population, but more than healthy controls. This study give evidence for the effect of 
the low FODMAP diet for symptom relief in these patients. We found that the level of 
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1.1 Coeliac disease 
 
1.1.1 Background 
Coeliac disease (CD) is described as a systemic autoimmune disease, where ingestion of 
gluten will cause damage to the small intestinal mucosa in genetically predisposed 
individuals. Gluten ingestion will initiate an immune reaction, and can cause villous atrophy, 
crypt hyperplasia and chronic inflammation in the mucosa [1]. The signs and symptoms of 
CD can vary substantially, but some of the common ones are malabsorption symptoms such 
as weight loss, diarrhoea, iron deficiency anaemia and growth retardation in children [2]. 
 
Gluten is a collective term for storage proteins found in wheat, barley and rye. Gluten is 
composed of two different proteins named glutenin and gliadin, and it is the gliadin protein in 
wheat that triggers an immune reaction. In barley and rye, these protein fractions are called 
hordeins and secalins, respectively. Another term for these proteins is prolamins, which refers 
to alcohol soluble proteins rich in proline and glutamine [2]. 
 
The prevalence of coeliac disease is 1 in 100 individuals, affecting more women than men [2, 
3]. CD was previously thought of as a rare disease occurring only in children, but we now 
know that it can develop at any age, and have many different manifestations. Some can have 
diarrhoea and serious classical malnutrition symptoms, whilst others have very diffuse or no 
symptoms. More atypical symptoms are joint pain, fatigue, constipation and abdominal 
distension [4, 5]. 
 
1.1.2 Diagnosis  
Diagnosis in adults is made by serological testing and small bowel biopsies. The gold 
standard at present is IgA tissue transglutaminase antibodies (IgA TTG), in combination with 
a small intestinal mucosal biopsy. It is recommended to measure total IgA as well, in order to 
identify those with IgA-deficiency [6]. If IgA is deficient, IgG deamidated gliadin peptide 
(DPG) is the preferred test to IgA TTG. In addition to positive serology, biopsy findings will 
essentially confirm the diagnosis [7]. It is important that a gluten containing diet is followed 
weeks before and during testing for CD. The histological findings are graded by the Marsh 




amount of intraepithelial lymphocytes (IEL) per 100 enterocytes, and degree of crypt 
hyperplasia and villous atrophy [8]. Marsh I refers to normal or minimal histological findings 
and intraepithelial lymphocytosis, which can also be found in other conditions such as 
Helicobacter Pylori-infection. Thus, this finding is not necessarily consistent with coeliac 
disease. In Marsh II, crypt hyperplasia is also present. Marsh III is the most common finding 
in CD-patients, and includes some or complete villous atrophy [9]. Marsh IV is rare and 
describes complete villous atrophy and no lymphocytes. This has been seen in non-responders 
[8]. 
 
Table 1: Marsh classification system  
Oberhuber et al. Eur J Gastroenterol Hepatol, 1999 [10]. 
 Marsh 
Type 
IEL / 100 enterocytes 
– jejunum 





0 <40 <30 Normal Normal 
1 >40 >30 Normal Normal 
2 >40 >30 Increased Normal 
3a >40 >30 Increased Mild atrophy 
3b >40 >30 Increased Marked 
atrophy 
3c >40 >30 Increased Complete 
atrophy 
IEL, intraepithelial lymphocytes 
 
Coeliac disease mainly affects the proximal small intestine. Damage to the small intestine 
causes malabsorption due to a smaller absorption surface and reduced amount of digestive 
enzymes, which in turn can lead to weight loss and malabsorption of micro-nutrients such as 
fat soluble vitamins A, D, E and K, iron, zinc, folate and vitamin B12. If a deficiency is 
present, it will usually normalize when gluten is excluded from the diet [5]. 
 
1.1.3 Etiology  
A crucial factor for disease development is gluten exposure. Besides this, a major genetic risk 
factor is predisposition with genes that code for human leucocyte antigen (HLA)-DQ2 or DQ8 
proteins. Around 99% of CD patients carry this; the majority carry HLA-DQ2, whilst a 
smaller fraction HLA-DQ8. However, these HLA-types is present in about 30% of the general 




an effective test for exclusion of coeliac disease, but does not give any confirmation of the 
disease [12, 13]. Studies on monozygotic twins reveal 75-80% concordance compared to 20% 
in dizygotic twins, and sibling relative risk of 20-60, implying a strong genetic component in 
CD development. HLA genes have shown to account for parts of this, while non-HLA genes 
and environmental factors accounts for the rest. This is less studied, but non-HLA genes, 
epigenetics and gut microbiota have all been proposed to be involved in CD development [3, 
14]. Individuals with type 1 diabetes, Down’s syndrome or Turner’s syndrome and 
autoimmune thyroid disease are at higher risk of developing CD, due to shared genetic risk 
factors [15]. 
 
1.1.4 Immunopathology  
In coeliac disease, an abnormal immune response to gluten proteins causes intestinal damage. 
It is mainly the adaptive immune system that is active in coeliac disease. Because of the high 
content of proline, gluten is difficult to digest and is only broken down to gliadin 
polypeptides. These peptides cross the enterocytes into lamina propria via para- and 
transcellular routes, where they are deaminated into negatively charged glutamic acid by the 
enzyme tissue transglutaminase (TTG). This increases the affinity for gliadin binding to the 
pockets of HLA DQ2/8, expressed on antigen presenting cells (APCs). The binding of gliadin 
on APCs leads to the activation of gluten-specific CD4+ T-cells, which in turn produces 
proinflammatory cytokines such as IL-21 and IFN-ɤ. These cytokines lead to the damage of 
the epithelial cells such as villous atrophy and crypt hyperplasia [16-18]. TTG is also able to 
crosslink with gliadin, which together with inflammatory cytokines are thought to activate B-
cells that produces antibodies, including autoantibodies towards TTG, and antibodies towards 






Figure 1: Immunopathology in coeliac disease  
Ingested gluten is degraded to gluten peptides, which are able to cross the enterocytes into the lamina 
propria. Here the peptides are deaminated by TTG and binds to HLA DQ2/8 found on APCs (denditric 
cells or macrophages). This binding leads to the activation of CD4+ T-cells which produce 
proinflammatory cytokines that cause intestinal tissue damage. B-cells are also activated and produce 
antibodies. APC; antigen presenting cells.  Kagnoff MF, Celiac disease: pathogenesis of a model 
immunogenetic disease. J Clin Invest. 2007 [16].   
 
1.1.5 Treatment  
The only treatment of coeliac disease today is through life long diet. By excluding all sources 
of gluten in the diet, most individuals will experience full mucosal healing and symptom 
relief. Gastrointestinal symptoms seem to resolve quickly and considerably after commencing 
a gluten free diet (GFD) [20]. The serology can take longer to normalize; a study by Bürgin-
Wolff et al. found IgA TTG to normalize within a year for patients in Switzerland and 
Germany [21]. A histological normalization can take years [22]. 
 
 A GFD in general refers to a diet as low in gluten as possible, as some contamination is 
inevitable. To follow a gluten free diet can be challenging, due to factors such as a higher 
cost, gluten contamination in production, storage or cooking and limitations in situations such 
as dining out. Some have minimal symptoms when ingesting gluten, which can make the 
adherence more difficult [2]. However, strict adherence to a GFD can reduce mortality risk in 





1.1.6 Non-responsive coeliac disease  
Some patients experience persistent or recurring symptoms despite following a GFD. This is 
often referred to as non-responsive coeliac disease (NRCD) [25]. The literature reports 
prevalence of NRCD varying from 7% to around 30% [22, 25, 26]. NRCD is defined as 
persistent or recurrent symptoms or signs and/or histological findings after 6 months or more 
on a GFD [26-28]. The definition varies some in the literature, where some use 12 months as 
a limit for making this diagnosis, and some definitions require abnormal histological findings 
[29-31]. It is reported that the major cause of NRCD is gluten contamination in the diet, either 
unintentional or voluntarily, accounting for 35-50% of the cases [28]. It can also be caused by 
several other coexisting conditions such as the irritable bowel syndrome (IBS), other food 
intolerances, small intestinal bacterial overgrowth (SIBO), pancreatic insufficiency, or 
refractory coeliac disease (RCD) [29]. The American College of Gastroenterology (ACG) 
Guidelines advises to reconsider the initial CD diagnosis through evaluating the biopsy results 
and serology as the first step towards determining the cause of NRCD. If the diagnosis is 
certain, a thorough assessment of the diet can identify any gluten contamination or other 
possible food intolerances. If diet can be excluded as a cause, a new biopsy is recommended, 
which can help with further determining the ethology [28]. 
 
1.1.7 Refractory coeliac disease  
For 1-2% of coeliac disease patients, villous atrophy and symptoms of malabsorption will 
continue or come back, resulting from refractory coeliac disease (RCD). We distinguish 
between type I and type II RCD. Both types are characterized by lymphocytosis as seen in 
untreated coeliac disease. Type II differs from type I because of abnormalities in the T-cells, 
which is responsible for a much poorer prognosis, as clonal expansion of these cells can 
develop into enteropathy-associated T-cell lymphoma. Type I is often treated 
symptomatically, and steroids or immunosuppressive agents can be used additionally in 
serious cases. Type II is treated much the same way, but response to treatment is often poor. 






1.1.8 Associated conditions and complications of coeliac disease  
There is an increased risk of developing osteoporosis in coeliac disease, which may be caused 
by several different factors. This includes malabsorption of calcium before diagnosis, 
persistent villous atrophy after diagnosis, low intake of calcium or lactose intolerance 
amongst other things [8]. There is also a link between coeliac disease and other conditions, 
such as type I diabetes, autoimmune thyroiditis and other autoimmune diseases, abnormal 
liver function and dermatitis herpetiformis, which is the skin manifestation of coeliac disease 
[8, 33]. 
 
1.2 Irritable bowel syndrome  
 
1.2.1 Background  
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, characterized by 
abdominal discomfort, bloating and altered bowel habits [34].  It is recognized as a functional 
gastrointestinal disorder (FGID), describing a group of digestive disorders where diagnosis is 
based solely on clinical symptoms and absence of structural abnormalities. We distinguish 
between different subtypes of IBS based on whether constipation (IBS-C) or diarrhoea (IBS-
D) is predominant, or a mix of both (IBS-M). The severity and frequency of IBS varies 
amongst individuals, from tolerable to severe and periodic to continuous symptoms [35, 36]. 
 
The global prevalence of IBS is between 10%-20% [37]. A Norwegian cross-sectional survey 
performed in 2001 shows a prevalence of 8% in Norway [38]. IBS affects more women than 
men, and more women seek medical attention than men. [39-41]. IBS is not associated with 
increased mortality, but it has significant negative influence on quality of life [42]. These 
patients have impaired social life, lower self-esteem and are more often absent from work 
[43]. Additionally, IBS sufferers generate large economic costs due to their medical care visits 
and investigations and increased sick leave. IBS is associated with other conditions such as 
fibromyalgia, fatigue and anxiety [42, 44]. 
 
1.2.2 Diagnosis  
The Rome III diagnostic criteria can be used to diagnose IBS (see Methods), but are more 
commonly used in research than a clinical setting [45]. As there is neither biomarker nor any 
structural or physiological abnormalities that can identify IBS, the elimination of any organic 




as unexplained weight loss, anaemia, nocturnal symptoms, rectal bleeding or family history of 
organic diseases, as well as other features. Colonoscopy is recommended for adults over age 
50 years [34, 45]. 
  
1.2.3 Pathophysiology  
The pathophysiology of IBS is multifactorial and still not fully understood, but increasing 
evidence show visceral hypersensitivity, a disturbance in the gut-brain-axis, chronic low grade 
inflammation, abnormal gut motility, intestinal microbiota, abnormal gastrointestinal 
endocrine cells and psychosocial factors to potentially be involved [34, 46-49]. Family and 
twin studies have also shown a possible genetic factor and parent-child interactions to be a 
part of the development of IBS [45]. 
 
Visceral hypersensitivity have for a long time been seen as a central mechanism in IBS. 
Abdominal pain is one of the most common symptoms, and is thought to be explained by this. 
It is in fact shown that IBS patients are hypersensitive to rectal distension, [50] and also the 
sensation of bloating is linked to hypersensitivity [51]. Gut microbiota may play an important 
role in the development of IBS, and a changed faecal and mucosal microbiota has been 
observed in IBS. This may in turn have an effect on the innate immune response, gut 
permeability and regulation of the enteric nervous system (ENS) [52]. There is reported faster 
gut transit in IBS-D and a reduced transit in IBS-C in some patients with IBS, supporting that 
gut motility is changed in at least a subgroup [53]. Abnormal endocrine cells found in IBS 
patients can be responsible for visceral hypersensitivity, disturbed gastrointestinal motility, 
and abnormal gut secretion [48]. 
 
1.2.4 Treatment   
No clear pathophysiology makes it difficult to develop potent treatments for IBS, but several 
approaches have been made, targeting both host and environmental factors of the 
pathophysiology.   
 
Pharmacological treatments include serotonin receptor agonist and antagonists targeting 
motility, sensation and secretion. Fibre, laxatives and antidiarrheal agents have been tested for 
IBS-C and IBS-D, respectively [45]. Small intestinal bacterial overgrowth (SIBO) is seen in 




to be beneficial for some. However, there is still not a large quantity of evidence, and there 
are several uncertain factors such as dosage, efficacy and the concern of antibiotic resistance 
[52]. A Cochrane review from 2005 concluded that evidence for the effects of drug therapy in 
IBS is weak [55]. Probiotics have been tested as a way of altering microbiota. They are 
defined as live microorganisms that can provide a health benefit, when given in sufficient 
amount [56]. Different types and mixtures of probiotics, including Bifidobacteria and 
Lactobacilli, are tested in several clinical trials and have had some effect on different 
symptoms associated with IBS, such as bloating, abdominal pain and flatulence [57]. Faecal 
transplantation has shown to be successful in treatment after Clostridium Difficile-infection, 
and has been tested as a possible treatment in IBS [58]. Also psychological treatments have 
been tested, such as cognitive behavioural therapy and hypnotherapy [45, 59, 60]. 
 
Many IBS patients report food as a symptom trigger, especially food containing 
carbohydrates and fats [61, 62]. Gluten has been considered to cause symptoms, but this has 
no convincing evidence [63, 64]. Traditional IBS dietary advice include regular meals, 
moderate fibre and fat intake, reduction of caffeine and avoidance of gas-producing foods 
such as cabbage, onion and beans. This successfully reduced symptoms in one randomized, 
controlled trial [46]. The most effective dietary treatment today is the elimination of 
FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) [65]. 
 
1.2.5 Coeliac disease and IBS 
Several symptoms in coeliac disease and IBS overlap, such as diarrhoea, abdominal pain and 
bloating, making misdiagnosis possible. The prevalence of CD amongst those already 
diagnosed with IBS have been studied, and found the prevalence to be around 4-5% [66-68]. 
Such studies have led to the recommendation to test for CD before diagnosing IBS [45]. 
 
The number of CD patients that fulfil the Rome criteria for IBS is reported to be between 15-
23.3% [25, 26, 69-71]. A study by Usai et al. in 2007 found a much higher rate, where 55% of 
CD patients had IBS-like symptoms [72]. A pooled prevalence of 38% was found was found 
in a meta-analysis by Sainsbury et al. [73]. These findings suggest a link between CD and 
IBS, but there is not much data to support this theory yet. It might be possible to have both 
CD and IBS at the same time, but O’Leary rather propose that these symptoms arise from a 
continued mucosal inflammation in treated CD patients, predisposing for IBS symptom 




mucosal permeability despite following a GFD might be involved [74]. However, a link 
between CD and IBS needs to be determined. What might support this idea is the prevalence 
of IBS after an infectious gastroenteritis, named PI-IBS (post infectious-IBS), and in patients 
with IBD in remission. A pooled prevalence of 10% develop IBS after an infectious 
gastroenteritis and a prevalence of 33-57% is reported in IBD patients in remission [74, 75]. 
Although there is no certainty, studies have found mechanisms that can possibly explain some 
of the pathophysiology in these patients. Failure to downregulate immune cells is shown in 
those with PI-IBS, which could alter gut function, such as motility and permeability, thus 
creating symptoms. A genetic predisposition to produce less of the anti-inflammatory 
cytokine interleukin-10 has been seen in PI-IBS [76].  
 
There is also overlapping symptoms between IBS and IBD, and a high prevalence of IBS-like 
symptoms in IBD patients in remission with no evidence of inflammation has been reported. 
A meta-analysis found a pooled prevalence of 35% [77]. This has raised questions on whether 
this is a very mild level of IBD, coexisting conditions or if IBD somehow predisposes for 
IBS-like symptoms [78]. A proposed management of these patients is to use inflammation 
markers such as C-reactive protein and calprotectin to exclude active IBD as the cause of the 
symptoms. If patients are confirmed to be in remission, but still have symptoms, symptom 
relieving therapy such as probiotics and soluble fibres should be tested [77].  
 
1.3 The low FODMAP diet  
Many with IBS can relate their symptoms to food ingestion, thus many have excluded 
different foods they expect to cause problems from their diet in order to improve symptoms. 
This has also been the basis for the dietary approaches made to reduce symptoms in these 
patients [46, 79].   
 
1.3.1 Rationale for the low FODMAP diet  
FODMAP is a grouping of short-chain carbohydrates with chains up to 10 sugar units. 
FODMAPs are generally poorly absorbed in the small intestines due to little absorptive 
capacity, lack of digestive enzymes or lack of absorptive pathways [80]. Instead of being 
degraded and absorbed in the small bowel, they travel to the colon where they are fermented 
by bacteria, which produce hydrogen, carbon dioxide and/or methane gases and small chain 




will draw water into the lumen of the small and large intestines. Increased volume of water 
and gas will lead to luminal distension, which are mechanisms tested in previous trials [81, 
82]. Increased water volume can also cause diarrhoea, as it has a laxative effect [83].  Luminal 
distension is thought to be responsible for many of the symptoms seen in IBS, such as 
abdominal pain and bloating [84].  The SCFA produced are acetate, propionate and butyrate, 
which are an important energy for the colonocytes, but can also affect the gut motility. Based 
on this, the reduction of FODMAP could be beneficial for IBS patients [84]. Importantly, 
FODMAPs are equally poorly absorbed in healthy individuals as in IBS patients, emphasizing 
the fact that the diet can improve symptoms, but not treat the cause of IBS.   
 
The evidence for symptomatic effect of a low FODMAP diet is accumulating, and 
randomized controlled trials are showing promising results. There is also evidence outside 
Australia, where the diet was first developed and tested [85-88]. A very recent follow-up 
study on IBS and IBD patients following a low FODMAP diet also show a long term efficacy 
of the diet on managing symptoms [89]. This study does however have several limitations, 
such as possible selection bias and a retrospective design, which calls for more studies 
confirming the long-term effects.  
 
1.3.2 Application of the diet  
Oligosaccharides refers to fructans and galactans, monosaccharides to fructose in excess of 
glucose, disaccharides to lactose, and polyols to sorbitol, isomalt, maltitol, mannitol and 
xylitol.  
 
Fructose is a monosaccharide found in fruits and honey. It is absorbed in the small intestines 
via two different pathways; by GLUT-2 carriers in co-transport with glucose and by GLUT-5 
carriers. In excess of fructose over glucose, the absorption of this “free fructose” is dependent 
of GLUT5-carriers, which only offer a low capacity transport. This results in malabsorption of 
some fructose, which will be fermented by bacteria. Fructose malabsorption is as present in 
healthy individuals as in FGIDs or coeliac disease [90]. 
 
The disaccharide lactose is found in milk and dairy products. We are dependent of the brush 
border enzyme lactase in order to digest the sugar before absorption, and the lack of 
expression of this enzyme leads to malabsorption. However, lactose malabsorption does not 




Asian and African countries, malabsorption in Nordic countries is rare [91, 92]. Secondary 
hypoclactasia can occur in coeliac disease or other conditions where intestinal damage is 
present, causing less expression of lactase. This condition will normally pass when the 
intestines are healed [93]. Some IBS patients still reports symptoms related to lactose without 
having lactose malabsorption, but the mechanisms of this is not investigated [94].  
 
Oligosaccharides refer to fructans and galactans. Fructans can also be referred to as fructo-
oligoshaccarides (FOS). Important sources of fructans in our diet are foods such as onion, 
garlic and wheat. These foods do not contain a large amount of fructans, but will represent a 
large part of the fructans in our diet due to a large consumption. Galactans or 
galactooligosaccharides (GOS) is found in legumes, pistachios, beans and lentils. Humans are 
not able to digest fructans and galactans due to lack of hydrolases, and they are therefore only 
fermented by bacteria in the distal small intestine and colon [94]. 
 
Polyols are sugar alcohols found naturally in different plants, fruits and vegetables. More 
commonly, they are commercially prepared and added to sweets, chewing gum and other food 
products because of its sweetening properties. They can be found naturally in foods such as 
avocado, apples, pears, peach, champignons and cauliflower. Polyols can only be absorbed 
passively through diffusion in the pores of the epithelium. The absorption relies on molecular 
size as the pore size along the small intestine varies, and causes malabsorption of some 
polyols. Transit time will also be of importance [80, 94]. 
 
The low FODMAP diet requires the elimination of carbohydrates with prebiotic effects, 
which can have an effect on gastrointestinal health long term. This elimination also increases 
the risk for nutritional deficiencies, as many different foods are cut for the diet. Most patients 
react to some, but not all FODMAPs, and the individual tolerance for different FODMAPs 
will also vary [95]. It is therefore important to start reintroducing FODMAPs after the 
elimination phase, in order to determine what FODMAPs you react to and to find individual 
tolerance [96]. Previous studies on the LFD have found that adherence to the diet is crucial for 





1.4 Intestinal microbiota  
Microbiota has become a popular field of research, as improved analysing methods have 
allowed us a greater understanding of the relation between microbiota and health. The human 
gut microbiota includes a higher number of microorganisms than cells in the body, as well as 
more genes than the human genome, and is often referred to as an organ itself [100]. Bacteria 
are found along the gastrointestinal tract, and the greatest abundance is found in the colon. 
Bacteria live in symbiosis with the host organism, and it appears that gut microbiota can be 
linked to many important functions in the human body [101]. This include the maturation of 
the immune system, protection towards pathogens, digestion and nutrient utilization, vitamin 
production, and may also be of significance in different diseases, including gastrointestinal 
disorders.   
 
Our first contact with bacteria may already happen in utero, as it is discovered bacteria 
present in the placenta, umbilical cord, amniotic fluid and meconium [102-106]. Studies on 
epigenetics and neonatal nutrition have also shown that diet during pregnancy might impact 
the gut microbiota in the offspring [107]. What is certain is that colonization starts 
immediately at birth, where the route of delivery plays an important role. Those born 
vaginally have more Lactobacillus, reflecting the bacteria found in the mother’s vagina, while 
those born with caesarean section have bacteria from the mother’s skin [108]. Other important 
factors for the composition of the microbiota are gestational age, feeding regime, use of 
antibiotics and exposure to different environmental factors. By the second to third year of life, 
the gut microbiota starts to stabilize and resembles an adult-like composition with a more rich 
and diverse microbiota [109]. The microbiota is classified into kingdom, phylum, class, order, 
family, genus and species. The adult microbiota is to a large degree dominated by the two 
phyla Bacteriodetes and Firmicutes, whilst Actinobacteria, Proteobacteria and 
Verrucomicrobia are also present, but less abundant. There has been proposed that the gut 
microbiome is divided into three different “enterotypes” where different bacteria predominate, 
namely Bacteroides, Prevotella and Ruminococcus [110]. Around 60-70% of the microbiota 
remains stable through life, whilst the remaining 30-40% can be altered by different 
environmental factors such as diet, stress, age, diseases, use of medication and antibiotics and 





1.4.1 Gut microbiota and diet 
Diet is one of the environmental factors that affect microbiota the most. It is important for 
microbiota establishment, but also later in life. Studies have shown that individuals on a diet 
based on plant-derived carbohydrates have microbiota predominated by Prevotella, whilst 
diets high in protein and fat results in microbiota predominated by Bacteroides [112]. Proteins 
also serves as substrate for bacteria, as 10% of ingested proteins will reach the colon and be 
degraded by proteolytic bacteria, such as Streptococcus, Bacillus and others. While the 
fermentation of carbohydrates gives metabolites considered beneficial for the host, the 
degradation of proteins can give products that are less beneficial and some potentially 
harmful. Also some fat are fermented by bacteria, and the fermentation of the macronutrients 
results in different bacterial metabolites with different physiological functions [108]. 
 
 
Figure 2: Different metabolites from the colonic fermentation of carbohydrates, proteins and 
fats  
BCFA; branched-chain fatty acid, SCFA; short-chain fatty acid, TMAO; trimethylamine N-oxide. 
Kashtanova et al. Association between the gut microbiota and diet: Fetal life, early childhood, and 
further life. Nutrition, 2016 [108].  
 
A low FODMAP diet involves restriction of fermentable carbohydrates, which in turn might 
affect the gastrointestinal health on a long term basis by affecting the bacterial composition 
[113]. Many colonic bacteria have fermentative abilities and uses fibres and undigested 
FODMAPs and proteins as their main source of energy. This fermentation results in 
metabolites such as SCFA, gases, ammonia and amines. The bacteria also participate in the 
production of vitamins and lignans. A reduction in indigestible carbohydrates may lead to a 




produced function as a source of energy for the colonocytes, as signalling molecules in the 
lipid and glucose metabolism, have anti-inflammatory effects, and can affect gut motility 
[101]. SCFA also stimulate colonic salt and water absorption, directly and indirectly by 
expression of transporters [52].  
 
There are done some studies on low FODMAP diet and its effect on the microbiota. 
Staudacher et al. found a significant reduction in Bifidobacteria, but no change in the SCFA 
as an effect of the low FODMAP diet [114]. A lower absolute abundance of total bacteria was 
found by Halmos et al. This involved less butyrate producing bacteria and less Akkermansia 
muciniphila compared to an Australian diet. This study did not find the same decrease in 
Bifidobacteria [115]. A recent study on a low FODMAP diet in patients with inactive Crohn’s 
disease did not find a change in bacterial abundance or Bifidobacteria, but more butyrate 
producing bacteria and Akkermansia muciniphila and less Ruminicoccus torques on an 
Australian diet compared to a LFD [116]. Also McIntosh et al. concluded that low FODMAP 
diet could affect the microbiota long term [86]. A study by Chumpitazi et al. found that gut 
microbiota may predict response to the low FODMAP diet in children with IBS, as 
responders of the diet had more saccharolytic baseline bacteria from different taxonomic 
levels, such as Bacteroides, Ruminococcacae and Dorea [117]. There are not done any studies 
on the long term effect on microbiota and the LFD, so we do not know whether an effect on 
the microbiota persist after reintroduction of FODMAPs.  
 
1.4.2 Methods for studying microbiota  
Before the advancement of today’s DNA techniques, many studies on gut microbiota have 
been based on culture-dependent techniques. Culturing bacteria has its advantages, as it 
allows us to study live bacteria and their physiological properties, and it is also a cheap and 
reproducible technique. However, a major disadvantage is the fact that somewhere between 
40-90% of our gut bacteria cannot be cultivated in the lab, making it an insufficient technique. 
Still, it has brought a lot of knowledge on the importance of gut microbiota [118, 119]. 
 
Culture-independent techniques have been developed, using DNA sequencing in order to 
identify bacteria. This is called “high-throughput sequencing”, and even newer methods are 
referred to as “next-generation sequencing” [120]. In the majority of these techniques, the 16S 
ribosomalRNA (16S rRNA) gene is used to identify and classify bacteria. This rather small 




species and strains [119]. These molecular methods have given us a lot more information on 
gut microbiota, especially the diversity of it, and allows us to determine sequences quickly 
and at low costs. There are now many different high throughput sequencing technologies and 
there are constantly new developments [118-120]. 
 
1.4.3 Dysbiosis  
Dysbiosis can be defined as any change in the bacterial composition compared to that found 
in a healthy population. It can involve loss of diversity, increased growth of potential 
pathogens and loss of beneficial bacteria [121]. Due to many inter-individual differences in 
the microbiota, it is not quite clear what can be determined as a healthy microbiota. 
Differences in diet, age, location, method of analysis and other environmental factors in 




Figure 3: Illustration of dysbiosis  
Homoeostasis of the gut microbiota can be disrupted by expansion of pathogens, a reduction in the 
diversity of microbes or loss of beneficial microbes. This state is called dysbiosis. 
Petersen et al., Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 





Dysbiosis have been seen in different diseases and conditions, such as coeliac disease, 
inflammatory bowel disease (IBD), IBS, type I diabetes, obesity, asthma and allergy [101]. It 
is thought that the change seen in the microbiota might be involved in either the development 
or the persistence of diseases, but it is hard to determine whether it is a cause or a 
consequence of the disease.  
 
The intestinal microbiota in IBS has been found to differ from that in healthy populations 
[122-125]. Microbiota has been linked to the pathogenesis of IBS because treatment 
approaches towards microbiota have shown results and because bacterial and viral infections 
have caused IBS [123]. Also possible pathogenic mechanisms in IBS such as low grade 
inflammation, immune and gut barrier dysfunction can be linked to the gut microbiota [126]. 
However, there is not found a specific microbiota signature amongst IBS patients.  
 
There is also detected dysbiosis in individuals with coeliac disease both in children and adults 
in faecal and duodenal samples, but there is not found any clear bacterial patterns in these 
patients [127-129]. There does seem to be a higher abundance of Firmicutes and 
Bacteroidetes, but there are also contradicting findings [128]. Most studies are done on 
children with coeliac disease, which might be different from microbiota composition in 
adults. The role of gut microbiota in coeliac disease is not determined, but it has been linked 
to gut barrier and immune response, which is central in the CD pathogenesis. There is also 
data suggesting that GFD might not restore gut microbiota completely, and also that the 
nature of the diet itself could lead to dysbiosis [129].  
 
1.5 Breath testing 
A H2-breath test is a simple, non-invasive and inexpensive test used for different purposes, 
such as testing for sugar malabsorption, SIBO and oro-coecal transit time. A breath test 
measures the amount of hydrogen and methane gas in expired air, which correlates to the 
amount of gas produced from fermentation by colonic bacteria. It is mainly non-digestible 
carbohydrates that work as substrates for gas production [130]. Oral administration of the 
sugars lactulose and glucose is commonly used when testing for SIBO. An early rise in 
hydrogen reflects fermentation by bacteria in the small intestines and SIBO, defined as an 
overgrowth of bacteria or abnormal bacteria present in the small intestines [54]. Glucose will 




bacteria. Lactulose is a synthetic non-absorbable sugar, and an early peak reflects bacterial 
fermentation in the small intestines or increased transit time and thus fermentation by colonic 
bacteria [130]. However, breath tests are not validated, and there have been discussion on 
error rates, different cut off values and interpretation of the tests [131]. Oral administration of 
lactose, fructose and sorbitol can be used to determine carbohydrate malabsorption, in 
example before commencing a low FODMAP diet [79, 130, 132]. 
 
Hydrogen breath tests have previously been used in studies on the low-FODMAP diet to 
determine carbohydrate malabsorption before conducting the diet or to determine degree of 
fermentation and adherence to the diet [95]. Halmos et al. found that patients following a low-
FODMAP diet had significantly less production of hydrogen compared to those following an 
Australian diet [85]. Ong et al. found the same for a low FODMAP diet compared to a high 
FODMAP diet [133]. Methane production has shown to be associated with constipation in 
IBS-patients on several occasions, although not the only cause of constipation [134, 135]. 
Methane production have also been associated with a slower transit time, possibly explaining 
its link to constipation [134, 136]. However, there have been some studies not finding the 
same associations. [137, 138].  
 
1.6 Rationale 
The primary aim of this project was to look at the microbiota profile in coeliac disease 
patients with IBS-like symptoms, and to compare it with an IBS- and a healthy population. 
We also looked for any change in microbiota and degree of fermentation, as well as effect on 
IBS-like symptoms after six weeks on diet. Additional aims were to look at baseline 
microbiota patterns as predictor for diet response.   
 
Also health-related quality of life was assessed in this study. Quality of life and symptoms are 






2 SUBJECTS AND METHODS 
 
2.1 Subjects 
To recruit patients we asked the question “Do you have coeliac disease, follow a gluten free 
diet, but still suffer from bothersome abdominal symptoms?” 
 
We only wanted to include patients with a confirmed coeliac disease diagnosis, which entails 
positive intestinal biopsy results. It was also important that the patients had followed a GFD 
properly, and six months was considered as a long enough period to ensure this. 
 
An age limit of 18-60 years was set. We did not want to include patients under 18 years of 
age, as this study did not have a paediatric focus. An upper age limit of 60 years was set in 
order to ensure best possible adherence to the diet. The intervention requires time, motivation 
and the ability to study and understand the diet, and individuals under the age of 60 years 
were considered more capable of following this intervention. Two of the patients included 
were over 60 years, but were considered very motivated and capable of doing what was 
required in the study.  
 
Table 2: Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
- Confirmed coeliac disease diagnosis 
for at least 6 months 
- IBS-symptoms confirmed by the 
Rome III-criteria 
- Score >75 on the IBS-Symptom 
Severity Scale (IBS-SSS) 
- Subjects between 18-60 years of age 
- Subjects with therapy-resistant 
coeliac disease 
- Recent biopsy with abnormal 
findings 





Patients were mainly recruited through announcements of the study on relevant Facebook 




disease at Haukeland University Hospital and amongst participants of coeliac disease or IBS 
education courses organized by the hospital. Newspaper notices, posters and word of mouth 
were also used. This creates a mixed group of patients both seeking healthcare for their 
symptoms and some who had not. In total 45 patients came to the first inclusion meeting, in 
which 44 patients fulfilled the inclusion criteria. 
 
2.3 Randomization  
The participants included were randomized through small and variable sized blocks into 
group A or group B. Block randomization is a technique used in studies with a small number 
of subjects, when equal sample sizes are desired [139]. 
 
Figure 4: Randomization process 
 
2.4 Intervention  
 
Group A 
Group A was assigned to follow a strict gluten free diet for 6 weeks. This involved excluding 
all wheat starch and trace amounts of gluten in their diet, even found in gluten free products. 
The patients were also instructed to be thorough with their gluten free diet in general, 
especially with kitchen hygiene. The patients received a list with an overview over some of 
the most common gluten free products they had to avoid or could use during the intervention 




Strict gluten free diet
Group B (n=20)
FODMAP-reduced diet in addtion to 






Group B was assigned to follow a low FODMAP diet in addition to their gluten free diet. This 
involved eating only foods classified as low FODMAP for 6 weeks. The patients were 
thoroughly instructed in the diet and the scientific background for it before commencing. 
They also received a booklet with instructions to the diet, of what foods to avoid during the 
intervention period and alternatives to these foods, which they could use as guidance in the 
beginning. There were also some recipes in this booklet. They were encouraged to start the 
diet the very same day as the baseline tests were performed.  
 
Study timeline  
 
Figure 5: Timeline showing the course of the study 
 
Visit 1: Screening. During the first meeting, the patients received detailed verbal and written 
information about the study and gave written consent. Following that, the patients filled out 
the forms IBS-SSS and Rome III to determine whether they were suitable for inclusion. 
Because of long travel distance, some patients received these forms by mail or e-mail.  
However, the majority of patients came to Haukeland University Hospital at three different 
occasions. The patients were informed that they would be randomly assigned into either group 
A or B.  
 
Visit 2: Intervention start. The patients performed a breathing test and filled out the form SF-




weeks by a master student in clinical nutrition. The patients were told to start the diet the 
same day.  
 
After three weeks, all participants filled out the form IBS-SSS for the second time. We had 
telephonic contact with all participants at this stage, to make sure they filled out the form and 
were following their diet. It also gave the patients an opportunity to ask any questions they 
might have and to talk about how they were doing. The participants were encouraged to make 
contact by e-mail, SMS or by phone if they had questions of any sort during the intervention 
period.   
 
Visit 3: End of intervention. After six weeks, all patients included came back and took a 
second breathing test and filled out IBS-SSS and SF-36. A compliance form was also filled 
out. Additionally, the diets and experiences during the intervention period were verbally 
evaluated with the patients. All patients in group A were offered an introduction to the 
FODMAP-diet after the end of intervention. Three patients came back for the last visit about 
3 weeks after scheduled time, because travelling was not possible at the scheduled time (n=1), 
and due to job obligations (n=2). These three patients all followed their assigned diet for three 
more weeks before coming in to the last visit.  
 
Four weeks after end of intervention, all patients in group B filled out an additional 
compliance form to evaluate the reintroduction phase of the diet.  
 
Blood tests and stool samples were collected at baseline and after 6 weeks of diet in both 
groups. The stool samples were stored at -20 Celsius until analysis.  
 
All patients kept a 4-day prospective food record before start of the intervention and at the 
end of the intervention. They were told to record all intake of foods and drinks for three 
working days and one weekend day, and to register as detailed as possible. The food records 
were used to calculate the total intake of FODMAPs before and at the end of the intervention, 








2.5.1 Rome III-criteria  
The Rome III diagnostic criteria for irritable bowel syndrome was used to confirm IBS-like 
symptoms. They were the following:  
 
“Recurrent abdominal pain or discomfort at least 3 days a month in the past 3 months, 
associated with two or more of the following: 
 Improvement with defecation 
 Onset associated with a change in frequency stool  
 Onset associated with a change in form (appearance) of stool  
Symptom onset greater than 6 months prior to the diagnosis, with the above criteria fulfilled 
for the past 3 months” [140]. 
 
2.5.2 IBS-SSS 
Severity of IBS-like symptoms were measured using the standardized and validated IBS-SSS 
[141]. The form has five questions concerning abdominal pain, distension, bowel habits and 
IBS’ impact on life in general, where a visual analogue scale (VAS-scale) ranging from 0 – 
100 mm is used for scoring. A score of 0 implies satisfaction and a score of 100 
dissatisfaction. One question asks for number of days with abdominal pain from 0-10; this 
question is multiplied by 10 to give a score from 0-100, similar to the other four questions. 
Together, they create a score from 0-500, that classify IBS in remission (≤75), mild IBS (75-
175), moderate IBS (175-300) or severe IBS (>300). A reduction of ≥ 50 is considered a 
successful improvement [141]. Using the score from IBS-SSS at baseline, three weeks and 
after the intervention allows assessing change over a short period of time. The form also has 
ten supplementary questions concerning additional symptoms that can be seen in IBS, also 
scored 0-100 on a VAS-scale.  
   
2.5.3 SF-36 
To measure health-related quality of life, the questionnaire Short Form Survey (SF-36) was 
used. This form includes 36 questions divided into 8 subcategories; physical functioning (PF), 
role limitations due to physical problems (RP), bodily pain (BP), general health perceptions 
(GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE) 




Physical component summary score (PCS) and mental component summary score (MCS). 
The higher score, the better health-related quality of life. The undercategories contribute to 
the main scores in varying degrees, where some categories are more impontant for MCS and 
vice versa, but there is a correlation between all the eight subcategories [142, 143]. 
 
2.5.4 Dietary compliance during intervention  
Adherence to the diet during the intervention period was assessed in both groups using 
compliance forms which were filled out at the end of study for both group A and B. This 
forms included a combination of VAS-scales and questions with answer options. This 
included questions about satisfaction, self-reported compliance and satisfaction with diet 
instructions given in forehand.  
 
2.5.5 Dietary compliance 4 weeks after end of study 
Group B also received a compliance form to fill out 4 weeks after end of study, with questions 
on whether the patients were still following the diet and whether they had started the 
reintroduction of different FODMAPs.  
 
2.6 Gut microbiota analysis 
The faecal samples were analysed by Genetic Analysis AS (Genetic Analysis AS, Nydalen, 
0401 OSLO, NORWAY) using the GA-map™ Dysbiosis Test (GA-map Dysbiosis Test, 
Genetic Analysis AS, Oslo, Norway), a novel test specifically developed to identify and 
define clinical dysbiosis. It is a high throughput test that uses 54 probes to target variable 
regions (V3-V9) within the 16S rRNA gene, where signals and signal strength from these 
probes are used to characterize a microbiota profile, as well as a Dysbiosis Index (DI). The 
16S rRNA gene is used because it is unique for bacteria. DNA is isolated form faecal samples 
and amplified using an 1180 basepar primer and PCR, and then labelled with probes. Signals 
from the probes are then identified and quantified. The probes used can discover bacteria from 
the phyla: Firmcutes, Proteobacteria, Bacteriodetes, Actinobacteria, Tenericutes and 
Verrucomicrobia, 10 bacterial classes and 36 genera. DNA of some bacteria is easier 
amplified than others, thus we cannot compare probe signals directly with each other. An 
algorithm is used to assess bacterial abundance and deviation in the microbiota from 
normobiosis, which results in a Dysbiosis Index. Dysbiosis Index from 1-5 is used to present 




the index is above 2, the more it differs from the defined normobiosis, and DI-score of 5 has 
no defined limit. The test is based on faecal samples from a Scandinavian reference 
population of 211 healthy individuals to determine a normobiotic profile. After analysis, a DI-
score and a microbiota profile was given for each patient before and after the intervention. 
The specific bacteria presented were chosen by Genetic Analysis AS due to their relevance 
for dysbiosis and gastrointestinal diseases.  
 
The validation cohort for this test included faecal samples from healthy (n=43) individuals 
and IBS (n=109) and IBD (n=135) patients from a Scandinavian population. Amongst the 
healthy individuals, 16% were dysbiotic versus 73% in the IBS cohort and 74% in the IBD 
cohort. The healthy and the IBS cohort serve as controls in this study when looking at 
dysbiosis index, and the healthy cohort serves as control when looking at microbiota profile. 
The GA-map test is compared to Illumina deep sequencing and found strong correlations in 
detecting many bacteria and accordance in determining dysbiosis [122].  
 
2.7 Hydrogen breath test  
A breath test was performed in both groups A and B at baseline and after the end of study. 
The breath tests were collected using the AlveoSamplerTM collection kit and analysed using 
Quintron Model SC MicroLyzer (Quintron Instrument Company, Milwaukee, Winsconsin, 
USA). The instrument measures the amount of hydrogen, methane and carbon dioxide in the 
inserted breath sample. We performed a 60-minute breath test, measuring breath at 0, 15, 30, 
45 and 60 minutes. The patients were told to inhale, and exhale instantly into the collection 
bag. When they felt they were nearly out of breath, they gave a sign so we could collect the 
alveolar air. The instrument uses a correction factor to give a truer estimate of alveolar air, 
due to possible sampling errors and contamination of room air into the sample. The level of 
CO2 in alveolar lies stable at 5,5%, and this value is used to normalize the hydrogen and 
methane values so they are more accurate to those in alveolar air. The rationale behind the 
breath test is the assumption that the amount of breath hydrogen correlates to the amount of 
gas produced by colonic bacteria [130]. The gases produced in the intestines will diffuse from 
the intestinal lumen to the circulation, be exhaled from the lungs and quantified in the breath. 
In this study we measured the degree of fermentation based on the patients’ habitual diet and 




was performed. The total hydrogen and methane gas production was found by calculating 
area-under-the-curve (AUC) using the trapezium rule and given in parts per million (ppm).  
 
2.8 4-day dietary registration  
The dietary registrations were analysed using Kostholdsplanleggeren, an online application 
designed to calculate nutrient intake (Kostholdsplanleggeren 2014. Mattilsynet og 
Helsedirektoratet. www.kostholdsplanleggeren.no). In order to calculate FODMAP-content, 
we used published data on the subject. We preferably used Norwegian data, but substituted 
with Danish and Australian data where needed. The majority of published data on FODMAP-
content per today is Australian, and accounted for most of the data we used. [83, 144] All data 
on lactose content was Norwegian and collected from Opplysningskontoret for 
Meieriprodukter [145]. We created our own FODMAP database using the free computer 
software Dietist Net Gratis (Kost och Näringsdata, Bromma, Sweden) and Fabrikanttabellen,, 
where we added all published data for total FODMAP-content for different foods. For 
composite dishes, we used standard recipes from the website www.matprat.no, a website 
containing a collection of food recipes created by Opplysningskontoret for egg og kjøtt, to 
calculate FODMAP-content and other nutrients. Standard portions from 
Kostholdsplanleggeren were used. We highlighted the sources of FODMAP in the recipe, and 
calculated total FODMAP-content, which we divided into lactose and non-lactose (referring 
to the amount of fructose, fructans, galactans and polyols).   
 
The cut off values in gram per portion for the different FODMAPs are [146]: 
Oligosaccharides (grains, legumes, nuts and seeds): <0.3 
Oligosaccharides (vegetables, fruit and other products): <0.2 
Polyols: sorbitol or mannitol     <0.2 
Total amount of polyols     <0.4 
Excess fructose      <0.15 
Lactose       <1 
 
2.9 Blood tests 
A coeliac disease panel were taken at baseline and after end of intervention. The panel 




tests and analysis were performed by the Laboratory of Clinical Biochemistry at Haukeland 
University Hospital.  
 
2.10 Ethical considerations 
The study was approved by REC Sør-Øst (regional committee for medical and health research 
ethics, Sør-Øst) in June, 2015. All participants gave written consent, and a copy was held both 
by the participant and a research study assistant. All personal data was handled in a 
confidential manner. The study was voluntarily and the participants could withdraw from the 
study at any point without providing any justification. There was no risk of harm in this study.  
  
2.11 Economics  
Travel costs, including public transportation and parking fees, were covered for all 
participants. Accommodation was covered for participants travelling from other parts of 
Norway.  
 
2.12 Statistical analysis 
All data was plotted into Microsoft Excel ® in order to create a database. GraphPad Prism 
version 6.00 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com, was used to perform statistical analysis. 
 
D'Agostino & Pearson omnibus normality test was used to test for data normality. Data were 
presented as mean ± SD, or as median with IQR (interquartile range) when not following a 
normal distribution. Paired t-test was used to compare means of two sets of data, and an 
unpaired t-test to compare means of two groups. If data was not following a normal 
distribution, Wilcoxon matched-pairs signed rank and Mann-Whitney U test was used, 
respectively. For categorical variables, a chi-square test was performed or a Fischer’s exact 
test if not following a normal distribution. Repeated measures one-way ANOVA was used to 
compare IBS-SSS-scores at baseline, three weeks and six weeks, followed by Tukey's 
multiple comparisons test. Here, Friedman test was used if the data was not following a 
normal distribution. A p-value of 0.05 or less was considered significant.  








The majority of patients were recruited through advertising on the Norwegian Coeliac Disease 
Society’s web page and their Facebook pages. A large group was also recruited after we made 
contact because they had been or were going to the Polyclinic for coeliac disease or the 
coeliac disease or IBS education course organized by the hospital. Newspaper notices, posters 




Figure 6: How patients were recruited to the study 
 
In total four patients dropped out of the study. The reasons for withdrawal was lack of time 
and motivation (n=2) and wish to be in the other intervention group (n=1). These patients 
were excluded before intervention start. One patient from group B was excluded after three 


























Baseline demographics for the whole study population show a majority of women and a mean 
age of 41 years. The majority of patients had IBS SSS scores equivalent to moderate IBS and 
more patients had constipation as their predominant stool pattern. 
 
Table 3: Demographics for the total study population (n=40) at baseline 
Included (n) 40 
Female/male (n) 33/7 
Age, mean ± SD 41 ± 14 
BMI (kg/m2), median (IQR) 23.3 (21-26,2) 
IBS-C, IBS-D, IBS-M, n, (%) 17 (42.5), 11 (27.5), 12 (30) 
IBS-SSS, mean ± SD 261.5 ± 79.2 
IBS-subtype; remission, mild, moderate, 
severe, n (%) 
0, 6 (15), 22 (55), 12 (30)  
Dysbiosis index, mean ± SD 2.48 ± 1.09 
 
Table 4 show that there were no statistically significant differences between group A and B in 
baseline characteristics.  
 
Table 4: Demographics and p-values for group A and group B at baseline 
 Group A (n=20) Group B (n=20) P-value 
Females, n (%) 18 (90) 15 (75) 0.408 
Age, mean ± SD 39 ± 15.1 43 ± 11.7 0.308 
BMI (kg/m2), median 
(IQR) 
23 (21.5-27.3) 23.3 (20.3-26.1) 0.654 
IBS-C, n (%) 9 (45) 8 (40)  
0.331 IBS-D, n (%) 7 (35) 4 (20)  
IBS-M, n (%) 4 (20) 8 (40) 
IBS-SSS, mean ± SD 259.8 ± 89.6 263.3 ± 69.5 0.889 
Dysbiosis Index 2.45 ± 0.94 2.50 ± 1.24 0.947 
Total FODMAP, g, 
median (IQR) 








Positive IgA TTG 
(>14,9 U/mL), n (%) 
5 (25%) 1 (0.5%) 0.182 
Positive IgG DPG 
(>14,9 U/mL), n (%) 
2 (10%) 3 (15%) 1.000 
Data are shown in n (%), mean ± SD and median (IQR).  
Unpaired t-test (age, IBS-SSS), Mann Withney U test (total FODMAP, hydrogen, Dysbiosis index, BMI),  





3.3 Diet intervention  
 
The diet intervention in group B was successful, with a total FODMAP-reduction from 11.5 
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Figure 7:  Change in total FODMAP intake for each individual from baseline (BL) to six weeks 
(6W) in grams 
Red line = median.  





The majority of the total FODMAP intake in group B was lactose, whilst other FODMAPs 
accounted for a smaller part.  
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Figure 8: Mean intake of total FODMAPs in grams at baseline and 6 weeks in group B, divided 
into lactose and other FODMAPs (fructans, galactans, lactose, fructose and polyols) 
There was a significant reduction in intake of energy, fat and total FODMAPs (including 
lactose and other FODMAPs) in group B after six weeks of a low FODMAP diet.  
 
Table 5: Dietary values for group B at baseline and 6 weeks based on 4-day food records.  
Data are given in mean daily intake ± SD and median (IQR). P-values and significance levels are 
shown 
Group B Baseline 6 weeks P-value 
Energy, kcal  2043 ± 492 1829 ± 446 0.011* 
Carbohydrates (incl. 
fibre), g 
227.0 ± 57.3 205.5 ± 72.0 0.063 
Dietary fibre, g 20.7 ± 6.4  18.8 ± 8.6  0.101 
Fat, g 93 ± 27.1 76.2 ± 20.2  0.012* 
Protein, g 89.2 ± 27.3  82.1 ± 20.5 0.213 
Calcium, mg 842 ± 377 849 ± 292 0.902 
Total FODMAP, g 11.5 ± 9.4 1.6 ± 0.8 0.0001**** 
Lactose, g 4.7 (1.2-16.4) 0.1 (0.04-0.3) <0.0001**** 
Other FODMAPs, g 2.6 ± 1.1 1.1 ± 0.7 <0.0001**** 





There was no significant change in intake of FODMAP in group A. There was a significant 
difference in fat and protein intake after six weeks of strict gluten free diet.  
 
Table 6: Dietary values for group A at baseline and 6 weeks based on 4-day food records. 
Data are given in mean daily intake ± SD and median (IQR). P-values and significance levels are 
shown 
Group A  Baseline 6 weeks P-value 
Energy, kcal  2051 ± 609 1790 ± 503 0.119 
Carbohydrates (incl. 
fibre), g 
269.4 ± 94.9 230.4 ± 75.7  0.127 
Dietary fibre, g 18.8 ± 80.6  16.5 ± 5.1  0.0975 
Fat, g 80.6 ± 31.3 64.2 ± 24.4 0.0329* 
Protein, g 81.3 ± 30.7 70.67 ± 21.2  0.0483* 
Calcium, mg  802 (587-1109) 778 (507-986) 0.231 
Total FODMAP, g 14.5 (10.9-21.6) 12.1 (6.4-19.5) 0.522 
Lactose, g 11.3 (7.6-17.3) 10.3 (4.8-15.4) 0.784 
Other FODMAPs, g 3.1 (1.8-5.5) 3.2 (1.8-8.3)  0.202 
Paired t-test and Wilcoxon signed rank test 
 
After six weeks, there was a significant difference between group A and B in amount of 
FODMAP (p=<0.0001), lactose (p=<0.0001) and other FODMAPs (p=0.0299) in the diet.  
There were no differences in the daily intake of energy, carbohydrates (incl. fibre), dietary 
fibre, fat, protein or calcium between group A and B at baseline or after six weeks. 
 
Table 7: P-values for diet comparison in group A and B 
Group A vs.  
Group B 
Baseline, p.value 6 weeks, p-value  




Dietary fibre, g 0.372 0.325 
Fat, g 0.188 0.0987 
Protein, g 0.394 0.0911 
Calcium, mg  0.698 0.369 
Total FODMAP, g 0.0786 <0.0001**** 
Lactose, g 0.150 <0.0001**** 
Other FODMAPs, g 0.1 0.0299* 







3.4.1 Dysbiosis Index 
 
Dysbiosis was defined by a Dysbiosis Index determined by the detection of bacteria and 
bacterial abundance through 54 probes, where a DI-score >2 equalled dysbiosis. The degree 














































Figure 9: Distribution of DI-score (1-5) in a healthy cohort, study cohort of patients with coeliac 
disease and an IBS cohort 
In our study group, 45% of the patients were dysbiotic at baseline. In comparison, 16% were 
dysbiotic in the healthy controls and 73% in the IBS cohort. The majority of the CD patients 





Table 8: Distribution of Dysbiosis Index scores in the study population (CD) compared to 






1 19 7 8 
2 17 15 21 
3 7 13 57 
4 0 2 11 
5 0 3 12 
 
 
Our patient group had significantly different degree of dysbiosis from both the healthy 
population (p=0.0007) and the IBS-population (p=0.0091).  
 
Table 9: Mean DI scores for all cohorts. P-values are given for the difference between the study 
cohort versus the other cohorts 
Cohort n DI, mean P-value  
Healthy 43 1.72 0.0007*** 
Coeliac disease (CD) 40 2.48 -  
IBS 109 2.98 0.0091** 
Unpaired t-test (IBS vs. CD) and Mann-Whitney U test (healthy vs. CD) 
 
3.4.2 Dysbiosis and diet intervention 
 
After the diet interventions, the rate of dysbiosis stayed constant in group A, but more patients 
seemed to have more severe dysbiosis. In group B, more patients seemed to have normobiosis 
after six weeks on diet.  
 
Table 10: Percentage of individuals in the different DI-groups in group A and B at baseline and 
after six weeks 
 Group A Group B 
DI group Baseline 6 weeks Baseline 6 weeks 
Normal (1-2) 60 % 60 % 50 % 60 % 
Mild (3) 30 % 15 % 35 % 30 % 





Between baseline and six weeks, the mean DI score had increased in group A and decreased 
in group B. None of the changes in DI score were statistically significant however, with p-
values of p=0.852 in group A and p=0.789 in group B. There was not a statistically significant 
change between the groups after six weeks (p=0.811). 
 
Table 11: Change in DI mean with p-value after six weeks in group A and group B 
 Group A Group B 
Baseline 6 weeks p-value Baseline 6 weeks p-value 
DI, mean ± SD 2.45 ± 0.94 2.55 ± 1.50 0.852 2.50 ± 1.24 2.45 ± 1.10 0.789 
Wilcoxon signed rank test in group A and paired t-test in group B 
 
The individual change in dysbiosis index after six weeks on diet varies a lot after six weeks 

































Figure 10: Individual changes in Dysbiosis Index in group A and B from baseline to six weeks  





The graph in figure 11 show that group A has a constant rate of dysbiois, but more severe 
dysbiosis after six weeks of a strict gluten free diet. However, this was not statistically 
significant. 
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The graph in figure 12 show that group B moved towards less dysbiosis after six weeks of 
low FODMAP diet, but it was not a statistically significant change.   
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Figure 12: Change in DI score in group B after six weeks of diet 
 
3.4.3 Bacteria at baseline  
 
Several bacterial genera were statistical significantly reduced or increased in the CD patients 
with IBS-like symptoms compared to the healthy controls, as displayed in the following 
figures. The figures also display the different diet groups at six weeks, but these figures do not 
show any change over time and are only used to characterize the baseline microbiota 
composition. The data are all displayed in figures with mean, median, IQR and confidence 
intervals. The figures where the 95% confidence interval lie outside the normal mean display 







Figure 13: Probe signal for Ruminiclostridium (genus) and Ruminococcus gnavus at baseline and 
after six weeks of diets The box displays IQR and the line within the box is the median. The big circle 
equals mean. The interval shows 95% Confidence Interval. Normal mean (dotted line) equals mean of 
a healthy cohort. g, genus. The single points outside the 95% confidence intervals are outliers. 
 
The abundance of the genus Ruminiclostridium was lower at baseline compared to healthy 
controls. Ruminicoccus gnavus was increased at baseline, but this was not statistically 







Figure 14: Probe signal for Bacillus (genus) and Eubacterium (genus) at baseline and after six 
weeks of diets. The box displays IQR and line within the box is median. The big circle equals mean. 
The interval shows 95% Confidence Interval. Normal mean (dotted line) equals mean of a healthy 
cohort. For Eubacterium (g), the normal mean equals 1.6, but this line lies outside the figure. g, genus. 
The single points outside the 95% confidence intervals are outliers. 
 
Bacillus (genus) had increased values at baseline, whilst Eubacterium (genus) was lower than 
the normal mean. The normal mean for Eubacterium (genus) lies outside the figure, but 







Figure 15: Probe signal for Lactobacillus (genus) and Prevotella (genus) at baseline and after six 
weeks of diets. The box displays IQR and the line within the box is the median. The big circle equals 
mean. The interval shows 95% Confidence Interval. Normal mean (dotted line) equals mean of a 
healthy cohort. g, genus. The single points outside the 95% confidence intervals are outliers. 
 
There was a higher abundance of both genera Lactobacillus and Prevotella at baseline 






Figure 16: Probe signal for Pseudomonas and Atopobium (genus) at baseline and after six weeks 
of diets. The box displays IQR and the line within the box is the median. The big circle equals mean. 
The interval shows 95% Confidence Interval. Normal mean (dotted line) equals mean of a healthy 
cohort. g, genus. The single points outside the 95% confidence intervals are outliers. 
 
Pseudonomas, a genus classified under Proteobacteria, and the genus Atopobium, classified 






Figure 17: Probe signal for Desulfitispora (genus) and Streptococcus (genus) at baseline and after 
six weeks of diets. The box displays IQR and the line within the box is tbe median. The big circle 
equals mean. The interval shows 95% Confidence Interval. Normal mean (dotted line) equals mean of 
a healthy cohort. g, genus. The single points outside the 95% confidence intervals are outliers 
 
Desulfitispora (genus) had significantly higher abundance than normal mean at baseline. 
Streptococcus (genus) had lower abundance than normal mean at baseline, but this was not 
statistically significant as the 95% confidence interval cross the normal mean (dotted line).  
 
For each of the patients’ faecal samples (baseline and six weeks), the GA-map Dysbiosis 
Test™ provided a microbiota profile with selected bacteria on different taxonomic levels. The 
probes presented are for specific intestinal bacterial genera and species shown to be associated 
with gastrointestinal disorders. Some genera or species are reported together because their 
signals were not distinguishable. The level of bacteria are presented in values from -3 to 3, 
where 0 equals the level in a healthy cohort. The values are an expression for the detected 
probe signal, and for how far away from a healthy cohort the bacterial level in each patients 
is. Numbers -3 to -1 refers to a reduced level, where -3 is the farthest away from a healthy 
cohort, and 1 to 3 equals increased levels where 3 is the farthest away. These deviations 
cannot be regarded as statistically significant, but are still of significance when looking at 





Table 12: Overview of level of selected bacteria in genera and species for patients with dysbiosis 
at baseline. The numbers -3 to 3 represent deviations from a healthy cohort which equals 0.  









Rum.a/ b Rum.g F.prau Lact  
(g) 
Strep. sa  
& th 






5 0 3 -2 0 1 0 0 0 -2 1 0 
5 0 0 0 1 0 0 0 0 0 3 0 
5 0 0 0 0 2 0 0 3 0 0 -1 
4 0 0 0 0 0 0 1 2 0 3 -1 
4 2 2 0 0 0 0 0 2 0 0 -1 
3 0 1 0 0 1 2 2 0 -2 0 -1 
3 0 0 0 0 2 0 0 0 0 0 -1 
3 0 2 -1 0 1 0 0 2 -3 1 0 
3 0 2 -1 0 2 0 2 0 0 1 0 
3 0 0 0 0 0 0 2 1 0 2 -1 
3 2 2 0 1 1 0 0 2 0 2 0 
3 0 0 -1 0 0 0 0 2 0 0 -1 
3 0 2 0 0 1 0 0 0 0 0 -1 
3 0 0 0 0 0 0 0 0 1 0 -1 
3 0 0 0 0 1 1 1 0 -3 0 0 
3 0 0 0 0 0 0 0 0 1 0 -1 
3 0 0 0 0 0 0 0 0 0 0 0 
3 0 0 -1 0 0 0 0 0 0 0 0 
DI, Dysbiosis Index; Rum.a/b, Ruminococcus albus/bromii; F.prau, Faecalibacterium prausnitzii; Lact, 
Lactobacillus; Strep.sa&th, Streptococcus sanguinis&thermophilus; D.invi, Dialister invisus; A.mun, 
Akkermansia munciniphila; B.frag, Bacteroides fragilis; Ali, Alistipes; Sh/Es, Shigella/Escherichia; Bf, 
Bifidobacterium. 
 
The different genus and species presented in table 12 show that there are different bacteria 
contributing to the dysbiosis in different patients at baseline. The bacteria presented cannot 
alone account for the dysbiosis in the patients, but are contributors when their abundance 
deviate from the healthy cohort. There did not seem to be any clear pattern of what bacteria 
contributed in all patients, but there were however some observations of bacteria that more 
frequently deviated from a normal level. A reduced level of the genus Bifidobacterium (phylum 
Actinobacteria) was seen in 55% of the dysbiotic patients. This genus was reduced also in 55% 
in all the patients combined (not shown in table). An increased level of Streptococcus 
sanguinins and Streptococcus thermophilus was seen in 50% of the dysbiotic patients. The 




abundance in about 40% out of the dysbiotic patients. Notably, the level of which the bacteria 
deviate from a normal level varies between the individual patients.  
 
The genera Shigella/Eschericia had increased abundance in three out of five with the highest 
DI-score (4 and 5), and also at a value of 3 for two of the patients. This observation might 
indicate that these genera contribute more to a severe dysbiosis.  
 
Table 13: Overview of level of higher taxonomy groups in patients with dysbiosis at baseline. 
Numbers -3 to 3 represent deviations from a healty cohort which equals 0. Each DI-score 
represent different patients 
DI Bs / Prev Firm (B) Firm (C) Pb 
5 1 0 3 0 
5 0 0 0 3 
5 1 1 0 0 
4 0 0 0 3 
4 -1 0 1 0 
3 0 1 0 0 
3 0 2 0 0 
3 0 0 2 0 
3 1 1 1 0 
3 0 -2 0 2 
3 0 1 1 2 
3 1 2 0 0 
3 1 0 0 0 
3 1 0 0 0 
3 1 0 0 0 
3 0 0 0 0 
3 0 0 0 0 
3 2 0 0 0 
Bs/Prev, Bacteroides/Prevotella; Firm (B), Firmicutes (Bacilli); Firm (C), Firmicutes (Clostridia); Pb, 
Proteobacteria.  
 
Table 13 shows higher taxonomic groups, which includes many species of bacteria. More 
patients seem to deviate from the genera Bacteroides/Prevotella, followed by Firmicutes 
(Bacilli), Firmicutes (Clostridia) and Proteobacteria. Bacteroides/Prevotella were increased 
in 52.5% of the total study group. These phyla will overlap some with the those presented in 
table 12 as some are classified under these genera or phyla, however, the probes for the phyla 





3.4.4 Bacteria and the low FODMAP diet  
 
A statistically significant reduction in the genus Bacteroides was seen in patients on the 
FODMAP diet, but not in patients on a stricter GFD (p=0.024). This was the only bacteria of 




Figure 18: Probe signal for Bacteroides (genus) at baseline and after six weeks of diets. These 
bacteria were statistically significant reduced after a low FODMAP diet, but not after a stricter 
GFD. The box displays IQR and line within the box is median. The big circle equals mean. The 
interval shows 95% Confidence Interval. Normal mean (dotted line) equals mean of a healthy cohort. 
Unpaired t-test was performed. g, genus. 
 
In table 14, the change in specific bacteria and genera are listed for each patient from baseline 
to six weeks of a low FODMAP diet. There were some individual changes, but no clear 
pattern shared between the patients. The table also show individual change in DI-score within 





Table 14: The change in DI-score and bacterial species and genera in patients from baseline to 
six weeks on a low FODMAP diet. Numbers -3 to 3 represent deviations from a healty cohort 
which equals 0.  Each row represent a patient at baseline or six weeks, where the grey shaded 
rows equals baseline level 
Pat. DI Rum. 
a/b 
Rum.g F.prau Lact. Strep.sa 
& th 
D.invi A.mun B.frag Alist. Sh/Es Bifido. 
1 BL 3 0 0 -1 0 0 0 0 2 0 0 -1 
1 6w 3 0 2 0 0 0 0 0 2 0 0 -1 
2 BL 3 0 2 0 0 1 0 0 0 0 0 -1 
2 6w 2 0 2 0 0 0 0 0 0 0 0 0 
3 BL 1 0 0 0 0 1 0 1 0 0 1 0 
3 6w 1 0 0 -1 0 0 0 0 1 0 1 -1 
4 BL 5 0 0 0 1 0 0 0 0 0 3 0 
4 6w 3 0 0 0 2 1 0 0 0 0 0 0 
5 BL 1 1 0 0 0 0 0 0 1 0 0 -1 
5 6w 1 0 0 0 0 0 0 1 1 0 2 -1 
6 BL 2 0 0 0 1 0 0 1 0 0 0 -1 
6 6w 2 0 0 0 1 1 0 0 0 0 0 -1 
7 BL 4 2 2 0 0 0 0 0 2 0 0 -1 
7 6w 5 0 2 0 0 0 1 0 3 0 2 -1 
8 BL 2 0 0 0 0 0 0 0 2 0 1 -1 
8 6w 2 0 0 0 0 0 0 0 0 -3 1 0 
9 BL 1 0 0 0 0 0 0 0 0 -3 0 -1 
9 6w 1 0 0 0 0 0 0 0 0 -3 0 -1 
10 BL 3 0 0 0 0 0 0 0 0 1 0 -1 
10 6w 3 0 2 -1 0 0 0 0 0 0 0 -1 
11 BL 1 0 0 0 0 0 1 0 2 -3 0 0 
11 6w 2 0 0 0 0 0 1 2 0 -3 0 0 
12 BL 3 0 0 0 0 1 1 1 0 -3 0 0 
12 6w 3 0 1 0 0 0 0 0 0 -3 1 -1 
13 BL 3 0 0 0 0 0 0 0 0 1 0 -1 
13 6w 2 0 0 0 0 0 0 0 0 0 0 -1 
14 BL 2 1 0 0 0 0 0 1 0 0 0 -1 
14 6w 3 0 0 0 0 0 0 0 0 0 2 -1 
15 BL 1 0 0 0 0 0 0 0 0 0 1 -1 
15 6w 2 0 0 0 0 0 0 1 0 0 0 -1 
16 BL 2 0 0 0 0 0 0 2 0 0 0 -1 
16 6w 3 1 0 0 0 0 0 2 0 0 0 -1 
17 BL 3 0 0 0 0 0 0 0 0 0 0 0 
17 6w 2 0 0 0 0 0 0 1 3 0 2 -1 
18 BL 3 0 0 -1 0 0 0 0 0 0 0 0 
18 6w 2 0 0 -1 0 0 0 1 0 0 0 1 
19 BL 2 0 0 -1 0 0 0 0 0 0 -1 -1 
19 6w 2 0 0 0 0 0 0 0 0 0 0 -1 
20 BL 5 0 0 0 0 2 0 0 3 0 0 -1 
20 6w 5 0 0 0 0 0 0 0 3 0 0 -1 
BL, baseline; 6w, 6 weeks; Pat, patient; DI, Dysbiosis Index; Rum.a/b, Ruminococcus albus/bromii; F.prau, 
Faecalibacterium prausnitzii; Lact, Lactobacillus; Strep.sa&th, Streptococcus sanguinis&thermophilus; D.invi, Dialister 





Individual changes on higher taxonomy levels are shown in table 15. Also here there will be 
some overlap with those bacteria presented in table 14. There was no clear pattern in bacteria 
on higher taxonomy levels amongst the patients. 
 
Table 15: The change in DI-score and bacteria at higher taxonomy levels in patients from 
baseline to six weeks on a low FODMAP diet.  Numbers -3 to 3 represent deviations from a 
healty cohort which equals 0. Each row represents a patient at baseline or six weeks, where the 
grey shaded rows equals baseline level  
Pat. DI Bs / Prev Firm (B) Firm (C) Pb 
1 BL 3 1 2 0 0 
1 6w 3 1 1 0 0 
2 BL 3 1 0 0 0 
2 6w 2 0 0 0 0 
3 BL 1 0 0 0 0 
3 6w 1 1 0 0 0 
4 BL 5 0 0 0 3 
4 6w 3 0 0 2 0 
5 BL 1 0 -1 0 0 
5 6w 1 0 0 0 1 
6 BL 2 1 0 0 0 
6 6w 2 1 0 0 0 
7 BL 4 -1 0 1 0 
7 6w 5 0 0 1 2 
8 BL 2 1 -1 0 0 
8 6w 2 -3 0 1 2 
9 BL 1 1 0 0 0 
9 6w 1 1 0 0 0 
10 BL 3 1 0 0 0 
10 6w 3 1 0 0 0 
11 BL 1 0 0 1 0 
11 6w 2 0 0 0 0 
12 BL 3 1 0 0 0 
12 6w 3 2 0 0 0 
13 BL 3 0 0 0 0 
13 6w 2 1 0 0 0 
14 BL 2 1 0 0 0 
14 6w 3 0 0 0 2 
15 BL 1 0 0 0 0 
15 6w 2 1 0 0 0 
16 BL 2 0 0 1 0 
16 6w 3 0 -1 2 0 
17 BL 3 0 0 0 0 
17 6w 2 0 0 0 2 
18 BL 3 2 0 0 0 
18 6w 2 0 0 0 0 
19 BL 2 0 0 0 0 
19 6w 2 0 0 0 0 
20 BL 5 1 1 0 0 




3.5 Breath testing 
As shown in figure 19, the hydrogen breath test taken at baseline and after 6 weeks showed no 
significant change in hydrogen after a low FODMAP diet in group B, median 266 vs. 244 
ppm,  (p= 0.927). There was no significant change in group A with median 424 vs. 90 ppm, 
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Figure 19: Area under the curve for hydrogen gas at baseline and after six weeks of diet in 
group A and B 
Red line = median. Wilcoxon signed rank test.  
 
There was no significant difference in hydrogen production at baseline or six weeks when 
comparing responders to non-responders of the LFD, when response was defined as an IBS-
SSS reduction of 100 or more. At baseline, median ppm in responders was 266.3 ppm versus 
453.8 ppm in non-responders, p=0.985. At six weeks, responders had median ppm of 180 





No significant difference was seen in methane production after 6 weeks of diet in group A 
(p=0.1563) or group B (p= >0.9999). Seven patients in group A produced methane at 
baseline, whilst six patients produced methane at six weeks. The methane production by three 
patients in group B remained stable.   
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Figure 20: Area under the curve for methane gas at baseline and after six weeks of diet in group 
A and B 








3.6.1 IBS-SSS total score  
Symptoms were registered at baseline, three weeks and six weeks using IBS-SSS. There was 
a significant reduction in IBS-SSS in both groups after six weeks of diet. Group A had a 
reduction in IBS SSS score from mean 259.8 to 203.7 (p=0.0022). In group B, IBS-SSS score 
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Figure 21: Change in IBS-SSS total score from baseline, after three weeks and six weeks of diet 
in group A and B  
0 = satisfaction, 100 = dissatisfaction. Red line = median. 







Tukey’s multiple comparison test show that the biggest change in symptom score in group A 
was between baseline and three weeks with a mean difference of 35.0, but this was not 
significant. There was a significant reduction from baseline to six weeks, with a mean total 
symptom score change of 56.1. In group B, there was a large score reduction both between 
baseline and three weeks (mean diff. 64.9) and between three weeks and six weeks (mean 
diff. 53.9), which both were statistically significant changes. The change in total mean score 
was 118.7. After diet, two patients were in remission (IBS-SSS <75) in group A versus five 
patients in group B.  
 
3.6.2 IBS-SSS main questions  
The IBS-SSS total score is comprised of five main questions which each have a VAS-scale 
that ranges from 0 to 100. These questions and their scores are listed in table 16 for group A 
and in table 17 in group B.  
 
In group A there was a statistically significant score reduction in abdominal pain severity 
(p=0.0015). There was less effect on the other four questions.   
 
Table 16: Mean score for the five different main questions at baseline, three weeks and six weeks 
in group A Data are given mean ± SD and p-values for change in score from baseline to six 
weeks 
Group A Baseline 3 weeks 6 weeks p-value 
1. Abdominal pain severity (0-100) 47.8 (±27.1)  33.2 (±29.4) 27.5 (±24.2) 0.0015** 
2. Abdominal pain duration (days x 10) 40.3 (±28.6) 42 (±39.3) 33 (±24.5) 0.372 
3. Abdominal distension (0-100) 51.3 (±31.3) 43.9 (±26.7) 42.3 (±25.2)  0.243 
4. Bowel habit satisfaction (0-100) 67 (±27.4) 56.6 (±26.3) 53.5 (±21.9) 0.0724 
5. Life disruption (0-100) 57.3 (±28) 49.3 (±25.3) 47.6 (±22.6) 0.155 





There was a statistically significant score reduction on all five questions after a low FODMAP 
diet in group B. The diet seemed to have the greatest effect on abdominal pain, abdominal 
distension and on life disruption.  
 
Table 17: Mean score for the five different main questions at baseline, three weeks and six weeks 
in group B. Data are given mean ± SD or median (IQR). P-values for change in score from 
baseline to six weeks 
Group B Baseline 3 weeks 6 weeks p-value 
1. Abdominal pain severity (0-100) 39.1 (±20.7) 25.1 (±21.9) 14.5 (0-23.5) <0.0001**** 
2. Abdominal pain duration (days x 
10) 
42.8 (±28.5) 38.8 (±32.3) 20 (0-40) 0.0016** 
3. Abdominal distension (0-100) 58.4 (±19.8) 38.8 (±27.5) 19.5 (2-34.5) <0.0001**** 
4. Bowel habit satisfaction (0-100) 63.2 (±26.1) 48.8 (±28.7) 44.9 (±23.8) 0.0196* 
5. Life disruption (0-100) 61.4 (±24.3) 47.1 (±25.6) 33.7 (±28.9)  <0.0001**** 
Repeated measures one-way ANOVA and Friedman test  
 
3.6.3 Responders to low FODMAP diet and bacterial pattern 
There was detected a distinctive pattern in bacteria for those who responded to a LFD, when 
response was defined as an IBS-SSS-score reduction of 100. This included less of the genus 
Lactobacillus, less Firmicutes (Clostridia) and more of the genus Apotobium This pattern was 




Figure 22: 3D plot of probe signal values in responders to the LFD  
Responders to the LFD (red) seem to have less Lactobacilli (g), more Atopobium (g) and less 
Firmicutes (Clostridia) than non-responders (green) at baseline. Responders was defined as an IBS-
SSS score reduction of 100. Fisher’s linear discriminant analysis was performed. 
 
3.7 Compliance  
 
3.7.1 Compliance during the intervention period 
We used a self-reporting questionnaire in order to evaluate compliance in both groups 
throughout the intervention period. The form was filled out at six weeks. The table below 
show the results of the questions that included a VAS-scale (0-100 mm).  
 
Table 18 show that there was a high self-reported degree of adherence to the diet in both 
groups, with a mean of 93.3% in group B and a median of 97% in group A. It is also clear that 
the LFD was more difficult to follow compared to the strict gluten free diet. More patients 






Table 18: Self-reported compliance during the intervention period in group A and group B 
 How satisfied are you 
with the diet as 
symptom relief? (0-
100, where 100 is very 
dissatisfied)  
How carefully how 
you followed the diet? 
(0-100, where 100 is 
full adherence)  
How was it to follow 
the diet? (0-100, where 
100 is very 
challenging)  
Group B, mean ± SD 41.3 ± 30.8 93.3 ± 8.3 64.3 ± 30.1 
Group A, mean ± SD 
and median (IQR) 
66.7 ± 31.1 97 (87.5-100) 27.9 ± 32.8 
Data are presented in mean ± SD  
 
3.7.2 The low FODMAP diet  
In group B, 50% replied that they wanted to continue the diet, 40% replied “maybe” and 10% 
replied “no”. The patients were also asked if they had any deviations from the diet, where 
35% answered “none”, 55% answered “1-5 times during the six weeks” and 10% answered 
“1-3 times a week”. Of those who had deviations from the diet, six out of 13 answered “only a 
mouthful”, three out of 13 answered “2-5 mouthfuls”, and four answered “a whole meal”. 
Fructose- and lactose containing foods were the most common foods in diet deviation.  
 
In response to how satisfied they were with the dietary guidance, nine of the patients 
answered that they were very satisfied, nine were satisfied, one answered “OK” and one was 
not satisfied.  
 
3.7.3 The strict gluten free diet  
50% answered that they wanted to continue excluding wheat starch and trace amounts of 
gluten whilst 25% answered “maybe” and 25% “no”. In question on any deviations from the 
diet, 40% answered “none”, 50% answered “1-5 times during the six weeks” and 10% 
answered “1-3 times a week”. The most common reason for any deviations was not knowing 
that the food contained either wheat starch or traces of gluten. Thirteen were very satisfied 
with the dietary guidance before commencing the diet, whilst six were satisfied and one 







3.7.4 Compliance 4 weeks after end of study   
Group B also filled out a questionnaire reporting adherence to the diet one month after end of 
study, which they sent back by mail. All 20 patients answered the questionnaire.  
 
Table 19 show that the patients have followed the diet to a varying degree after end of 
intervention. 
 
Table 19: Self-reported compliance 4 weeks after end of study in group B 
 How well have you maintained 
your diet 1 month after end of 
study? (0-100, of which 100 is 
only eaten low FODMAP) 
How did you find the 
reintroduction of foods? (0-
100, of which 100 is very 
challenging)  
Group B, mean ± SD 61.9 ± 36.5 42.6 ± 32.5 
 
Eight of the patients still followed the diet at this stage, seven patients answered “partially”, 
one patient answered “occasionally” and four patients did not follow the diet anymore. In 
question to why they no longer followed the diet completely, most answered that the effect of 
the LFD was not big enough to sacrifice their habitual diet, while some answered that there 
were only a few foods they reacted to or that they missed too many food items. Only one 
answered that they had no effect of the diet.  
 
It seems the reintroduction was not too difficult, with a mean of 42.6% where 100% is very 
challenging. Eight answered that they had started reintroducing FODMAPs, while seven had 
only reintroduced certain food items. What the majority found most difficult with 
reintroduction, was to identify whether the symptoms came from that exact food item, and 
also to differ between “normal symptoms” still persisting on a LFD and symptoms that might 
come from reintroduction of different FODMAPs. Sixteen out of twenty patients suspected 
that they reacted to two or more FODMAPs.  
 
In response to whether they were going to continue the diet at this stage, four answered “yes” 
and 12 answered “partially”. One said “maybe”, while three said “no”. The most frequently 






3.8 Blood tests  
Blood test were taken at baseline and after six weeks of diet. These included serology tests 
and some other parameters. IgA TTG antibodies were reduced for four out of five patients and 
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Figure 23: IgA TTG levels at baseline and after six weeks of diet in group A and B  
Dotted line equals reference limit 14.9 U/ml. Wilcoxon signed rank test.  
 
The level of IgA TTG and IgG DPG were significantly reduced in both groups. Elevated IgG 
DPG were however not considered as having elevated antibodies, because we did not have 
any information on IgA deficiency. Vitamin D was signicantly reduced in group A. 
 
Table 20: Antibodies and Vitamin D levels at baseline and after intervention in both groups 
 Group A Group B 
 Baseline 6 weeks p-value Baseline  6 weeks p-value 
IgA TTG 5.2 5.1 0.0175* 4.8 4.3 0.0072** 
IgG DPG  4.8 4.3 0.0012** 0.9 0.7 0.0039** 
Vitamin D 71 63 0.0037** 78 81 0.961 






4.1 Main findings  
We performed a prospective, randomized and controlled clinical trial to look at the microbiota 
profile and Dysbiosis Index in coeliac disease patients with IBS-like symptoms, and to see the 
effect of two different dietary interventions on microbiota and symptoms. One group followed 
a low FODMAP diet, and the other group followed a stricter GFD excluding wheat starch and 
trace amounts of gluten from their diet. Both groups followed their assigned diet for six 
weeks.   
 
There was a successful reduction of total FODMAPs from mean 11.5 to 1.6 grams (p=0.0001), 
as well as in lactose (p=<0.0001) and other FODMAPs (p=0.0001) in group B. We also found 
a significant reduction in energy and fat intake in this group. There were no change in FODMAP 
intake in group A, following a strict GFD. We found a significant change in fat and protein 
intake in this group. 
 
At baseline, we found that 55% of the patients were normobiotic, whilst 45% had dysbiosis. Of 
these; 32.5% had a mild dysbiosis (DI=3) and 12.5% had a severe dysbiosis (DI=4-5). Several 
bacterial genera were statistically significantly different at baseline compared to healthy 
controls, including Ruminiclostrididum, Bacillus, Eubacterium, Lactobacillus, Prevotella, 
Pseudomonas, Atopobium and Desulfitispora. There were observations of several bacteria that 
deviated from the level in healthy controls in the dysbiotic patients, although we cannot 
determine whether this is statistically significant or not. These bacteria include less 
Bifidobacterium, and more Streptococus sanguinis, Streptococcus thermophilus, 
Shigella/Escherichia and Bacteroides fragilis. There was a statistically significant reduction in 
the genus Bacteroides after the LFD compared to the stricter GFD (p=0.024). The degree of 
dysbiosis tended to decrease on a LFD (p=0.789), and worsen when following a stricter GFD 
(p=0.852), but these were not statistically significant findings.  
 
IBS-SSS-score was significantly reduced in both groups after six weeks of diet, with p-values 
of p=0.0022 in group A and p=<0.0001 in group B. Group B had a significant reduction in all 
five main questions, including abdominal pain and duration, abdominal distension, bowel 
habit satisfaction and life disruption. Group A had a significant reduction in abdominal pain, 




more Atopobium (g) and less Firmicutes (Clostridia) at baseline than the non-responders, 
when response is defined as a score reduction of 100 on IBS-SSS.  
 
There were no significant change in the hydrogen breath test in group A (median 424 vs. 90 
ppm, p= 0.140) or group B (median 266 vs. 244 ppm, p= 0.927). Of those producing methane, 
there were no significant reduction in group A (p=0.1563), nor group B (p= >0.9999). One 
patient in group A produced methane at baseline, but not after six weeks.  
 
IgA TTG was reduced in four out of five patients in group A and reduced in the one that had 
elevated levels in group B. 
 
4.2 Discussion of findings 
We found that the group of CD patients with IBS-like symptoms had more dysbiosis than a 
healthy population where 16% suffered from dysbiosis, but less than an IBS population in 
which 70% had dysbiosis [122]. It was somewhat expected to find some dysbiosis, as an 
altered microbiota have been detected in untreated and treated CD patients and in IBS patients 
previously [122-125, 127-129]. What causes our patient group to have an altered bacterial 
composition is not identified, and there are several potential factors. Firstly, we know that all 
CD patients have shared HLA DQ2 or DQ8-genes, which might have an impact on the 
microbiota composition. However, these genes are shared with 30% of the population, and if 
HLA subtype was important, many more of the general population should be dysbiotic. The 
tissue antigens make up a very complicated system, however. But also other susceptible genes 
besides the HLA genes are thought to be involved in CD development, and may affect 
microbiota. Another shared factor is that all patients follow a GFD, and we know that diet is 
very potent to affect microbiota. What clearly distinguishes a GFD from a normal diet is the 
exclusion of gluten, which also involves a reduction in prebiotic carbohydrates such as 
fructans. Thus, a long term GFD could affect microbiota and either be a possible cause or a 
factor that maintains dysbiosis. An altered bacterial composition could also have arisen before 
the CD diagnosis was made, and a GFD might have failed to restore it. Wacklin et al. [147] 
have suggested that the fact that most patients go a long time before the CD diagnosis is being 





It is tempting to assume that dysbiosis in these patients is a contributing factor to the IBS-like 
symptoms they are experiencing. Although previous studies have detected dysbiosis in both 
treated and untreated CD patients, we should ideally have studied those groups as well, using 
the same technique. A DI score for untreated CD patients and treated CD patients without 
IBS-like symptoms would help determine whether the degree of dysbiosis is distinctive for 
our patient group or not. Possible mechanisms for why dysbiosis could lead to IBS-like 
symptoms is the involvement gut microbiota has on maintaining a normal gut barrier and 
immune response, and a disruption here may lead to such symptoms. It is proposed as a 
pathogenic factor in IBS that dysbiosis may activate the immune system and as a consequence 
affect motility and permeability and cause symptoms [52]. If the dysbiosis is in fact causing 
the IBS-like symptoms, perhaps probiotics could reduce symptoms in these patients. Another 
important aspect is that our study only looked at faecal microbiota, which does not necessarily 
have the same composition as mucosal microbiota [148-150]. It is not certain that dysbiosis of 
the faecal microbiota can explain mechanisms which would mainly involve the mucosal 
microbiota [151].  
 
Although all included patients met the Rome III-criteria used for IBS diagnosis, we still 
cannot say whether this particular group of patients actually suffer from IBS in addition to 
their CD, or if other mechanisms are responsible for their symptoms. Those with elevated 
antibodies may have IBS-like symptoms due to a gluten contamination in their diet, which 
causes inflammation and symptoms. Interestingly, the patient with elevated IgA TTG 
antibodies in group B did experience symptom relief from the FODMAP diet, but it is 
possible that an ongoing intestinal inflammation will cause reactions to FODMAPs in higher 
degree than in a healthy intestine. Four out of five with elevated IgA TTG antibodies in group 
A experienced symptom relief (IBS-SSS reduction >50) and all had reduced antibodies after 
diet, which indicates that they possibly had gluten contamination in their diet. This is reported 
to be the most common cause of persisting symptoms in CD [28]. It is also possible that some 
patients have a concomitant IBS diagnosis, which is proposed in IBD patients in remission 
with IBS-like symptoms, and has been called IBS-IBD. Considering that as much as 10-20% 
of the general population suffers from IBS, it is not unlikely that some CD patients have 
concomitant and unrelated IBS. The prevalence of IBS-like symptoms in CD is reported to be 
between 15 and 23.3%, which is quite similar to the prevalence of IBS in the general 
population. However, it is reported even higher in some studies, suggesting that there may be 




inflammation when the intestines are exposed to gluten, which normally resolves on a GFD, 
but maybe a failure to downregulate this inflammation completely predisposes for IBS-like 
symptoms, possibly triggered by stress or an infection as seen in IBS. SIBO can also give 
similar symptoms to those seen in these patients. We did not test for SIBO as it requires an 
ileo-colonoscopy, and thus we cannot exclude it as a cause. One study did find SIBO to affect 
CD patients with persistent symptoms [152]. This study did however only use lactulose breath 
test to test for SIBO and had a small study sample. Maybe this patient group is not a 
homogeneous group, but rather made up of CD patients with similar symptoms of different 
origin. Regardless, it is important to address these symptoms as they are known to have great 
impact on quality of life in IBS patients, and quality of life has also been reported to be lower 
in CD patients with IBS-like symptoms compared to those without [42, 69].  
 
A low FODMAP diet led to numerically less dysbiosis in these patients, although not a 
statistically significant finding. This is possibly a random finding, and do not reflect the 
nature of the diet. The diet involves a temporary elimination of many different foods as well 
as foods known for their prebiotic effects, and theoretically it does not seem likely that such a 
diet would improve the bacterial composition. However, we do not know whether the LFD 
have the same effect on microbiota in these patients as it have in IBS patients. Additionally, 
the stricter GFD had constant rate of dysbiosis, but led to more patients having severe 
dysbiosis. Again, this was not a statistically significant finding. This intervention did lead to a 
reduction in protein and fat intake, but otherwise no change in diet other than the exclusion of 
wheat starch and products with traces of gluten. It is not evident that this diet intervention 
would lead to more severe dysbiosis, and might be just random variation over time. If we had 
a larger study sample, it is possible that we could have seen a more pronounced effect of the 
diet on dysbiosis. There was also a lot of individual movement in the dysbiosis index of the 
patients from baseline to six weeks, which indicate that the bacteria that comprise this index is 
part of a variable or hypervariable part of the microbiota. Thus, we cannot be certain that the 
changes in DI-score seen in these patients are driven by diet or if these changes would have 
happened regardless of an intervention.  
 
A paradox of the LFD is that the diet has been shown to have a negative impact on gut 
microbiota. Interestingly, we did not see the same changes in microbiota after six weeks on 
diet as seen in IBS populations, such as a reduction in the butyrate-producing bacteria 




associated bacteria. It was not seen any reduction in Firmcutes (Bacilli) or Firmicutes 
(Clostridia) either. The phyla Firmicutes is known to contain a lot of fermenting bacteria, and 
it is expected to see less fermenting bacteria after a diet with reduced amount of non-
digestible carbohydrates, because these bacteria are being starved on a LFD. An increase in 
other bacteria might also be expected because when some species are starved and reduced, 
other bacteria take their place. We did find a statistically significant reduction in the genus 
Bacteroides after the LFD, but not after the stricter GFD. More of the bacteria in this genus is 
associated with a higher intake of animal products compared to plant polysaccharides [112]. 
However, the phyla also contains saccharolytic bacteria, which may explain the reduction 
when FODMAPs are restricted [153]. An explanation to why we did not find the same 
changes in microbiota as previously seen might lie in the baseline diet of these patients. A 
study by Halmos et al. [116] looked at the effect of a LFD in patients with inactive Crohn’s, 
and did find some of the expected results on microbiota. However, this change in bacteria was 
seen between an Australian diet and a LFD, and not between the habitual diet of the patients 
and a LFD. The authors note that the patients had a low intake of FODMAPs in their habitual 
diet compared to an Australian diet (23g/day), and that this might have been the reason for 
lack of response in the microbiota. Even though we have a different patient group, it is 
possible that an already low FODMAP intake of mean 11.5 g/day in our patient group also 
before diet intervention led to less response in the microbiota. It must be mentioned that the 
study by Halmos et al. had a small study sample of eight patients. Previous studies have 
shown that a diet change over a short period of time does not necessarily affect microbiota 
very much, especially if the change in diet is not that radical [154, 155]. Or maybe an effect 
on the microbiota will come apparent in time if the FODMAP diet is continued by the 
patients. It may also be that we would have seen a greater effect on the microbiota if the 
patients were to consume a high FODMAP diet more similar to the total FODMAP intake in 
the general Norwegian population at first, and then switch to a LFD. However, we cannot 
exclude that that our patient group reacts differently to the diet compared to an IBS patient 
group when it comes to microbiota and fermentation. Maybe the microbiotic effect of the diet 
differs amongst different diagnosis, likely due to different bacterial composition at baseline. 
 
At baseline, 55% of the dysbiotic patients had a reduced abundance of the genus 
Bifidobacteria, regardless of the degree of dysbiosis (DI-score 3-5). In fact, 55% of the whole 
study group had reduced abundance of this genus at baseline. Bifidobacteria colonize the 




as beneficial bacteria because of their health benefits, such as inhibiting growth of pathogenic 
bacteria. These bacteria are also able to ferment non-digestible carbohydrates in the colon 
[156]. Interestingly, a reduction in Bifidobacteria has been detected in IBS patients when 
following a LFD [114]. Maybe the reduction in Bifidobacteria at baseline in our patients can 
be linked to a reduction in FODMAP intake after commencing a GFD, as this involves less 
FODMAPs. A reduction of Bifidobacteria has been seen in healthy individuals following a 
GFD [157]. A reduced level of Bifdobacteria has also been seen in both treated and untreated 
children with CD before, as well as in IBS patients [158-160]. Also patients without dysbiosis 
(DI-score 1-2) had a reduction in Bifidobactera, which might indicate that their microbiota 
composition is driven by some imbalance. This also indicates that Bifidobacteria were not the 
bacteria contributing most to dysbiosis in these patients. However, a reduction in one genus 
opens for other bacteria to multiply. Streptococcus sanguinis and Streptococcus thermophilus 
were both increased in 50% of the dysbiotic patients at baseline. S. sanguinis is regareded as a 
commensal bacteria most known for its presence in the oral cavity [161]. S. thermophilus is a 
bacteria producing lactic acid and used as a probiotic for its health benefits, such as easing 
digestion of milk and decreasing malabsorption symptoms [162, 163]. It is not clear why 
these bacteria seem to be increased in some of the dysbiotic patients, but maybe these 
commensal bacteria become less beneficial for the host in an altered gut environment. 
Shigella and Escherichia are two genera possibly contributing to severe dysbiosis in this 
patient group, and are in general increased in 40% of the dysbiotic CD patients. These genera 
are closely related to each other, include pathogenic bacteria and are normally just a small 
part of the human microbiota. Shigella is the cause of dysentery, an intestinal inflammation 
causing bloody diarrhoea [164]. Shigella/Escherichia are also found to contribute to dysbiosis 
in IBS and IBD populations [122, 165]. Although just an observation, is seems reasonable 
that these pro-inflammatory bacteria could be associated with severe dysbiosis in our patients. 
Shigella/Escherichia are classified under the phyla Proteobacteria, and bacteria belonging to 
this phyla have been reported increased in treated and untreated CD patients in both faecal 
and duodenal samples [159, 160, 166], and in the mucosal microbiota of CD patients with 
persistent symptoms [147]. Ruminococcus gnavus was also increased in about 40% of the 
dysbiotic patients, and increased abundance has also been detected in IBD patients and in IBS 
patients previously [167, 168]. These bacteria have the ability to form toxic products through 
b-glucuronidase activity, which may cause local colonic inflammation [169]. A higher 
abundance of Bacteroides fragilis has been detected in children with both active and non-




of proinflammatory cytokines when in contact with gliadin peptides, and therefore associated 
with CD pathogenesis. Its effect in CD patients on a GFD is not clear, but it may be that a 
higher abundance compared to normal is a result of the microbiota failing to restore after CD 
diagnosis was made.  
 
It must be mentioned that although all 54 probes were used to determine the Dysbiosis Index 
in these patients, only selected probes were used for creating an individual microbiota profile 
before and after diet due to their association with gastrointestinal diseases. This means that 
also other bacteria not presented in this study may contribute to dysbiosis, and does not make 
these findings specific enough to call it a microbiota signature in these patients. We have no 
information on diversity either. However, these bacteria might still be involved in the 
persistent symptoms of these patients. If this finding can be reproduced in other studies on CD 
patients, it could be targeted with probiotics. Probiotics have been tested as a treatment 
alternative in IBS patients, and although what species of bacteria are most effective remains 
uncertain, it has proven to have effect on symptoms [171]. There are little data on probiotics 
in CD patients, and to our knowledge, none are performed on CD patients with persistent 
symptoms [172].  
 
When looking at the total study population of 40 patients, there was a statistically significant 
decrease in the genera Ruminiclostridium and Eubacterium, and an increase in Bacillus, 
Lactobacillus, Prevotella, Pseudomonas, Atopobium and Desulfitispora at baseline. There 
have been done some studies on microbiota composition in patients with active and non-
active CD, mostly in children and mostly on duodenal microbiota, but none have found a 
distinct microbiota profile in CD patients. As far as we know, the composition of microbiota 
in CD patients with IBS-like symptoms has not been assessed before, and it is too early to tell 
what an alteration in these bacteria might entail. These results should be reproduced in order 
to be able to draw firm conclusions from it. 
 
We found a distinctive pattern in baseline bacteria in the responders of the LFD, with less 
Lactobacillus, more Atopobium (genus) and less Firmicutes (Clostridia) compared to non-
responders. If this is a true finding, it can be useful in determining who would benefit from 
the diet. Why exactly these bacteria might predict response is not so clear. Clostridia (phylum 
Firmicutes) is an abundant genus in the gut, important for homeostasis, and metabolic and 




important feature for bacteria in both these genera is the fermenting capacity of non-digestible 
carbohydrates and production of SCFA, called saccharolytic bacteria. A pattern with higher 
abundance of saccharolytic bacteria at baseline was found in responders to a LFD in children 
with IBS [117]. A possible mechanism for why more of these bacteria could determine diet 
response is their production of SCFA and gas creating symptoms in IBS patients. It is likely 
that those with lot of these bacteria would respond symptomatically to a diet where one cuts 
down on the main substrate for these bacteria, thus starving them. In our patients, there was 
more of some saccharolytic bacteria and less of others. It is not clear why exactly this would 
predict a response, but perhaps some saccharolytic bacteria are more important than others 
when it comes to diet response? Or maybe less Firmicutes (Clostridia) is an expression for 
higher abundance of other bacteria that determine diet response?   
 
An unexpected finding of the breath tests was the lack of reduction in the AUC for hydrogen 
after a LFD, despite a reduction in FODMAP intake and symptom relief. Reduction in 
fermentable substrate should in theory lead to less production of hydrogen from colonic 
bacteria. This has been shown in previous studies in patients with IBS on a LFD [85, 133]. 
Hydrogen breath test has been used in a LFD study to assess adherence to the diet, where a 
reduction in hydrogen was associated with a successful reduction in FODMAP intake and 
fermentation [85]. If we were to transfer this onto our study, our results imply that the patients 
did not reduce their FODMAP intake during the intervention. This is not very likely, with a 
self-reported compliance of 93% in group B and a reduction of FODMAPs from a mean of 
11.5 to 1.6g confirmed by patients’ food records. One can speculate also here, that since the 
FODMAP intake at baseline was relatively low, a further reduction did not impact the 
hydrogen production. It is also noteworthy that we did not see a shared decrease in fermenting 
bacteria after diet amongst the patients following the LFD. However, maybe another method 
would have been better for assessing the degree of fermentation. We decided to perform the 
breath test based on the food the patients had eaten the day before, but we had no information 
on what their last meal before the breath test was, and the patients were given no restrictions 
other than to follow their assigned diet. This opens for the possibility that some ate slowly 
digestible foods, which might have increased the amount of hydrogen. There was also seen a 
bigger reduction in hydrogen in group A, whom did not change their total FODMAP intake. 
Maybe more patients in this group by random ate easily digestible GFD meals containing low 
FODMAP the night before the second breath tests were taken? It might have been a better 




hydrogen based on that meal for three or more hours. This is more similar to previous 
methods used when assessing the LFD, which have shown reduced hydrogen production 
when on diet. 
 
Methane was produced in ten individuals at baseline. Six of these had IBS-C, three had IBS-
M and one had IBS-D. This is in accordance with previous data, showing that methane 
production is associated with constipation. One patient in group A did not produce methane 
after six weeks, which might be due to change in bacterial composition of methanogens. This 
does not imply that methanogenic bacteria are absent, as they are present in the microbiota of 
the majority of the population. However, they need to be in a sufficient amount for methane 
gas to be detected [174]. 
 
We detected an effect of the LFD on symptoms and give evidence for the effect of low 
FODMAP diet in CD patients with IBS-like symptoms, measured by IBS-SSS score 
reduction. A further improvement in symptoms during the last three weeks of diet shows that 
an elimination period of six weeks seems reasonable to evaluate effect and exclude a placebo 
effect. We also detected statistically significant symptom improvement in group A. Although 
not as effective as the LFD, it seems that some patients also benefit from excluding wheat 
starch and trace amounts of gluten from their diet. This is supported by serologic tests. It is 
also possible that some were stricter with their GFD in general during the intervention, and 
therefore experienced some symptom relief.  
 
Despite being a complex diet, there is reported a high compliance of the LFD in previous 
studies, and adherence of up to 75% could be expected. In accordance with this, our patients 
reported an adherence of 93%, which is likely to result from the patients experiencing 
symptom relief. There was observed a reduction in energy and fat intake in group B, which 
may be a result of a limited choice of foods. A reduction in fat and protein intake was also 
seen in group A, which implies that a diet intervention itself may lead to a lower food intake, 
perhaps due to more awareness of what one eats and/or skipping certain meals/snacks to avoid 
having to weigh and register. There is reported an underestimation of energy intake when 
registering food intake, but this should however be similar at baseline and six weeks. In 
general, the patients seemed to maintain a rather balanced diet throughout the intervention, 
also in fibre intake and calcium which is one of the concerns when following a LFD. The 




major carbohydrate sources, such as bread and pasta, due to already being on a GFD. This 
may have helped maintain an adequate intake. A reduction in vitamin D in group A may be 
season related, but also associated with the reduction in protein intake which may include less 
foods rich in vitamin D.  
 
It is fair to say that in general the patients seemed satisfied with the LFD instructions, as nine 
were very satisfied and nine were satisfied, but one patient answered “OK” and one was not 
satisfied. This might be an expression for the complexity of the diet, and that although 
instructed by a dietitian it can be difficult to comprehend the diet. The patients were not 
supplied with any meals during the intervention, which requires more of the patients in terms 
of planning and knowledge of the diet. However, the patients were encouraged to make 
contact if they had questions of any kind. Dietitian delivered diet instructions therefore seems 
important to ensure comprehension and compliance. 
   
4.3 Study limitations  
 
4.3.1 Recruitment and inclusion criteria  
We should have kept record of how many patients we assessed for inclusion, later contacted 
and from where they came during the recruiting phase of patients. This would have given us a 
clearer picture of what patient group we actually included in the study, and how representative 
they were for the CD population.  
 
Perhaps we should have excluded patients who had positive serology, as this finding indicates 
gluten contamination in the diet. Also, patients with possible gluten contamination in diet can 
have an ongoing inflammation which can affect microbiota, thus dysbiosis in these patients 
may be a consequence of gluten in their diet. Although recent abnormal histological findings 
was an exclusion criterion, we did not collect new duodenal biopsies. Thus, we cannot rule 
out RCD completely as a cause of persistent symptoms.  
 
Some of the patients were already familiar with the term FODMAP, and some randomized to 
group B were excited to try the diet, whilst some in group A were disappointed because they 
wanted to try the FODMAP-diet. This might have created some bias, with a placebo effect in 
group B due to expectations of effect, and a nocebo effect in group A, where some patients 




group A did not involve any great changes in the patients’ diets, which also may have 
contributed to a nocebo effect. We could have excluded all patients with knowledge of 
FODMAP in order to reduce the possible placebo/nocebo-effect. However, this would have 
protracted the recruitment process and made it more difficult.  
 
Ideally, we should have had a larger study sample. This could have given bigger effects of the 
intervention, as well as given us the opportunity to draw firmer conclusions from the study, 
rather than observations. Still, the patient number was adequate for assessing symptom relief.   
 
4.3.2 Data collection  
We did not weigh the patients, so the weight they reported at baseline is not necessarily as 
accurate as it could have been. We did not weigh the patients after the diet intervention either, 
which would have been interesting, as both group consumed less calories at six weeks 
according to their food records. There was a significant reduction in energy and fat intake in 
group B, and in fat and protein in group A. There are also studies on the low FODMAP diet 
that report a lower intake of calories during the diet, which may be an unwanted effect of the 
diet.  
 
We did not measure total IgA in the patients, so we cannot know whether those with elevated 
IgG DPG have IgA deficiency or not. Thus, only those with elevated IgA TTG were 
considered as having elevated antibodies in this study.  
 
4.3.3 Diet instructions  
The diet instructions were not given in the same way for all patients, as we were two students 
who shared this task and took turns on instructing patients in a low FODMAP diet and a strict 
gluten free diet. We also got more experienced in instructing along the study, which also will 
lead to some differences in how well the patients were instructed.  
 
4.3.4 Method for microbiota analysis  
The GA technology was useful for determining dysbiosis, and provided a microbiota profile 
report for each patient. This profile included data on bacteria relevant for gastrointestinal 
disorders, which is very central in this thesis. The test also correlates well with Illumina deep 




information on general bacterial diversity or richness. And although the human gut microbiota 
is starting to get more defined, the use of probes cannot detect unknown bacteria or low 
abundance bacteria [111, 122]. PCR amplification may also cause some bias. Due to such 
limitations, whole genome sequencing is considered to be the ideal analysis which provides 
the most information on bacterial composition, but this cost much more money and is more 
time consuming. Another alternative is shotgun metagenomic sequencing where also the 
functionalities of the bacteria are detected. It has been suggested that the metabolic 
functionalities of the bacteria are more important than taxonomy [111].   
 
4.3.5 Calculation of FODMAP-content  
As described under methods, we used Norwegian, Danish and Australian data to calculate 
FODMAP-content and intake. Most data except lactose were based on Australian analyses, 
which may differ in FODMAP-content from Norwegian foods and therefore makes our 
estimations uncertain. For composite dishes, we used standardized recipes and portion sizes to 
estimate the FODMAP-content. This is probably the most correct way to find the FODMAP-
content (unless the patient had specified the recipe and portion size), but still makes our 
estimates somewhat imprecise. There was also missing data on FODMAP-content for some 
foods known to contain FODMAPs, so the estimation of total FODMAPs in this study is 
probably lower than in real life. Total FODMAP-content was calculated and divided into 
lactose and non-lactose. The ideal would have been to separate between all the different 
FODMAPs, because they have different effect on the gastrointestinal physiology [83, 175]. 
Due to time limitations, we were not able to do that. We still wanted to divide between lactose 
and other FODMAPs, because lactose accounts for a large part of the total FODMAP-content 
in the diet, but is not likely the biggest symptom trigger in Norwegians.  
 
4.4 Future aspects  
 
Defining this patient group in terms of identifying the cause for the IBS-like symptoms 
requires further investigation. Although their symptoms resemble those seen in IBS patients, 
it is not certain that it is a subgroup of IBS.  
 
Dysbiosis should also be assessed in CD patients without IBS like symptoms and in untreated 
CD patients to determine whether the degree of dysbiosis detected in this study is distinct for 




these patients should also be assessed, which is likely to differ from the luminal microbiota 
and is more involved with the epithelial cells and the immune system.  
 
This study showed that a larger fraction of these patients had dysbiosis and a reduction of 
Bifidobacteria at baseline, as well as deviations in other bacteria. Based on these findings, it 
would have been interesting to test probiotics as a mean for symptom relief in this patient 
group. If dysbiosis in fact contributes to the IBS-like symptoms, it is possible that probiotics 
can give symptom relief.   
 
5 CONCLUSION 
We found in this study that 45% of the CD patients were dysbiotic at baseline, which is more 
than healthy controls, but less than what is found in IBS patients.  
 
We did not find the same negative effect of the low FODMAP diet on microbiota as seen in 
previous studies on IBS patients. Whether this is caused by a different bacterial composition 
at baseline, a less radical intervention or different response to the FODMAP diet than IBS 
patients is hard to tell. A small study sample does not allow us to draw any firm conclusions 
from this finding.  
 
Although we cannot determine if these patients suffer from IBS in addition to their CD, if CD 
has triggered IBS or if other mechanisms cause IBS-like symptoms, these patients do 
resemble IBS patients symptom-wise. Unless any contraindications, they should be offered 
the same dietary treatment as IBS patients, namely a low FODMAP diet in addition to their 
gluten free diet. This study has shown it to be effective for symptom relief.  
 
We also found a pattern of bacteria at baseline predictive of response to a low FODMAP diet. 
These patients seem to have a microbiota composition characterized by less Lactobacillus and 
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Appendix 2: IBS-SSS 
 
1.  Har hatt tilfredsstillende lindring av dine IBS-smerter/-ubehag de siste 7 dager? 
Sett en ring rundt svaret ditt. JA NEI 
 
 
2. a) Har du magesmerter? Sett en ring rundt svaret ditt.  JA NEI 
 
 
b) Dersom ja, hvor sterke er magesmertene? (marker på linja) 
0 %          100 % 
 
 
Ingen smerte        Veldig mye smerte 
                                                                                                                                              
 
 
c) Oppgi antall dager du har kjent magesmerter i løpet av en 10 dagers periode. 
Dersom du f.eks. skriver 4 betyr det at du har smerte 4 av 10 dager. Om du har 
smerte hver dag, skriver du 10. 
 




3. a) Har du oppblåst og/eller spent mage? Sett en ring rundt svaret ditt.  JA
 NEI 
 
b) Dersom ja, hvor mye plaget er du? (marker på linja) 
0 %          100 % 
 
 




4.  Hvor fornøyd er du med dine avføringsvaner? (marker på linja) 
0 %          100 % 
 
 
Veldig fornøyd       Veldig misfornøyd
   
      
 
5.  Angi med en strek på linja nedenfor hvor mye dine IBS-plager påvirker livet ditt                          
generelt. 
0 %          100 % 
 
 





Lider du av følgende: 
 
a) Kvalme og/eller oppkast? 
0 %          100 %  
aldri          hele tiden 
       
b) Vanskelig for å spise opp alt ved måltidet? 
0 %          100 %  
aldri          hele tiden 
 
c) Hodepine? 
0 %          100 %  
aldri          hele tiden 
 
d) Ryggsmerter? 
0 %          100 %  
aldri          hele tiden 
 
e) Uopplagt eller trøtt? 
0 %          100 %  
aldri          hele tiden 
 
f) Raping og/eller gassavgang? 
0 %          100 %  
aldri          hele tiden 
 
g) Halsbrann? 
0 %          100 %  
aldri          hele tiden 
 
h) Hyppig eller plutselig trang til vannlating? 
0 %          100 %  
aldri          hele tiden 
 
 
i) Smerter i låret? 
0 %          100 %  
aldri          hele tiden 
 
 
j) Smerte i muskler og ledd? 
0 %          100 %  





Appendix 3: SF-36 
 
SF-36 Norsk versjon 
 
SF-36® Health Survey© 1988, 2002 by JE Ware, Jr., MOT, Health Assessment Lab, 
QualityMetric Incorporated – All rights reserved 
SF-36® is a registered trademark of the Medical Outcomes Trust (MOT) 
 
 
Vi spør deg her om hvordan du opplever din egen helse. Vi ønsker å vite hvordan du 
føler deg og hvordan du mestrer dine vanlige aktiviteter.  
 
Vær snill å svare på alle spørsmål. Noen av spørsmålene ligner på hverandre, men alle er 
forskjellige. Ta deg tid til å lese spørsmålene nøye og svar med et kryss for det alternativ 
som du velger! 
 


















   
2.  Sammenlignet med for ett år siden, hvordan vil du si at helsen din stort sett er nå? 
 
Mye bedre 
nå enn for 




nå enn for 










nå enn for 




nå enn for 





















3.  De neste spørsmålene handler om gjøremål som du kanskje utfører i løpet av en 
vanlig dag. Er din helse nå slik at den begrenser deg i utførelsen av disse aktivitetene? 










meg ikke i 
det hele 
tatt 
Anstrengende aktiviteter, som å løpe, løfte tunge 
gjenstander, delta i anstrengende idrett 
○ ○ ○ 
Moderate aktiviteter, som å flytte et bord, 







Løfte eller bære en handlekurv 
○ ○ ○ 
Gå opp trappen flere etasjer ○ ○ ○ 
Gå opp trappen en etasje ○ ○ ○ 
Bøye deg eller sitte på huk ○ ○ ○ 
Gå mer enn to kilometer ○ ○ ○ 
Gå noen hundre meter ○ ○ ○ 
Gå hundre meter ○ ○ ○ 
Vaske deg eller kle på deg ○ ○ ○ 
 
  
4. I løpet av de siste fire ukene, har du hatt noen av følgende problemer i ditt arbeid 


















Har du redusert tiden du har brukt 
på arbeidet ditt eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du utrettet mindre enn du hadde 
ønsket 
○ ○ ○ ○ ○ 
Har du vært hindret i visse typer 
arbeid eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du hatt vansker med å utføre 
arbeidet ditt eller andre aktiviteter 








5.   I løpet av de siste fire ukene, har du hatt følelsesmessige problemer som har ført til 
vanskeligheter i ditt arbeid eller i andre av dine daglige gjøremål (for eksempel fordi du 


















Har du redusert tiden du har 
brukt på arbeidet ditt eller andre 
aktiviteter 
○ ○ ○ ○ ○ 
Har du utrettet mindre enn du 
hadde ønsket 
○ ○ ○ ○ ○ 
Har du ikke arbeidet eller utført 
andre aktiviteter like nøye som 
vanlig 




6.   I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller følelsesmessige 


































































8. I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige arbeid 
























 9.   De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt 
det de siste 4 ukene. For hvert spørsmål, vennligst velg det svaralternativet som best 

















følt deg full av tiltakslyst? ○ ○ ○ ○ ○ 
følt deg veldig nervøs? ○ ○ ○ ○ ○ 
vært så langt nede at 
ingenting har kunnet muntre 
deg opp? 
○ ○ ○ ○ ○ 
følt deg rolig og harmonisk? ○ ○ ○ ○ ○ 
hatt mye overskudd? ○ ○ ○ ○ ○ 
følt deg nedfor og trist? ○ ○ ○ ○ ○ 
følt deg sliten? ○ ○ ○ ○ ○ 
følt deg glad? ○ ○ ○ ○ ○ 
følt deg trøtt? ○ ○ ○ ○ ○ 
 
 
10.   I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske helse eller 














































Det virker som jeg blir litt lettere syk enn 
andre 
○ ○ ○ ○ ○ 
Jeg er like frisk som de fleste jeg kjenner ○ ○ ○ ○ ○ 
Jeg forventer at min helse vil bli 
dårligere 
○ ○ ○ ○ ○ 

















NAVN   ___________________________________________________ 
 
 
ADRESSE  ___________________________________________________ 
 
 






HØYDE  ___________________________________________________ 
 
 




KLINISK ERNÆRINGSFYSIOLOG  ______________________________________ 
 
 
Skjemaet returneres i utfylt stand til: 
 
Helse Bergen HF 














For at vi skal kunne beregne næringsstoffinntaket ditt så nøyaktig som mulig, er det nødvendig 
at du noterer alt du spiser og drikker i løpet av en 4 dagers sammenhengende periode. Perioden 
onsdag til lørdag (evt. søndag til onsdag) er best, for da får du med én helgedag. 
 
Det er vesentlig at du spiser slik som du pleier i registreringsperioden. 
 
 Angi klokkeslett for hver gang du spiser eller drikker noe.  
 Beskriv mat og drikke så nøyaktig som mulig 
 - Brød: Type, navn, grovhet, tykkelse på skiver, antall skiver. Ev. rundstykke, 
knekkebrød.. 
 - Fett på brødet: Type, navn, mengde, lett eller vanlig 
 - Pålegg: Type, mengde, produktnavn, lett eller vanlig  
 - Middag: Type kjøtt, fisk, kjøttfarse-/fiskeprodukt. Produktnavn. Fettprosent. 
 - Frukt og grønnsaker: Rå, kokt eller hermetisk.  
 Beskriv hvordan maten er tilberedt. 
- Kokt, bakt, stekt, grillet eller varmet i mikrobølgeovn 
 - Er maten er renset for skinn og/eller fett? 
 Hjemmelagede matretter beskrives i detalj, gjerne ved å skrive ned oppskriften bak på arket. 
 Notér alt tilbehør, som saus, pickles, rømme, dressing eller krem, med navn/produsent. 
Oppgi også om du bruker sukker på gryn, grøt eller i te.  
 Få med alle mellommåltider, samt tilfeldig spising og drikke utenom de faste måltidene.  
 Kosttilskudd, som tran, vitamintabletter o.l. skal også noteres, med navn, produsent og 
mengde. 
 Mengder kan beskrives på følgende måte: 
 - aller helst skal du veie maten og føre mengden opp i gram 
 - hvis du ikke kan veie, kan du angi mengder i husholdningsmål, som   
   spiseskje, glass, desiliter eller antall, alt ettersom hva som er hensiktsmessig  
- oppgi størrelse på glassene du bruker i dl 
 
Eksempel: 
Kl Tirs dag 14 / 1 / 11 Produktnavn/Produsent Vekt  
0730 1 butikkskåret skive kneip Bakers 30g 
 m/ skrapet lag margarin Soft Soya  
 3 høvelskiver hvitost, 16% fett Norvegia, Tine  
 1 stor grapefrukt  200g 
 1 stort glass lettmelk (Stort glass = 2 dl) Tine  
1100 1 beger fruktyoghurt Yoplait Dobbel 0%, mango 125g 
 1 melkesjokolade  Freia 100g 
 1 kopp svart kaffe  150g 
1500  kokt torsk  140g 
 3 små potete, kokt  150g 
 3 toppede ss revet gulrot   
 1 ss remulade Idun  
 2 store glass saft Lerum uten tilsatt sukker  






Kl ...... dag  ... / ... / ... Produktnavn/Produsent Vekt 
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Kl ...... dag  ... / ... / ...  Produktnavn/Produsent Vekt 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    







Appendix 5: Compliance questionnaires for the low FODMAP diet 
 
Overholdelse av lav-FODMAP dietten gjennom 6 uker 
 
Hvor fornøyd er du med lav-FODMAP dietten som symptomlindring?  
 
Svært fornøyd                                                                         Svært misfornøyd 
 
0%                                                                                                                          100% 
 
 




 Kun dersom jeg får videre veiledning 
 
 
Hvis nei, hvorfor: 
 For tidkrevende 
 Savner for mange matvarer 
 Ble ikke bedre 
 For dyrt 
 
 
Hvor nøye har du fulgt lav-FODMAP dietten gjennom de 6 ukene? 
 
Ikke fulgt den i det hele tatt       Kun spist lav-FODMAP mat                                                                                                                                                                       
  




Hvor ofte hadde du avvik fra dietten løpet av de 6 ukene: 
 Ingen ganger 
 1-5 ganger i løpet av de 6 ukene 
 1-3 ganger i uken 
 4-6 ganger i uken 
 
 
Hvor store mengder FODMAPs inntok du ved avvik fra dietten? 
 En munnfull 
 2-5 munnfull 
 Et helt måltid 








Hvor lenge gikk du på dietten før du spiste matvarer med FODMAPs : 
 Ingen dager 
 1-3 dager 
 4-7 dager 
 2-3 uker 
 3-5 uker 
 
 
Hvilken matvarer inneholdt avvik fra dietten: 
 Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, 
svisker, aprikos), asparges  
 Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose 
(vafler, boller, kaker, is etc.), melkesjokolade. 
 Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel 
brød, boller, vafler, kjeks, middagsmat med hvetemel. 
 Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, 
krydder, ferdigretter.  
 Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
 Polyoler som man finner i sukkerfrie pastiller eller tyggis. 




Hvordan synes du det var å følge dietten: 
 
Kjempelett          Veldig utfordrende 
            
  0%                                                                                                      100% 
  
 
Hvorfor spiste du matvarer som inneholdt FODMAPs: 
 Spiste kun lav-FODMAP mat 
 Ikke tilgang på lav-FODMAP mat på restaurant/gatekjøkken 
 For tidkrevende å lage lav-FODMAP mat 
 Hadde lyst på mat med FODMAP 
 Lav-FODMAP mat var for dyr 
 Visste ikke at matvaren inneholdt FODMAPs 
 
 
Hvor fornøyd er du med informasjonen du fikk om dietten: 









Overholdelse av lav-FODMAP dietten én måned etter 
diettslutt 
 







Hvor godt har du oppretthold lav-FODMAP dietten etter 1 mnd? 
 
Gått tilbake til  
mitt normale kosthold                                                   Kun spist lav-FODMAP 
 




Hva er grunnen til at du ikke spiser 100 % lav-FODMAP lenger? 
 Ikke aktuelt, følger fortsatt dietten for fullt 
 Merket ikke noe effekt av dietten 
 Merket ikke god nok effekt til å ofre mitt vanlige kosthold 
 Det er kun noen matvarer jeg reagerer på 
 Savnet for mange matvarer 
 
 
Dersom du har fulgt dietten, har du reintrodusert noen FODMAPs? 
 Ja 
 Nei 
 Kun noen matvarer 
 Prøvd, men ble dårlig av alt 
 
 
Hvordan synes du det var å reintrodusere matvarer til dietten? 
 
Kjempelett                                                                                  Meget vanskelig 
 






Hva var utfordrende med reintrodusering av matvarer: 
 Visste ikke hvordan jeg skulle gjøre det 
 At jeg mest sannsynligvis kom til å få symptomer av den matvaren 
 Vanskelig å skille «normale symptomer» med strikt diett (jeg ble ikke helt frisk 
med dietten) og symptomer jeg evt får når jeg innfører ulike FODMAPs igjen 
 Vanskelig å vite om jeg fikk symptomer fra akkurat den matvaren 
 Hadde ikke problemer med re-introdusering 
 Ville ikke reintrodusere noen matvarer 
 
 
Hva var det du prøvde å reintrodusere først? 
 Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, 
svisker, aprikos), asparges  
 Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose 
(vafler, boller, kaker, is etc.), melkesjokolade. 
 Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel 
brød, boller, vafler, kjeks, middagsmat med hvetemel. 
 Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, 
krydder, ferdigretter.  
 Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
 Polyoler som man finner i sukkerfrie pastiller, tyggis, avokado, aprikos, blomkål, 
plomme, sopp og vannmelon. 
 
 
Kommer du til å fortsette på lav- FODMAP dietten fremover? 






Hvilken type FODMAP tror du at du ikke tåler? Flere kan krysses av. 
 Tåler alle 
 Tåler ingen 
 Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, 
svisker, aprikos), asparges  
 Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose 
(vafler, boller, kaker, is etc.), melkesjokolade. 
 Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel 
brød, boller, vafler, kjeks, middagsmat med hvetemel. 
 Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, 
krydder, ferdigretter.  
 Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
 Polyoler som man finner i sukkerfrie pastiller, tyggis, avokado, aprikos, blomkål, 







Appendix 6: Compliance questionnaire for a stricter gluten free diet  
 
Overholdelse av strikt glutenfri kost gjennom 6 uker  
 
Hvor fornøyd er du med strikt glutenfri kost som symptomlindring?  
 
Svært fornøyd                                                                                   Svært misfornøyd 
 
0%                                                                                                                        100% 
 
 




 Kun dersom jeg får videre veiledning 
 
 
Hvis nei, hvorfor: 
 For tidkrevende 
 Savner for mange matvarer 
 Ble ikke bedre 
 For dyrt 
 
 
Hvor nøye har du fulgt strikt glutenfri kost gjennom de 6 ukene? 
 
Ikke fulgt den i det hele tatt                    Kun spist strikt glutenfri kost  
  




Hvor ofte hadde du avvik fra dietten i løpet av de 6 ukene: 
 Ingen ganger 
 1-5 ganger i løpet av de 6 ukene 
 1-3 ganger i uken 
 4-6 ganger i uken 
 
Hvor store mengder inntok du ved avvik fra dietten? 
 En munnfull 
 2-5 munnfull 
 Et helt måltid 








Hvor lenge gikk du på dietten før du spiste matvarer med hvetestivelse/spor av gluten: 
 Ingen dager 
 1-3 dager 
 4-7 dager 
 2-3 uker 
 3-5 uker 
 
 
Hvordan synes du det var å følge dietten: 
 
Kjempelett          Veldig utfordrende 
            
  0%                                                                                                      100% 
  
 
Hvorfor spiste du matvarer som inneholdt hvetestivelse/spor av gluten: 
 Spiste kun strikt glutenfri kost  
 Ikke tilgang på mat uten hvetestivelse/spor av gluten på restaurant/gatekjøkken 
 For tidkrevende  
 Hadde lyst på mat med hvetestivelse/spor av gluten 
 Mat uten hvetestivelse/spor av gluten var for dyr 
 Visste ikke at matvaren inneholdt hvetestivelse/spor av gluten 
 
 
Hvor fornøyd er du med informasjonen du fikk om dietten: 













Appendix 7: Information on gluten free diet  
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Hva er gluten?  
  
Gluten er en fellesbenevnelse på tre forskjellige, men likevel ganske like, proteiner 
som finnes i hvete, rug og bygg. Vanlig havre kan også inneholde gluten på grunn av 
forurensing fra andre kornslag. Kornslagene spelt, dinkel, kamut og rughvete 
inneholder også gluten.  




Ved cøliaki skades tarmen ved inntak av gluten, og evnen til å fordøye maten avtar. 
Dette medfører at en redusert mengde av matens næringsstoffer tas opp som igjen 
kan føre til magesmerter og underernæring   
Hos barn er et vanlig symptom på cøliaki at vekstkurven flater ut.   
Hos voksne er de klassiske symptomene på ubehandlet cøliaki jernmangel, diaré og 
avmagring, mens noen opplever trøtthet og dårlig matlyst. Det er heller ikke uvanlig å 
ikke ha symptomer i det hele tatt.   
  
  
                
  Frisk tarm        Skadet tarm  
  
Når de som har fått stilt diagnosen cøliaki konsekvent holder en glutenfri kost, vil 
tarmen leges. Fordøyelsesproblemene vil avta og kroppen vil kunne utnytte maten på 
vanlig måte.   
  
Tarmslimhinnen vil alltid reagere på gluten og selv små mengder kan gi tilbakefall, 
med eller uten symptomer. Derfor må et glutenfritt kosthold følges strengt og vare 
livet ut.   
  













Dermatitis herpetiformis (DH)  
  
Dette er en relativt sjelden hudsykdom med kløende utslett og væskefylte blemmer. 
Tarmslimhinnen er også angrepet på lignende måte som ved cøliaki, men vanligvis i 
noe mindre grad. Dette fører i mange tilfeller til underernæring, men sjelden til større 
problemer med fordøyelsen. Glutenfri kost er en viktig del av behandlingen av DH.   
  
Tarmslimhinnen blir normal på glutenfri kost og hudsymptomene vil ofte bedres, 
men det kan ta opptil et par år.   
  
Enkelt kan også ha nytte av jodredusert kost, og vil kunne få veiledning i forhold til 
dette.   
  
  
Hveteallergi / hveteintoleranse   
  
Ved hveteproteinallergi og hveteintoleranse vil det i tillegg til reaksjon på hvete ofte 
forekomme kryssreaksjoner på rug og bygg. Derfor brukes ofte glutenfri kost.  
Samtidig intoleranse overfor havre er mindre vanlig, men vanlig havre kan være 
forurenset med små mengder hvete som gir reaksjon. Velg derfor havre som er 
merket ren eller glutenfri. (se s. 7).  
  




  Grant Cochrane/FreeDigitalPhotos.net  
  
  
Innholdsdeklarasjon og merking av glutenfrie produkter  
  
Alle ferdigpakkede matvarer skal være merket med en innholdsdeklarasjon, som skal 
være skrevet på norsk, svensk, dansk eller engelsk. Innholdsdeklarasjonen er det 
beste hjelpemiddel man har til å vurdere om et sammensatt produkt er glutenholdig.   
  
Merkeforskriften setter særlige krav til merking av allergener. Dette innebærer at en 
rekke matallergener inkludert gluten/glutenholdige ingredienser alltid skal 




ingredienser som inneholder gluten (se side 10). Matvarer som er merket med svært 
lavt gluteninnhold eller glutenfritt kan brukes uten at man må sjekke 
ingredienslisten.   
  
Dessverre er ikke alle matvarer merket med innholdsdeklarasjon. Dette gjelder bl.a. 
ferskvarer og andre produkter som selges i løs vekt. I slike tilfeller må man forhøre 
seg hos butikkbetjeningen eller produsenten. Ikke bruk matvarer med ukjent 
sammensetning!  
  
Det forekommer en gang i blant at produsenten endrer oppskrifter slik at tidligere 
glutenfrie produkter får ny, glutenholdig, ingrediens, sjekk derfor deklarasjonen på 
produkter du kjenner fra tid til annen.  
  
Et nytt, strengere, regelverk for merking av glutenfrie produkter trådde i kraft i 2012. 
Det nye regelverket innebær at den øvre grensen for innhold av gluten senkes fra 200 
mg gluten/kg til 100 mg gluten/kg.  
  
  
Svært lavt gluteninnhold:   
Produkter merket med ”svært lavt gluteninnhold” kan ikke ha et gluteninnhold som 
overstiger 100 mg/kg i produktet som selges til forbrukeren.  Gluteninnholdet i disse 
matvarene er så lave at de kan trygt brukes av de aller fleste med cøliaki.   
  
Glutenfri:      
Produkter merket med ”glutenfri” skal inneholde mindre enn 20 mg gluten/kg ferdig 
produkt. Produkter som tidligere ble merket ”naturlig glutenfri” skal i henhold til den 
nye forskriften merkes ”glutenfri”.    
  
Ubearbeidet frukt, bær, grønnsaker, kjøtt og fisk vil ikke bli merket som glutenfrie 











”Kan inneholde spor av...”  
  
Mange matvarer er merket med ”spor av” hvete, gluten eller andre glutenholdige 
ingredienser. Denne merkingen innebærer ikke at hvete eller andre glutenholdige 
ingredienser inngår som en del av produktet, men at produktet er laget i omgivelser 
der det også lages glutenholdige varer. Produksjonsomgivelsene innebærer altså en 
risiko for at det merkede produktet kan være kontaminert.  Erfaring tilsier at disse 
produktene kan brukes av de aller fleste med cøliaki fordi spormengdene er svært 













   




     
  
  
Rene råvarer fra matvaregruppene melk, kjøtt, fisk, egg, ris, poteter, grønnsaker, frukt 
og bær er naturlig frie for gluten. Disse matvarene er en viktig del av et næringsrikt 
kosthold, og bør inngå i glutenfritt kosthold.   
  
Spis normale mengder kjøtt, fisk, egg og meieriprodukter, som gir protein, vitaminer 
og mineraler. Grønnsaker, poteter, frukt og bær gir i tillegg karbohydrater og fiber, og 
bør brukes i større mengder hver dag. Som i sunn kost ellers bør man begrense 
inntaket av produkter rike på fett og sukker, som ”fast food”, kaker, kjeks, godteri og 
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Kan inneholde gluten.  
  
Glutenfrie alternativer må  




Havre ved cøliaki  
  
Glutenfri havre / Ren havre  
Glutenfri havre tåles av de fleste med cøliaki. Vanlig havre kan være forurenset med 
gluten fra industriell produksjon og bearbeiding. Det må derfor kun brukes havre og 
havreprodukter som er merket ”ren” eller ”glutenfri”.   
Det anbefales at havre introduseres etter at glutenfri diett er veletablert og pasienten 
er symptomfri. Eventuelle reaksjoner på havre kan da lettere oppdages og følges opp. 
Fordi noen kan få mage-tarmsymptomer på grunn av det høye fiberinnholdet i havre, 
anbefales gradvis innføring av havre i kostholdet. Bruk av havre kan på en positiv 
måte bidra til økt fiberinntak i glutenfri kost og kan gi større variasjon i kosten.  
For barn anbefaler fagrådet i Norsk cøliakiforening at man venter med å introdusere 





   www.axa.no  
Laktoseredusert kost  
  
Fordøyelsen av melkesukker (laktose) er ofte nedsatt når tarmen er skadet. Vanlig 
melk, brunost og iskrem medfører ofte mageknip og mye luft i tarmene.   
Laktosefrie melkeprodukter og alle hvitoster inneholder ingen laktose og tåles godt. 
Syrnede melkeprodukter, som kulturmelk og yoghurt i begrensede mengder, samt 
laktoseredusert lettmelk, tåles også av de fleste. Etter ca 6 uker tåler de fleste noe 
laktose, og melk og brunost kan gradvis introduseres i kosten igjen.   









Oversikt over matvarer som er glutenfrie, samt matvarer som 
inneholder glutenholdige ingredienser  
Matvarer  Glutenfritt/svært lavt gluteninnhold  Glutenholdig, kan ikke brukes  
Melk og ost  Alle sorter melk og andre 
meieriprodukter som   
Yoghurt, skyr  
Ost  
Rømme, kesam, creme fraiche,   
  
  
Yoghurt m/müsli  
Søst, gomme lagd med glutenholdige 
matvarer   
  
Kjøtt, fisk og 
egg  
Alle sorter rent kjøtt, innmat,  




Alle sorter ren fisk, lever, rogn, 
farsevarer uten gluten.  
  
Alle sorter skalldyr.  
  




Pølser, panert kjøtt og kjøttfarser tilsatt 
glutenholdige ingredienser.   
  
Leverpostei kan inneholde hvetemel.  
  
Panert fisk og fiskefarser tilsatt 
glutenholdige ingredienser.  Fiskekaker 
o.l. kan være tilsatt glutenholdige 
ingredienser som kavring/hvetemel  
  
Griljert og fritert mat kan inneholde mel 
og kavring.   
 Gryn, mel  




















Flak, gryn og mel av amarant, 
bokhvete, hirse, mais, ris, soya, 
tapioka, quinoa og teff.  
  
Ren havre (merket glutenfri)  
  
Polentagryn, potetmel, potetfiber, 
sagogryn, kastanjemel, ,arrowrot,  
sesamfrø, solsikkefrø, linfrø, 
valmuefrø, kokosmasse, 
sukkerroefiber og psylliumfrøskall.  
  




Glutenfrie varianter av brød, 
knekkebrød, flatbrød, kjeks, kaker, 
pølsebrød, rundstykker, kavring og 
lomper.  
  
Flak, gryn og mel av hvete, rug, bygg  
og vanlig havre   
Rughvete, spelt  
  
Vanlig havre.  
  
Semulegryn, hvetekli, hvetekim  








Vanlig brød, knekkebrød, kjeks,  








Gryn, mel  
og brød  
  
Puffet ris, cornflakes uten 
maltekstrakt,  Glutenfri 
pasta, ris.   
  
Barnegrøt: ris- og maisgrøt og andre 
glutenfrie grøter. Sinlac grøt.  
  
Sausejevning av mais.  
  
  
Vanlig pasta, hveteris, byggris  
  




frukt og bær  
Alle rene varer.  
  
Stuinger o.l. tilsatt glutenholdige 
ingredienser.  
Sprøstekt løk kan inneholde hvetemel.  
  
Fett, olje  Olje, margarin, smør, majones, 





Søtt pålegg, honning, drops, sjokolade 
uten glutenholdig kjeks/crisp, ekte 
marsipan, lakris, lakrisprodukter uten 
gluten og karamell uten gluten.   
  
Sjokolade/sjokoladepålegg med 
kjeks/crisp, mandelmasse tilsatt gluten, 
enkelte lakris- og karamellprodukter, 
maltekstrakt og konfekt med 
glutenholdig fyll.  
Drikke  Kaffe, te, melk, juice, saft, iste, kakao og 
smoothie (uten glutenholdig 
gryn/korn)  
  
Øl laget på malt fra glutenfrie 
kornsorter som hirse, bokhvete, 
sorghum eller teff.  
  





Øl   






Soyasaus uten gluten, buljong uten 
gluten, krydder og ølgjær uten gluten.  
  
De fleste sauser, gryteretter og supper.  
  
Enkelte chipstyper og nøtteblandinger 
kan være tilsatt kavring/brødsmuler.  
  
Maltekstrakt, soyasaus med hvete, 
buljong med gluten, krydderblandinger 






Ingredienser   
  
Produsenter er forpliktet til å oppgi om et sammensatt produkt inneholder 
glutenholdige ingredienser men det krever at man selv vet hvilke ingredienser det 
gjelder.   
  Ingredienser* som inneholder gluten:  Ingredienser* som er glutenfrie  
A    Amarant, Arrowrot,  
B  Bygg, Brødsmuler  Bakepulver, Bokhvetemel  
C  Cous-cous  Carob,  
D  Dinkelhvete, Durumhvete    
  
E    E-nr. (alle er glutenfrie), Emulgeringsmel,  
F  Fullkornsmel   Fruktkjernemel, Fortykningsmiddel,  
G  Grynmel, Grahamsmel  Glukosesirup av hvete, Glutamat,  
Glutaminsyre, Glutinous (ris), Glukosesirup  
(alle typer), Glyserol, Guarkjernemel,  
Guargum, Glutenfri havre   
H  Havre (vanlig), Havrekli, Havrekorn,  
Havremel, Hvete, Hvetekim, Hveteprotein, 
Hvetestivelse**  
Havre (glutenfri), Hirse, Humle,  
Hvetestivelse**, Husk (psylliumfrøskall),   
J    Johannesbrødkjernemel,  
  
K  
Kamut (egyptisk hvete), Kavring, Kim, Kli, 
Korn, Kruskablanding  
Kastanjemel, Kikertmel (rent),  
Klumpforebyggende middel, Kostfiber 
(produsenten opplyser dersom kostfiber er 
fra glutenholdige råvarer),  
    Linfrø,  
M  Malt, Maltekstrakt, Maltsirup  Maltodextrin (fra hvete), Maltarom, Maltose, 
Maltsukker, Mandelmel (rent), Modifisert 
stivelse (dekstrin fra hvete), 
MSGsmaksforsterkere E621 og E637,  
N  Nudler    
P  Puffet havre, Puffet hvete  Polentagryn, Potetfiber, Potetmel, Prekokt 
rismel, Psylliumfrø, Psylliumfrøskall (husk)  
Q    Quinoamel,  
R  Rug, Rugmel, Rugmalt  Ris/villris, Risbakemel, Rismel,  
  
S  
Semulegryn, Spelt, Strøkavring, Strømel  Soyagryn, Soyamel, Sorghummel, Sesamfrø,  
T  Tritikale   Tapioka, Tarakjernemel, Teff,  
V    Valmuefrø  
Ø  Ølgjær.    
  
* Listen er ikke komplett. Se www.ncf.no for bredere oversikt.  
**Hvetestivelse kan være glutenfri og glutenholdig, avhengig av hvor godt renset hveten er. Dette 
opplyses det oftest om på varedeklarasjonen. Ved usikkerhet kontakt produsenten. Hvetestivelse 




Stivelse og maltsukker  
  
Både maltsukker, maltodekstrin og maltose er glutenfrie karbohydrater som ikke 
inneholder gluten. Stivelse kan være utvunnet av hvete, potet, ris eller annet. Dersom 
det er hvetestivelse skal dette være angitt på pakken. Hvetestivelse er renset for 
gluten, slik at den kommer under definisjonen ”glutenfri”, og produkter med 
hvetestivelse inngår derfor i den glutenfrie kosten. Noen få cøliakere med veldig 
sensitiv tarm kan likevel reagere på hvetestivelse og må utelate dette fra kosten.   
  
Vegetabilsk protein  
  
Hydrolyserte og modifiserte vegetabilske proteiner, som for eksempel er i 
buljongpulver og buljongterning, har gjennomgått så store forandringer at de ikke 
gjenkjennes som gluten og gir dermed ikke tarmskade, selv om det skulle være 
proteiner fra hvete, rug eller bygg.    
  
Tilsetningsstoffer (E-nummer)  
 
Alle tilsetningsstoffer (E-numre) som er godkjente for bruk i Norge er glutenfrie og 
hvetefrie. Dette gjelder også alle typer glutamat, glutaminsyre og alle 








                          
              
    
Norsk cøliakiforening (NCF) 
gir ut et Ingrediensleksikon 
som kan bestilles fra deres 




Glutenfrie spesialprodukter  
Det finnes en rekke glutenfrie varianter av brød, melblandinger, pølsebrød, kjeks, 
kaker, knekkebrød osv. Slike glutenfrie spesialprodukter bør erstatte de matvarer 
som må fjernes fra kosten. Produsenter av glutenfrie produkter er (listen er ikke 
fullstendig).  
  
• Toro  
• Finax  
• Semper   
• Hammermühle   
• Schär  
• Holmen Crisp  








Forhandlere av glutenfrie produkter  
   
De fleste matvarebutikker og helsekostforretninger har glutenfrie produkter i 
varierende utvalg.  Det finnes også flere nettbutikker som har et omfattende 
sortiment av glutenfrie varer og som leveres per post, f. eks. www.allergikost.no eller 
www.allergimat.no. For flere nettsteder, se www.ncf.no og klikk på Linker  
  
Mange bakerier produserer glutenfritt brød som kan fås ferskt på bestilling og ellers 


















Gode råd for glutenfri baking og matlaging  
Her følger noen tips fra erfarne cøliakere som det kan være verdt å ta med seg:  
 
Det viktigste bakerådet: Bruk fiberhusk i all gjærbakst!    
Fiberhusk løses i væske i et par minutter og tilsettes melet. Du får en mye bedre deig å 
arbeide med, og du får et saftigere bakverk som holder seg lenger uten å smule. Bruk 1 
ss per ½-1 kg mel. Fiberhusk er psylliumfrøskall som virker ved å øke innholdet av 
geldannende fibre i brødet.  
   
• Til brødbaking kan du gjerne velge grov brødmix og tilsette linfrø, sesamfrø, hirse, 
solsikkefrø og/eller bokhvete for å øke fibermengden i brødet. NB! Mengden bør 
ikke være for stor, for da holder ikke brødet ikke sammen. Opptil 1 dl pr brød går 
bra, prøv deg frem. For dem som ikke liker ”klumper” i brødet kan man male nøttene 
før man tilsetter det til brød.   
• Frys brødet ferskt hvis du baker mer enn det du trenger for en dag. Del det gjerne 
opp slik at du kan ta frem mindre mengder om gangen.  
• Litt olje i brødet forbedrer holdbarhet og konsistens.  
• Bokhvete, hirse, mais, soyabønner og ris finnes som mel, flokker og gryn/bønner, og 
kan brukes til baking og i matlaging. Det vil øke matens fiberinnhold, 
næringsinnhold og ikke minst gi variasjon. Ferdig kokte linser kan også tilsettes 
baksten.  
• Pannekaker, vafler, kjeks og kaker kan lages av glutenfri brødmix, gjerne tilsatt 
fiberhusk. Varier gjerne ved å tilsette soyamel, bokhvetemel og/eller andre typer 
glutenfrie gryn eller mel.  
• Supper, sauser og stuinger kan jevnes med lys melblanding, f.eks Toro’s fin kakemix, 
eller maisenna.   
• Glutenfri panering og strøbrød kan lages av glutenfritt brød som tørkes og males, 
eller det kan kjøpes ferdig i helsekostbutikken.  
• De fleste vanlige oppskrifter på kokosboller, kokosmakroner, kransekake og 
marengs er glutenfrie.  
• Dekk brødformen med smurte strimler av bakepapir så slipper brødet.  
• Mange av dine «gamle» oppskrifter kan brukes.  Erstatt hvetemel med glutenfritt 
mel, doble mengden hevemiddel, og tilsett et egg for å få det til å henge bedre 
sammen. I stedet for egg kan du øke mengden glutenfritt mel i forhold til mengden 
hvetemel.   
• Bruk kjøkkenmaskin til gjærbakst, lag deigen løs og la maskinen arbeide deigen 
godt.  Deigen kan være klisset, og i stedet for å bake brødene kan de helles rett i 
brødformer. Ved utbaking av boller og rundstykker kan det hjelpe å fukte hendene 
med olje eller lunkent vann og hjelpe til med en skje for å få form. Kjevle og 
bakeunderlag i plast egner seg ekstra godt til glutenfri baking.  
• Tørt bakverk kan fuktes litt og varmes i f. eks brødrister. Mange synes glutenfritt 
brød smaker bedre når det er ristet.  
• Mange foretrekker å kjøpe en brødbakemaskin som baker brød på natten. Da kan 






Oppskrifter på glutenfritt bakverk og matretter er det ikke blitt plass til i dette heftet. 
Det finnes en rekke kokebøker med glutenfrie oppskrifter som du kan kjøpe i 
bokhandelen. Det finnes også flere nettsteder og blogger med oppskrifter og råd om 
glutenfri matlaging.   
  
Norsk cøliakiforening arrangerer forskjellige matlagings- og bakekurs.   
  
Et utvalg av glutenfrie kokebøker:  
- Glutenfrie tradisjoner fra hele verden. Henriette Pecühle (2011) Kolofon.  
- Glutenfri mat godt og sunt. Gjærbakst og kaker. Else Lill Münter Rolfsen, Ruth 
Solheim Aag (2007) Kolibri forlag.   
- Glutenfri mat - godt og sunt. Småretter og middager. Else Lill Bjønnes og Bjørn 
Wiborg (2010) Kolibri forlag.  













Litt mer informasjon  
  
- om cøliakiforeningen  
Norsk Cøliakiforening (NCF) er en interesseorganisasjon/pasientforening for 
mennesker med cøliaki eller dermatitis herpetiformis (DH). NCF ble opprettet i 1974. 
De har utarbeidet flere informasjonsbrosjyrer om cøliaki og glutenfritt kosthold og 
utgir medlemsbladet Cøliaki-nytt fire ganger årlig. De arbeider kontinuerlig for å 
ivareta medlemmenes interesser gjennom informasjon, opplysning og bidrag til 
forskning. De arbeider for å bedre tilgangen til glutenfrie produkter og bevisstgjøring 
av produsenter på betydningen av korrekt deklarering av alle matvarer.  
  
NCF har en informativ hjemmeside på internett som oppdateres jevnlig og har lenker 
til andre nyttige hjemmesider: www.ncf.no   
  
Du kan også kontakte foreningen per brev eller telefon:   
Norsk Cøliakiforening, Pb 351 – Sentrum, 0101 Oslo.   
Telefon: 22 40 39 00  
         
- om lokallaget  
NCF har et aktivt fylkeslag i Hordaland og Sogn og Fjordane, som arrangerer bl.a. 
møter og bakekurs. De har opprettet kontaktpersoner som bistår med hjelp til 
nydiagnostiserte cøliakere.   
  
- om cøliaki-poliklinikken  
Du kan også ringe cøliakipoliklinikken på Haukeland universitetssykehus: 55 97 29 
40, tirsdager klokken 16-18. Telefonen bemannes av frivillige fra cøliakiforeningen.  
  
- om grunnstønad:  
Diagnosen cøliaki gir automatisk rett til grunnstønad for å dekke merutgifter til 
matvarer. For tiden (juni 2011) gjelder sats 2: 948 kr/mnd, for barn opp til 3 år og 
sats 4: 1833 kr/mnd, for alle andre.   
  





Første uken på glutenfritt  
Kjøp ferdigbakt glutenfritt brød til hele første uken, skjær i skiver og frys ned. Glutenfri 
baking krever trening. Du kan ikke regne med å få godt bakeresultat de første gangene 
du prøver, så sørg for å ha nok brød, knekkebrød og kjeks den første tiden.  Mesteparten 
av maten kan du kjøpe i dagligvarebutikken.   
Handleliste med glutenfrie matvarer   
• Potet og ris  
• Glutenfri pasta og glutenfritt brød/knekkebrød  
• Rene kjøttprodukter (inkl. karbonadedeig og kjøttdeig)  
• Kjøtt (rent) fra kylling, kalkun og andre fugler  
• Kjøtt (rent) fra fisk og skalldyr  
• Egg  
• Hvitost, brunost og de fleste smøreoster  
• Syltetøy  
• Melk og melkeprodukter (yoghurt, rømme, fløte etc, ev laktosefrie 
alternativ)  
• Frukt og bær   
• Grønnsaker og rotfrukter  
• Margarin, lettmargarin, smør, flytende margarin og olje  
• Salt, pepper og alle rene urtekrydder   
• For jevning: Maisenna eller potetmel  
 
- bibliotek, bokhandel eller internett  
En glutenfri kokebok er god å ha. Foruten oppskrifter finner du informasjon om 
andre korn- og melsorter som kan erstatte hvetemel, fibertilskudd og bakeråd. Mye 
av denne informasjonen finner du også på internett. Start på hjemmesiden til 
cøliakiforeningen: www.ncf.no og benytt lenkene derfra.  
 
- cøliakiforeningen  
Kontaktpersonene i cøliakiforeningen vet at det kan være tøft å få diagnosen cøliaki, 
spesielt hvis baksten slår feil og maten smaker annerledes. Kontakt de dersom du har 
spørsmål om glutenfri matlaging eller om du bare vil prate litt.   
 
- trygdekontoret  
Kontakt trygdekontoret for å få sendt inn søknad om grunnstønad så fort som mulig, 
slik at du raskt får utbetaling av merkostnader i forbindelse med dietten. 
Diagnosetidspunktet regnes som diettstart og du får betalt fra denne dagen. Det er 
også mulig å søke trygdekontoret om refusjon av utgifter til tannskader som har 
sammenheng med cøliaki.   
 
-”glutenfri sone”  
For å unngå at smuler fra vanlig brød kommer i kontakt med glutenfritt brød, kan det 
være lurt med egen brødboks til glutenfritt brød, egen skjærefjøl, egen brødkniv og 
kanskje en egen brødkurv. Dersom det brukes mye, kan det være praktisk med en 
egen brødrister til glutenfritt brød. Eventuelt kan man bruke toastposer utenpå 
brødskivene i brødristeren. Toastposer er også praktisk å ha med seg på reise (kan 
kjøpes blant annet på allergimat.no og allergikost.no).    













I denne brosjyren finner du informasjon om FODMAP og tips til hvordan en FODMAP-
redusert kost kan settes sammen. 
 
Hva er irritabel tarm? 
Irritabel tarm, eller irritable bowel syndrome (IBS), er en tilstand som kan medføre ulike 
plager i mage og tarm. Typiske symptomer er kvalme, mageknip, magesmerter, 
oppblåsthet, utspilt mage og luft/gass og rumling i tarmen. Man kan også oppleve 
avføringsforstyrrelser som diaré, forstoppelse eller vekslende løs og hard avføring. 
Symptomene kan komme og gå i perioder. Stress og bekymring kan forverre 
symptomene, og for noen kan plagene utløses eller forverres av mat eller drikke. 
Irritabel tarm kan være plagsom, men ikke farlig. Det er ikke kjent hva som er årsakene 




Generelle råd ved irritabel tarm 
 
Mange opplever bedring når de følger disse rådene: 
 
    Regelmessige måltider med sunn og variert kost 
    Flere små måltider er bedre enn få store 
o 4-6 måltider daglig, med ca. 3-4 timer mellom hvert måltid 
    Ro rundt måltidet 
    Regelmessig liv med god balanse mellom aktivitet og hvile 
    Tilskudd av geldannende fiber, som ViSiblin, FiberHusk, Psyllium og Benefiber. 
NB! Viktig med rikelig væskeinntak i tillegg. 
    Mat som kan gi problemer: 
o Fet mat 
o Stekt mat 
o Røkt og sterkt saltet mat 
o Sterkt krydret mat 
o Mye kostfiber 
o Mat med mye tungtfordøyelige karbohydrater (FODMAPs) 
o Kaffe og annen koffeinholdig drikke (te, cola og energidrikker) 
 
© Nasjonal kompetansetjeneste for Mage-tarm sykdommer 





Inneholder ikke FODMAP 
Inneholder FODMAP 
FODMAP-redusert kost 
Australske forskere (Peter Gibson og Sue Shepherd) har utviklet en kost, «FODMAP-




Hva er FODMAP? 
FODMAP er en forkortelse for fermenterbare oligo-, di- og monosakkarider og (and) 
polyoler. Dette er karbohydrater som tynntarmen kan ha vanskeligheter med å bryte ned 
og absorbere. Når de ufordøyde karbohydratene kommer til tykktarmen, vil de trekke til 
seg væske og forårsake gjæring. Dette kan gi problemer med gassdannelse, 
magesmerter, oppblåsthet, diaré og/eller forstoppelse. 
 
Slik går du fram 
En rekke studier har vist at flesteparten av alle som lider av irritabel tarm har god effekt av 
FODMAP-redusert kost. Dersom du vil teste om denne dietten kan ha effekt hos deg, 
anbefales det å unngå/begrense matvarer med høyt FODMAP-innhold i 4-8 uker. 
Se tabelloversikt fra neste siden, hvor matvarene er kategorisert i rød, oransje og grønn 
kolonne. Matvarer i grønn kolonne har lavt innhold av FODMAP og kan brukes. Motsatt 
har matvarer i rød kolonne høyt innhold av FODMAP, og bør unngås/begrenses. Matvarer 
i oransje kolonne kan brukes i moderate mengder. For å få ideer om hvordan kosten kan 
settes sammen i denne perioden, -se siste del av brosjyren, side 11-19. Der finner du 
menyforslag og oppskrifter. 
 
 
Hvis du ikke merker noen bedring/effekt innen 4-8 uker, har det ingen hensikt å 
fortsette med dietten. Blir du bra bør du på en systematisk måte forsøke og 
reintrodusere de matvarene du har fjernet fra kosten, slik at du til slutt får et 
«skreddersydd» kosthold som holder magen i orden, og ikke er mer begrenset enn det 
behøver å være. Se side 9-10, som handler om reintroduksjon av FODMAPene.  
 





















Bilde: Redigert kostholdssirkel Helsedirektoratet. 





Tabelloversikten viser matvarer med høyt, middels og lavt FODMAP-innhold. 
Matvaregruppe Høy FODMAP 
Unngås/brukes i 
svært små mengder 
I mindre mengder Kan brukes i moderate 
mengder 



















Større porsjoner frisk 
frukt og smoothie. 
Hermetisk frukt i egen 
juice 
Tørket frukt/bær (se 



































Løk, hvit og rød 




Vårløk (hvit del) 
 
Tørkede belgfrukter: 
-    erter 
-    bønner 





















Oliven (sorte og grønne) 
Paprika (Grønn) 
Paprika * (Rød) 
Pastinakk 
Potet 





















Matvaregruppe Høy FODMAP 










Brunost og prim 



















Faste hvite oster (norvegia o.l.) 
Lagrede hvite oster 
(brie, camenbert, roquefort etc.) 





Soyamelk av soyaprotein 
Rismelk 
 
Iskrem basert på laktosefri melk/fløte/ 





Sukker/søtstoff Fruktose (fruktsukker) 







Mannitol (E421)  





Sirup, lønnesirup, ris malt 
 
(Kunstige) søtstoff som ikke ender på 
–ol Stevia Aspartam 








Glutenfri havre < 25 g per porsjon 





Brød, pasta og 
kornvarer som er 
glutenfrie og/eller 
basert på ovenfor 
nevnte kornsorter. 
 
FODMAPs er en gruppe karbohydrater. 

















Mer om ulike typer FODMAP 
Hva er forskjellen mellom FODMAP og andre karbohydrater? 
Karbohydrater er energirike molekyler som fungerer som energikilde og energilager hos 
alle planter og dyr. De er bygget opp av én eller flere sukkerenheter som er bundet 
sammen i korte eller lange kjeder. Under fordøyelsen må karbohydratene i kosten brytes 
ned til enkle sukkermolekyler før de kan absorberes i tynntarmen og nyttiggjøres av 
kroppen. Det som kjennetegner FODMAP-karbohydratene, er at de er små (består av én 
eller noen få sukkerenheter), absorberes dårlig og gjæres lett. 
 
Karbohydrater som vanligvis ikke gir besvær: 
   Glukose (druesukker) er ett enkelt sukkermolekyl som lett absorberes i tynntarmen. 
Tåles godt ved IBS. Finnes i 
frukt og bær. 
 Sukrose (vanlig sukker) består av et fruktose- og et glukosemolekyl som er 
bundet sammen. Fordøyes og absorberes lett, men inntaket bør begrenses av 
hensyn til den generelle helsen. 
 Stivelse er lange kjeder av glukose. Disse brytes raskt ned og absorberes 
fullstendig i tynntarmen og er derfor uproblematisk ved IBS. Finnes i kornvarer, 
pasta, rotgrønnsaker og poteter. 
 Kostfiber er langkjedede karbohydrater som ikke brytes ned i tynntarmen. Finnes i 
grove kornvarer, grønnsaker og frukt. Kostfiber er viktig for tarmfunksjonen og 
bidrar til å gi avføringen riktig konsistens. Vi skiller mellom vannløselige og ikke-




 Fruktose (fruktsukker) er et monosakkarid, det vil si at det består av bare ett 
sukkermolekyl. Finnes i frukt, bær, fruktjuice og honning, ofte sammen med 
glukose (Tabell 1).  Fruktose absorberes godt sammen med like store mengder 
glukose, og 30- 
40 % av befolkningen (både friske og personer med IBS) absorberer ikke 
overskudd av fruktose. Inntak av mat som inneholder mer fruktose enn glukose, 
kan skape problemer hos dem som lider av irritabel tarm. 
 
 Laktose (melkesukker) finnes i melk og melkeprodukter (Tabell 2). Laktose er 
et disakkarid og består av to sukkermolekyler (glukose og galaktose) som er 
bundet sammen. Under fordøyelsen spaltes de to sukkerenhetene fra 
hverandre ved hjelp av enzymet laktase, som produseres i tarmslimhinnen. 
Mangel på enzymet fører til laktosemalabsorpsjon. Genetisk betinget 
laktasemangel er svært utbredt på verdensbasis, og forekommer ofte hos 
innvandrere, men sjelden blant etnisk norske. Tarminfeksjoner og skader på 
tarmen kan også føre til laktasemangel, som regel av forbigående type. 
 
 Sorbitol og andre søtstoff som ender på –ol, som mannitol, maltitol og xylitol, er 
polyoler (også kalt sukkeralkoholer). Disse absorberes ikke fullstendig i 
tynntarmen og større inntak kan forårsake diare og luftplager hos alle. Ved 
irritabel tarm kan også mindre inntak gi symptomer. Sukkeralkoholer forekommer 
naturlig i visse typer frukt og grønnsaker og brukes i sukkerfri tyggegummi, drops 
og pastiller (Tabell 3). 
 
 Fruktaner er korte kjeder av fruktose og tilhører gruppen oligosakkarider. Finnes i 
løk, hvete og rug. Galaktaner er også oligosakkarider og finnes i belgfrukter. 
Disse stoffene brytes ikke ned av enzymene i tynntarmen, men blir i stedet mat for 








Tabell 2: Mat som inneholder 
LAKTOSE 
Begrenses ved laktosemalabsorpsjon 
Melk og melkeprodukter  











Tabell 1: Mat som inneholder overskudd 
av FRUKTOSE 
Tabell 3: Mat som inneholder 
SORBITOL og/eller andre POLYOLER 































Høy fruktose maissirup 
Gir et høyt totalinntak av fruktose 





Isomalt (E953)  
Laktitol (E966)  
Maltitol (E965)  
Mannitol (E421)  
Sorbitol (E420)  
Xylitol (E967) 








Tabell 4: Mat som inneholder 




















(som hovedingrediens i brød/bakverk, 











Hvorfor tåler noen FODMAP dårligere enn andre? 
Sorbitol, fruktaner og galaktaner absorberes dårlig av alle mennesker, og 
fruktosemalabsorpsjon er like vanlig hos friske personer som hos individer med IBS. Folk 
flest tåler likevel FODMAP godt. 
Grunnen til at personer med irritabel tarm får plager av FODMAP, kan være følgende: 
 
Tarmoverfølsomhet for gassproduksjon 
Ved irritabel tarm er tarmen mer følsom for gassen som blir produsert, og den trykkøkningen i 
tarmen som gassen forårsaker, oppleves mer smertefull og ubehagelig. 
 
Bakteriell overvekst i tynntarmen 
Noen av de bakteriene som normalt er lokalisert i tykktarmen, kan bevege seg over i 
tynntarmen. Dette kalles bakteriell overvekst i tynntarm og forekommer hos opptil 50 % 
av de som har irritabel tarm. Når FODMAP gjæres av bakterier i tynntarmen, vil gassen 









Reintroduksjon av FODMAP-grupper 
Da man ikke nødvendigvis reagerer på alle FODMAP-gruppene, anbefales det å teste 
toleransen for hver enkelt gruppe. Før du gjør dette er det anbefalt å følge FODMAP- 
redusert kost i 4-8 uker, til du er symptomfri, for så å innføre én og én FODMAP-
gruppe. 
Det er viktig å reintrodusere gruppene enkeltvis på en systematisk måte for å finne din 
egen toleransegrense og hvilke typer FODMAP du reagerer på. 
 
Forslag til reintroduksjon 
Det er opp til den enkelte hva man ønsker å gjeninnføre først. Det kan være en idé å 
starte med det man har savnet aller mest. Det anbefales å starte med en liten mengde 
av en matvare som kun inneholder en type FODMAP om gangen. 
Se forslag til gode testmatvarer i tabelloversikt under, og ellers på side 7-8. 
 
Følgende matvarer egner seg godt til testing fordi de inneholder mye av én FODMAP-




Fruktose (tabell 1): ¼ Mango eller 1 ts honning 
Laktose (tabell 2): 125 ml melk (søtmelk) eller 1 skive brunost (15g) 
Polyoler (tabell 3): 2 tørket aprikoser, 1 stk sukkerfri tyggegummi eller et par 
sukkerfrie pastiller (med sorbitol) 
Fruktaner (tabell 4):  1 ss tilberedt løk, purre, eller 1 fedd hvitløk. 
Galaktaner (tabell 4): 2 ss bønner eller linser 
Fruktose og polyoler En kombinasjon av fruktose og sorbitol kan tolereres 
dårligere enn gruppene enkeltvis. For å teste toleransen for 




Dersom du gjennom utprøvingen finner ut at du tolererer laktose dårlig, kan du ha 
nytte av preparater med laktaseenzym. Disse selges reseptfritt på apotek, og 
finnes i flere varianter. Kerutabs tabletter og Lactrase kapsler virker slik at man tar 
1-3 tabletter/kapsler i forbindelse med måltid som inneholder laktose. Med disse 
vil du kunne nyte et måltid på restaurant, i selskap, ved festlige anledninger eller 















Gjennomfører du tre hele dager med en ny matvare uten å få symptomer, kan matvaren 
på sikt kunne inngå i kosten igjen. Test kun nye matvarer når du ikke har symptomer.  Når 
du skal teste neste matvare anbefales det å ta ut den matvaren du har testet av kosten 
igjen. Dette er viktig fordi summen av de to matvarene med mye FODMAP kan overstige 
din toleransegrense for total mengde FODMAPs. Dette kan illustreres som et beger som 
flyter over. Det kan være at man tåler små mengder fruktaner og fruktose, eller fruktaner 





Praktiske råd ved FODMAP-redusert kost 
 
Når du reduserer inntaket av FODMAP, er det fortsatt mulig å ha et sunt og variert 
kosthold. Dette er en veileder til hvordan du selv kan sette sammen måltider som 
har et lavt innhold av FODMAP. 
 
Frokost/Lunsj/Kvelds 
 2 skiver glutenfritt brød/knekkebrød/rundstykker med pålegg. 
    Glutenfri havregrøt med vann/laktosefri melk (og eventuelt bringebær/ jordbær/        
blåbær/banan) 
    Glutenfri havregryn eller glutenfri cornflakes med laktosefri melk/ yoghurt/ Biola 
 Omelett (med skinke, kokt potet, og FODMAP-reduserte grønnsaker som 
paprika, tomat, vårløk (grønn del), squash, oliven) 
    Salat 
o FODMAP-reduserte grønnsaker og frukt, eks salat, tomat, agurk, 
gulrot, vårløk (grønn del), oliven, appelsin, druer og honningmelon 
o Glutenfri pasta 
o Kylling/kjøtt/egg/fisk/sjømat 
o 1 ss gresskarkjerner 
 
Middag 
    Rene produkter av hvitt og rødt kjøtt, egg, fisk og sjømat 
o Les innholdsliste på blandingsprodukter- begrens ingredienser med mye 
FODMAP 
    Poteter, ris, glutenfri pasta, risnudler, quinoa 
    Pai/pizzabunn av glutenfritt mel. 
    Eggeretter 
    Pannekaker lagd med glutenfritt mel og laktosefri melk 
    Hjemmelaget suppe av grønnsaker, kjøtt mm. 
    Stekte grønnsaker/salat (se lunder oppskrifter) 
Tilsett smak til maten: 
    Oljer til steking/marinade 
    Sitronsaft 
    Laktosefri rømme/kesam – med og uten urter 
 Friske urter, som for eksempel: basilikum, koriander, persille, rosmarin, timian 
    Chili, Ingefær, salt og pepper 
    Lønnesirup 
    Vårløk (den grønne delen) 
*  Olje med hvitløksmak (legg store biter hvitløk i olivenolje, la den trekke en ukes tid. 
Ta vekk hvitløksbitene før du bruker oljen i matlaging) 














    Kjøttpålegg: kokt skinke, skinkestek, spekeskinke, kalkun- og kyllingskinke naturell 
    Egg 
    Reker og annen sjømat 
 Rene fiskepålegg som røkelaks, 
tunfisk, påleggslaks og sardiner 
    Kaviar 
    Majones 
 Ost: Hvitost, brie, cottage cheese , 
cheddar, edamer, mozzarella, 
camembert og fetaost. 
    Syltetøy av bringebær, jordbær og blåbær. 
    Lønnesirup 
    Peanøttsmør 
    Banan 




    Hasselnøtter, 10 stk 
    Mandler, 10 stk 
    Macadamia, 20 stk 
    Peanøtter, 28 g 
    Pekan, 10 stk 
    Valnøtter, 10 halve 
    Pinjekjerner, 1 ss 
    Chiafrø, 2 ss 
    Gresskarkjerner, 2 ss 
    Solsikkefrø, 1 ts 
    Sesamfrø, 1ss 
    Sorbetis laget av lav-FODMAP frukt. 
 1 glass smoothie av lav-FODMAP frukt som banan og 
bær, og laktosefri yoghurt og eventuelt glutenfrie 
havregryn 
    Tortillachips, potetchips med salt/pepper. 
    Glutenfrie kjeks og kaker 
    Fruktsalat med laktosefri yoghurt og lønnesirup 
    Riskaker med peanøttsmør og banan 
    Mørk sjokolade 
 Pannekaker og vafler med glutenfritt mel og laktosefri 
melk 
    Glutenfri havrekjeks med nøtter og mørk sjokolade 
    Haribo Eldorado vingummi. 
 Mentos mint, Polo peppermyntepastiller, Wrigleys 

















Mengde frukt: Det anbefaler maks 2-3 porsjoner à 100g med lav FODMAP 










Frukt og bær,  
lav fodmap 
 










Vær oppmerksom på 
 Ikke alle glutenfrie produkter er lav-FODMAP. Veldig ofte tilføres eple eller 
annet som er høy-FODMAP for bedre smak osv. Sjekk ingredienslisten. 
    Konsentrert fruktjuice, f.eks. fra eple og pære, brukes iblant som søtstoff. 
    Dipper og dressinger inneholder ofte løk og hvitløk. 
    Smakstilsatt vann kan inneholde fruktose - les innholdsfortegnelsen. 
    Yoghurt kan være tilsatt fruktose. 
 Inulin er en fruktantype og brukes iblant som fiber eller prebiotikum i yoghurt, 
brød eller müsli. 
    Dersom du reagerer på mye kostfiber, begrens matvarer med mye fiber, og velg 
heller fine produkter enn grove.  En gradvis økning av fiber kan bedre toleransen. 
 
 
På varedeklarasjonen skal alle ingrediensene oppgis i rekkefølge etter vekt. Den 
ingrediensen det er mest av nevnes først, og den det er minst av til sist. Bruk 
denne kunnskapen når du skal vurdere om en matvare kan inngå i kostholdet ditt.  
Små mengder FODMAP går som regel bra. Står for eksempel hvete listet opp 




For mer inspirasjon, informasjon, matvarelister og oppskrifter: 
Helse Bergen:        Nasjonal Kompetansetjeneste for Funksjonelle Mage-tarm 
sykdommer. www.helse-bergen.no/nkfm 
 
Monach University: http://www.med.monash.edu/cecs/gastro/fodmap/ 
Til mobil: LowFODMAPdiet App fra Monach University. 
 
Bøker på norsk:      Stine Junge Albrechtsen, Mette Borre, Lisbeth Jensen, Marianna 
Lundsteen Jacobsen & Cæcilie Gamsgaard Seidel: 
For deg med irritabel tarm.LowFODMAP-dietten gir ro i 
magen. Iris forlag 2014 
 
Cecilie Hauge Ågotnes: 
LavFODMAP. God mat for sensitive 
mager. Aschehoug 2015 
 
Julianne Lyngstad: 
LavFODMAP. En komplett håndbok for deg med sensitiv 
mage. Frisk forlag 2014
Appendix 9: Information and consent form 
 
 
Forespørsel om deltakelse i forskningsprosjektet: 
 
Effekt av FODMAP-reduksjon i tillegg til glutenfri kost 
ved cøliaki 
 
Bakgrunn og hensikt 
Det er kjent at mange pasienter med diagnostisert sikker cøliaki opplever begrenset eller 
ingen symptomlindring av glutenfri kost, tross normalisering av blodprøver og evt. 
tynntarmsbiopsi. Dette er derfor et spørsmål til deg om å delta i en forskningsstudie hvor vi 
vil sammenligne de to behandlingsalternativene som finnes for dette. Den ene gruppen vil få 
en grundig veiledning i strikt glutenfri kost, mens den andre vil få en FODMAP-redusert kost. 
Vi vil se på tilleggseffekten av en lav-FODMAP- diett hos personer med cøliaki og 
mageplager i forhold til en streng glutenfri diett. 
 
FODMAP er en forkortelse for fermenterbare oligo-, di-, og monosakkarider og polyoler. 
Dette er karbohydrater som gir næring til bakterier i tarmen og som hos enkelte kan forårsake 
mageplager som diaré, forstoppelse, magesmerter og oppblåsthet. Matvarer som inneholder 
FODMAP er blant annet hvete, rug, visse melkeprodukter, løk, bønner, søtstoffer, epler, 
mango, brokkoli og plommer. Lav-FODMAP-diett går ut på å unngå å spise matvarer med 
høyt innhold av FODMAP.  
 
Du er valgt ut til å få tilbud om å delta i studien fordi du er i alderen 18-60 år, har cøliaki og 
har vært på cøliakikurs. Du har spist glutenfri kost i minst seks måneder, men har likevel 
ubehag og mageplager. I tillegg har du scoret 75 eller mer på spørreskjemaet IBS-SSS og 
scoret på Roma III-kriteriene for IBS, og har dermed symptomer på «irritabel tarm». Det 
finnes forskning som viser at lav-FODMAP diett kan gi symptomlindring ved irritabel tarm. 
Det er imidlertid ikke forsket på om dietten kan være nyttig for cøliakere med irritabel tarm, 
og derfor spør vi om du vil være med på denne studien som kan vise oss om FODMAP-
restriksjon i tillegg til glutenfri kost gir mer effektiv symptomlindring enn innskjerpet 
glutenfri kost alene.  
 
Studien er en åpen, kontrollert studie utført av to masterstudenter i klinisk ernæringsfysiologi, 
veiledet av overlege/professor ved Universitetet i Bergen og Haukeland Universitetssykehus 
og klinisk ernæringsfysiolog ved Haukeland Universitetssykehus, som er ansvarlige for 
prosjektet. 
 
Hva innebærer studien? 
Studien innebærer at du over en periode på seks uker enten spiser en strikt glutenfri kost 
(gruppe A) eller at du spiser en spesiell kost som inneholder lite FODMAP i tillegg til strikt 
glutenfri kost (gruppe B). Det vil være tilfeldig om du havner i gruppe A eller gruppe B. En 
lav FODMAP-kost betyr at du må kutte ut ulike typer matvarer. Havner du i gruppe B, vil du 
senere få en detaljert oversikt over matvarer du ikke kan spise, og en liste med alternativer til 
de matvarene du må kutte ut. Dersom du velger å delta i studien, vil du bli invitert til et møte 






vil du også få mer informasjon om glutenfri kost, men dersom du havner i gruppe B vil du få 
mer informasjon om lav-FODMAP-dietten. Du skal møte opp på Haukeland 
Universitetssykehus tre ganger for å ta blodprøver og pusteprøver og for samtaler med 
studentene i klinisk ernæringsfysiologi. Du skal også avgi avføringsprøver, fylle ut noen 
spørreskjemaer og fylle ut en kostdagbok for 4 dager. Dette gjøres før oppstart av studien, 
etter 3 uker og etter 6 uker, og i tillegg skal noen skjemaer fylles ut 4 uker etter avsluttet 
studie. Dette kan gjøres hjemme og deretter sendes i posten. 
 
Mulige fordeler  
Fordelen ved å delta er en mulig bedring i symptomene. Det betyr mulig mindre diaré, mindre 
forstoppelse, mindre magesmerter og/eller mindre oppblåsthet. En bedring av symptomer fra 
tarmen vil ofte også medføre en bedring i livskvalitet. 
 
Mulige ulemper 
Det er usannsynlig at studien kan medføre bivirkninger eller ubehag. Det er mulig at du ikke 
får noen bedring av dietten. Utover dette er det ingen risiko forbundet med studien. Du må 
møte opp på Haukeland Universitetssykehus tre ganger, noe som kan oppleves som 
belastende og/eller tidskrevende for enkelte. Du må også ta tre avføringsprøver, blodprøver og 
tre pusteprøver. Dietten du skal følge fører også til at du sannsynligvis må kutte ut en del 
matvarer som du vanligvis spiser, noe som kan oppleves som vanskelig for noen. Det kan 
også være en utfordring å gå på diett i sosiale sammenhenger. 
 
Hva skjer med prøvene og informasjonen om deg?  
Avføringsprøvene, blodprøvene og pusteprøvene som er tatt av deg, og informasjonen som 
registreres om deg, skal kun brukes slik som beskrevet i hensikten med studien. Alle 
opplysninger og prøver vil bli behandlet uten navn og fødselsnummer eller andre direkte 
gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og prøver gjennom en 
navneliste. Det betyr at opplysningene er avidentifiserte. Det er kun autorisert personell 
knyttet til prosjektet som har adgang til navnelisten og som kan finne tilbake til deg. 
Avføringsprøvene og blodprøvene vil destrueres etter at nødvendige analyser er tatt. Ved 
publisering av resultatene vil identiteten din ikke komme fram. 
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst, uten å oppgi noen grunn, trekke ditt 
samtykke til å delta i studien. Dette vil ikke få noen konsekvenser for din videre behandling. 
Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste side av dette skrivet. 
Om du nå sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din 
øvrige behandling. Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan 
du kontakte studentene i klinisk ernæringsfysiologi Ida Serine M. Strindmo (Telefon: 900 31 
585, e-post: ist104@student.uib.no) og/eller Kamilla Nuland (Telefon: 988 45 679, e-post: 
knu030@student.uib.no). Eventuelt kan ansvarlig lege Jan Gunnar Hatlebakk kontaktes på 
telefonnummer 977 07 817 eller på e-post jan.hatlebakk@helse-bergen.no. 
 
Ytterligere informasjon om studien finnes i kapittel A – utdypende forklaring av hva 
studien innebærer. 
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B – 
Personvern, biobank, økonomi og forsikring.  
 






Kapittel A- utdypende forklaring av hva studien innebærer 
 
Kriterier for deltakelse 
Du er valgt ut til å forespørres til å delta i studien fordi du er i alderen 18-60 år, har cøliaki, 
har vært på cøliakikurs, gått på glutenfri kost, men har allikevel ubehag og symptomer etter 
seks måneder. I tillegg har du scoret 75 eller mer på spørreskjemaet IBS-SSS og scoret på 
Roma III-kriteriene for IBS, og har dermed symptomer på «irritabel tarm». 
 
Bakgrunnsinformasjon om studien 
Ikke alle med en sikker cøliakidiagnose blir symptomfrie på glutenfri kost, på tross av at 
antistoffer i blodprøver og eventuelt tynntarmsbiopsier er normaliserte. Det er kjent at 
personer med cøliaki har en overhyppighet av irritabelt tarm syndrom (IBS). Cøliakere med 
IBS kan tenkes å ha en positiv effekt av FODMAP-redusert kosthold, men dette er ikke 
undersøkt tidligere, og det er derfor nyttig å kartlegge. Kan FODMAP-restriksjon gi 
symptomlindring hos cøliakipasienter som ikke har tilfredsstillende effekt av bare glutenfri 
kost? 
 
Matvarer som inneholder mye FODMAPs (fermenterbare oligo-, di-, og monosakkarider og 
polyoler) kan gi plager fra mage- tarm området, særlig hos de med irritabel tarm. Mat som 
inneholder FODMAP blir fermentert i tykktarmen. Det betyr at bakterier i tykktarmen 
omdanner ufordøyd mat til gass og til energi (korte fettsyrer). Dette er en normal og viktig 
prosess, og det er blant annet essensielt for tarmcellenes helse. Fermentering er noe som i ulik 
grad skjer hos alle mennesker, men de med irritabel tarm får antageligvis mer plager av dette 
enn friske.  
 
Ved irritabel tarm skjer det en unormal respons i mage- tarm kanalen som kan skyldes 
overfølsomhet i tarmen. Det kan også skyldes en unormal respons fra nervesystemet i tarmen, 
en forstyrrelse i bakteriefloraen, motilitetsforstyrrelse (unormal bevegelse av tarminnholdet) 
eller smerter på grunn av gassdannelse fordi det blir en utvidelse av tarmen. Dette kan gi de 
typiske symptomene på irritabel tarm, som oppblåsthet, magesmerter, gassdannelse, diaré 
og/eller forstoppelse. Tanken ved lav-FODMAP diett er å redusere inntak av mat som kan 
fermenteres av bakterier slik at det blir mindre fermentering i tarmen, og dermed mindre 
plager. 
 
Blodprøver, avføringsprøver og pusteprøver 
Før oppstart av studien skal du ta en blodprøve for å sjekke betennelsesmarkører. Blodprøven 
tas på sykehuset i forbindelse med gruppemøtet før oppstart av selve dietten. Du skal også 
avgi en avføringsprøve som skal analyseres for å studere bakteriesammensetningen. 
Avføringsprøven kan tas hjemme og sendes i posten i en spesial-emballasje. Pusteprøver vil 
bli gjort på sykehuset før oppstart av studien for å se på grad av fermentering av bakteriene i 
tykktarmen. Du vil bli tildelt time for dette og undersøkelsen tar ca. 60 minutter. Blod-, 
avførings- og pusteprøver vil bli repetert etter tre og seks uker. 
 
Spørreskjemaer og kostregistrering 
Du skal svare på fire spørreskjemaer før oppstart av studien, etter tre uker og etter seks uker. 
Disse skjemaene er Rome III (kriterier for irritabel tarm), IBS-SSS (symptomer på irritabel 
tarm), SF-36 (livskvalitet) og compliance (overholdelse av FODMAP-dietten). I tillegg skal 







Tidsskjema – hva skjer og når skjer det? 
Du har blitt kontaktet og blitt forespurt om å delta i studien. Dersom du er villig til å være 
med i studien, signerer du samtykkeskjemaet bakerst i dette skrivet. Du skal deretter møte opp 
på tre møter, som alle vil finne sted på Haukeland sykehus på dagtid så langt det lar seg gjøre. 
 
Du vil bli invitert til et gruppemøte med 4-6 andre deltakere. Avhengig om du er havnet i 
gruppe A eller gruppe B vil studentene i klinisk ernæringsfysiologi der gi grundig 
informasjon om strikt glutenfri kost (gruppe A) eller lav-FODMAP-dietten (gruppe B) og hva 
som skal skje fremover. Du skal også ta en blodprøve og en pusteprøve, før eller etter dette 
møtet. Dette gjøres også på Haukeland Universitetssykehus og pusteprøven tar ca. 60 
minutter, hvor du puster inn i et rør hvert 15.minutt. Litt ventetid før og etter må beregnes. 
Disse kan gi nyttig informasjon som kan hjelpe deg til å minske IBS-symptomene.  
 
Du vil også få utdelt skriftlig informasjon. Skjemaene SF-36, IBS-SSS og Rome III angir 
hvor plaget du er av irritabel tarm og hvordan det påvirker din livskvalitet. Disse skal fylles ut 
og leveres en av studentene før eller etter møtet. Du skal også gjøre en 4 dagers prospektiv 
kostregistrering der du noterer ned alt du spiser. Etter at du har registrert kosten din i 4 dager, 






Du skal også avgi en avføringsprøve som du kan levere før eller etter møtet, eller som kan tas 
hjemme og sendes til adressen ovenfor. Dersom du er havnet i gruppe B, får du også med deg 
et compliance-skjema som skal fylles ut etter tre uker og tas med neste gang. 
 
Andre møte blir tre uker etter oppstart av studien, altså etter at du har gått på den strikte 
glutenfrie dietten i tre uker dersom du havnet i gruppe A, eller etter at du har gått på lav 
FODMAP-diett i tillegg til glutenfri diett i tre uker. Du vil få detaljert informasjon på hva som 
ikke kan spises og eventuelle alternativer til den matvaren i forkant. Dette møtet blir også et 
møte med 4-6 deltakere der eventuelle spørsmål og problemer diskuteres. I forkant av dette 
møtet skal du på ny registrere alt du spiser i løpet av 4 dager ved hjelp av en kostdagbok og ta 
dette med til møtet. I tillegg skal du på forhånd (samme dag eller dagen før) ha fylt ut 
skjemaene SF-36 om livskvalitet, IBS-SSS om IBS-symptomer og Rome III om IBS-kriterier 
som du gjorde ved oppstart av studien, og ta disse med på møtet. Dersom du havnet i gruppe 
B som går på FODMAP-redusert kost i tillegg til glutenfri kost, skal du også ha med deg et 
ferdig utfylt compliance-skjema som går på overholdelse av dietten etter tre uker. Før eller 
etter møtet vil du på ny ta samme pusteprøve som du gjorde første gang og du skal ta med deg 
en ny avføringsprøve. 
 
Tredje og siste møte blir så når studien er avsluttet, altså etter seks uker. Det betyr at du skal 
ha gått på dietten i seks uker. Dette er også et møte med 4-6 deltakere. Eventuelle problemer 
og spørsmål kan tas opp. Du har også mulighet til å kontakte studentene på telefon eller e-post 
(se kontaktinformasjon på andre side) hvis det oppstår problemer underveis. Du kan eventuelt 
også ringe den ansvarlige legen. Dersom du er i gruppe A, vil du på dette møte få informasjon 
om FODMAP-dietten. Dersom du er i gruppe B, vil du på dette møte få informasjon om 
gradvis reintroduksjon av FODMAPS. Igjen tar du med fire ferdig utfylte skjemaer (SF-36, 






forkant eller etterkant av dette møtet skal du ta pusteprøve og blodprøve, og du skal også ta 
med deg en avføringsprøve.  
 
Én måned etter at du har fullført dietten skal du sende inn/levere compliance-skjemaet til oss. 
 
Alternative prosedyrer dersom du velger å ikke delta i studien: 
 
Dersom du ikke ønsker å delta i studien vil det ikke få noen konsekvenser for din videre 
behandling. Dersom du underveis i studien ønsker å trekke deg kan du ta kontakt når som 
helst. Da vil du bli invitert til en samtale, og eventuelle problemer vil bli diskutert. Du har 
selvfølgelig fortsatt rett til å slutte i studien når som helst uten å oppgi grunn. Dersom du 
ønsker å slutte med dietten, så vil du få tilbud om å få andre generelle råd for hva du kan gjøre 
for å lindre symptomene.  
 
Studiedeltakerens ansvar: 
Som deltaker i denne studien ber vi om at du setter deg inn i informasjonen og følger diettene 
så godt som mulig. Tid og dato for møtene, pusteprøvene, blodprøvene og avføringsprøvene 
(skal gjøres samme dag) skal avtales slik at det passer for begge parter. Med tanke på at det 
vil være 4-6 deltakere på hvert møte i tillegg til to mastergradsstudenter i klinisk 
ernæringsfysiologi, ber vi om at du er fleksibel på tid og dato for møtene og prøvetakningene. 
Du må også møte opp til avtalt tid, eller eventuelt ringe i god tid hvis timen ikke passer. Du 
har også ansvar for å fylle ut skjemaene som avtalt, ta dem med på møtene og sende de i 
posten før avtalt frist. På det første møtet med studentene vil du få mer nøyaktig informasjon 
enn det som står i dette skrivet. 
 
Endringer i planen: 
Dersom det skjer en endring i planen, eller en tidligere avslutning av dietten, vil du bli 
informert så raskt som mulig. Du vil også bli orientert dersom ny informasjon blir tilgjengelig 
som kan føre til at du ikke lenger vil delta i studien. Dersom det oppstår en uforutsett hendelse 
som gjør at studien må avsluttes vil du bli kontaktet snarest mulig. 
 
Utgifter 
Du vil få kompensasjon for reiseutgiftene til og fra Haukeland Universitetssykehus. Du får 






















Kapittel B - Personvern, biobank, økonomi og forsikring 
 
Personvern 
Opplysninger som registreres om deg er informasjon om symptomer og livskvalitet fra 
forskjellige skjemaer. Resultater fra blodprøver, pusteprøver og avføringsprøver vil også bli 
registrert, men selve prøvene vil bli destruert etter at analysene er gjort. Kontaktinformasjon 
(navn og telefonnummer) om deg vil bli lagret. Det er kun vi som holder på med studien som 




Avføringsprøver og blodprøver kastes etter analyse, det vil si at det ikke opprettes en biobank. 
 
Utlevering av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger kun brukes til denne studien ved Haukeland Universitetssykehus i Bergen. 
Avidentifiserte opplysninger skal ikke sendes til andre foretak eller foretak i andre land. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er 
registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har 
registrert. Dersom du trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og 
opplysninger, med mindre opplysningene allerede er inngått i analyser eller brukt i 
vitenskapelige publikasjoner.  
 
Økonomi og Haukeland Universitetssykehus’ rolle 
Studien er finansiert gjennom forskningsmidler fra gastroenterologisk seksjon ved Klinisk 
Institutt 1 ved Universitetet i Bergen. De vil bidra med personell til analyser av blodprøver. 




Forsikringsordningen som gjelder er pasientskadeerstatning, idet du som deltaker er under 
behandling ved Haukeland Universitetssykehus.   
 
Informasjon om utfallet av studien 
Du har som deltaker i studien rett til å få informasjon om utfallet av studien når dette er klart. 


















Samtykke til deltakelse i studien 
 



















Appendix 10: Research protocol  
 
The effect of FODMAP-reduction in addition to gluten free diet in celiac 
disease 
Background     
Celiac disease is a common autoimmune disease, where ingestion of gluten will cause an 
immune reaction in predisposed individuals.  The immune reaction can cause intestinal 
damage such as villous atrophy, crypt hyperplasia and chronic inflammation. The only 
treatment of celiac disease is a lifelong gluten-free diet, and strict adherence to such a diet 
will lead to full mucosal healing and symptom relief in the majority of patients. However, a 
part of celiac disease patients also have IBS-symptoms in addition to their gluten intolerance, 
thus not responding fully to a gluten free diet. The inflammation of the mucosa seen in celiac 
disease is thought to predispose for functional bowel disorders such as IBS. (1) These patients 
will possibly benefit from a FODMAP-reduced diet, as the diet has been shown to give 
significant symptom relief and increased quality of life in many IBS-patients. (2, 3) 
 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, affecting 10-20% of 
the general population, and is characterized by altered bowel habits and abdominal 
discomfort. IBS can be diagnosed using the Rome III-criteria. (4) IBS is a diagnosis of 
exclusion, which means that the ruling out of other possible diseases is essential before 
diagnosis is set. The cause behind IBS is not fully understood yet; but several hypotheses 
have been proposed. Visceral hypersensitivity, gut dysmotilty and disturbance in the brain-
gut-axis are assumed to be of importance in its pathophysiology. The best treatment available 
for IBS-patients per se is diet. The FODMAP-diet was developed by the dietician Susan 
Sheperd and her research group in1999, when they started to exclude several foods IBS-
patients reported as symptom triggering. FODMAP is short for fermentable oligosaccharides, 
disaccharides, monosaccharaides and polyols, and is a grouping of carbohydrates that are 
inadequately absorbed in the small intestine and instead fermented by intestinal bacteria.  
 
There are several hypotheses on why FODMAPs trigger symptoms in IBS-patients, some 
being thought to have more significance than others. FODMAPs are thought to have an 
osmotic effect on the gut, and also the fermentation by gut bacteria resulting in production of 
gas and small chain fatty acids are thought to cause pain and discomfort in IBS-patients (5). 






treatment alternative that can offer symptom relief for these patients.  
 
Purpose and objectives 
The purpose of the study is to investigate whether celiac disease patients with IBS-symptoms 
can have a symptomatic and a quality of life benefit from FODMAP-reduction in addition to 
their gluten free diet. Another objective is to investigate whether a FODMAP-reduced diet 
will have any effect on the gut microbiota or influence the degree of fermentation by gut 
bacteria.  
 
Ha1: A FODMAP-reduction in addition to a gluten free diet will give symptom relief and 
increased quality of life in celiac disease patients with IBS-symptoms.  
Ha2: A FODMAP-reduction will affect the microbiota and the degree of fermentation  
 
Separately from the study of FODMAP-reduction, we will also follow a group of newly 
diagnosed celiac disease patients for 6 weeks. The objective here is to investigate whether 
there will be a change in the degree of fermentation and in the microbiota after 6 weeks of 
gluten free diet. 
 
Design and method  
The study is an open, prospective, randomised, and controlled study consisting of an 
intervention group and a control group, where ideally, each group will consist of 
approximately 20 subjects. The participants will be recruited between June and December 
2015, mainly from the Norwegian Celiac Society (NCF) and Læring- og mestringssenteret 
(LMS). Some may also be recruited from the polyclinic for celiac disease at Haukeland 
Universty Hospital.  
 
The intervention group will follow a low FODMAP diet in addition to their gluten free diet 
for 6 weeks, whilst the control group will follow their regular gluten free diet. The 
intervention group will receive dietary counselling on how to follow a low FODMAP diet, 
and the control group will receive additional dietary counselling on the gluten free diet. After 









Inclusion criteria:  
- Confirmed celiac disease diagnosis for at least 6 months  
- IBS-symptoms confirmed by the Rome III-criterion  
- Score > 75 on the IBS-Symptom Severity Score (IBS-SSS) 
- Subjects between 18 - 60 years of age 
 
Exclusion criteria:  
- Subjects with therapy-resistant celiac disease  
- Recent biopsy with abnormal findings   
The group of newly diagnosed celiac disease patients will consist of approximately 20 
subjects, and will be recruited in the same time period from Læring- og mestringssenteret. 
The subjects included in this group will be those with a new diagnosis who is about to 
commence on a gluten free diet.   
 
Variables  
Variables included in the study will be the following:  
Symptoms 
Quality of life  
Microbiota  
Hydrogen breath test  
Blood tests  
 
Collection of data  
Data will be collected through questionnaires, biological material and breath tests.  
In order to measure symptoms we will use the standardized and validated IBS-Symptom 
Severity Score (IBS-SSS). This scheme includes five different questions with a score from 0-
100, and offers a classification of symptom severity. We will also use the Rome III-criteria to 
confirm IBS-symptoms. To measure quality of life, we will use the questionnaire Short Form 
Survey (SF-36). This scheme includes questions regarding physical and mental health. A 









There will be taken serological test for celiac disease at baseline off all participants. These 
will be included in the study as a possible explanatory variable.  
All participants will do a 4-day prospective food dairy at baseline and after the intervention.   
 
At baseline, both groups will fill out these questionnaires regarding their symptoms and 
quality of life. They will be asked to fill out the same questionnaires after 3 weeks and at the 
end of study (at 6 weeks). The subjects in the intervention group will also fill out the 
compliance scheme at 3 weeks and 6 weeks of diet, and also at 10 weeks (4 weeks after end 
of study). The questionnaires will be filled out when the participants are present at Haukeland 
University Hospital for collection of data at baseline and after 6 weeks. Ideally, the 
questionnaires at 3 weeks will be filled out during follow-up at Haukeland University 
Hospital. For those who are not able to attend this follow-up, the questionnaires will be 
mailed.  
 
We will perform a breath test in both the intervention group, the control group and in the 
group of newly diagnosed celiac disease patients. The breath test will be performed using a 
“Model SC MicroLyzer”.  
The principle behind the breath test is to measure the amount of hydrogen breathed out, which 
correlates to the production of hydrogen by the bacteria in the intestines. We will perform a 
60-minute breath test, measuring breath at 0, 15, 30, 45 and 60 minutes. The breath test will 
be done on the basis of their diet, comparing degree of fermentation on their normal diet at 
baseline, after 3 weeks and after 6 weeks of diet.    
 
The stool samples will be collected at baseline, after 3 weeks and after 6 weeks of diet in the 
intervention group, control group and in the group of newly diagnosed celiac disease patients. 
The stool samples will be sent to a laboratory in Oslo; Genetic Analysis (GA), who will 
perform the microbiota analysis. The stools samples will be tested utilizing DNA sequences 
within the 16S rRNA gene of the bacteria in order to identify any bacterial imbalance in the 









The data will be summarized in figures and/or tables. We will use STATA or SPSS to 
perform statistical analysis.  
Economy 
Funding: Kamilla Nuland, Ida Serine Melhus Strindmo, the main supervisor and co-
supervisors will not receive any form of remuneration. 
 
Time schedule  
February – April 2015  Writing of protocol and applying to REC 
June – December 2015  Recruiting of patients and performance of study  
February – March 2016  Data analysis  




There is no risk of harm in this study. The intervention and the data collection may be 
perceived as demanding for some, but it will not cause any harm to the participants. The study 
is voluntarily and the participants can withdraw from the study at any point without providing 
any justification 
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REK sør-øst Hege Holde Andersson 22845514 
  01.07.2015 2015/915 REK sør-øst B 
     Deres dato: Deres referanse: 
     12.05.2015  
  
Vår referanse må oppgis ved alle henvendelser 
Jan Hatlebakk 
Helse Bergen HF 
2015/915  Effekt av FODMAP-reduksjon som tillegg til glutenfri kost ved coeliaki  
Forskningsansvarlig: Helse Bergen HF  
Prosjektleder: Jan Hatlebakk  
 
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av Regional komité for 
medisinsk og helsefaglig forskningsetikk (REK sør-øst) i møtet 08.06.2015.  
Vurderingen er gjort med hjemmel i helseforsikringsloven (hfl) § 10, jf. forskningsetikkloven § 4. 
 
Prosjektleders prosjektbeskrivelse 
«Ca.30% av pasienter med coeliaki blir på ikke fri for symptomer som smerter, oppblåsthet og endret avføringsmønster. Dette 
ligner sykdommen irritabel tarm og vi vil se om de har nytte av kost som er redusert i innhold av kullhydrater som fermenteres i 
tykktarm. Pasienter som har diagnosen coeliaki og som oppfyller kriteriene for irritabel tarm, vil bli randomisert til enten: (1) 
kost redusert i slike karbohydrater, eller (2) kvalitetssikret glutenfri kost. Begge grupper blir veiledet av masterstudenter i klinisk 
ernæring. Pas fyller i kostliste i 4 dager før og under diett, tar blodprøver for coeliakistatus, leverer avføringsprøver og deltar i 
pusteprøver for å måle nivå av fermentering i tarmen. Diett følges i 6 uker og symptomer og livskvalitet sammenlignes i 
spørreskjemaer. En gruppe av nydiagnostiserte coeliakipasienter vil bli bedt om å delta med kostliste, pusteprøve og 
avføringsprøve før og etter 6 uker på standard glutenfri kost, for å se om fermentering endres.» 
 
Komiteens vurdering 
Komiteen har ingen forskningsetiske innvendinger til at prosjektet gjennomføres. 
Under punkt 5.7 Håndtering av data etter prosjektslutt i søknadskjema skriver prosjektleder at data skal slettes etter prosjektslutt. 
Komiteen gjør oppmerksom på at avidentifiserte opplysninger skal som hovedregel lagres i 5 år etter prosjektslutt av 
dokumentasjonshensyn, og skal deretter slettes eller anonymiseres. 
 
Biobank 
I søknadskjema står det at det biologiske materialet skal oppbevares i en tidligere godkjent generell forskningsbiobank; 
Forskningsbiobank for mage-tarmsykdommer. I informasjonsskrivet til deltagerne står det imidlertid at; Avføringsprøver og 
blodprøver kastes etter analyse, det vil si at det ikke opprettes en biobank. Sekretariatet i REK-sør øst har vært i kontakt med 
prosjektleder for å oppklare hvordan materialet skal oppbevares. I e-post til sekretariatet 19.06.2015 skriver prosjektleder at 
Prøvene skal samles gjennom prosjektperioden for så å bli analysert samlet i februar 2016. Siden det humant biologiske 
materialet skal 
 
Besøksadresse: Telefon: 22845511 All post og e-post som inngår i Kindly address all mail and e-mails to 
Gullhaugveien 1-3, 0484 Oslo  E-post: post@helseforskning.etikkom.no  saksbehandlingen, bes adressert til REK the Regional Ethics Committee, REK 
 Web: http://helseforskning.etikkom.no/ sør-øst og ikke til enkelte personer sør-øst, not to individual staff 
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oppbevares i mer enn 2 måneder er det behov en spesifikk forskningsbiobank i prosjektet. Komiteen oppretter derfor en 
spesifikk forskningsbiobank «Effekt av FODMAP-reduksjon som tillegg til glutenfri kost ved coeliaki.» Ansvarshavende er 
Jan Hatlebakk. Biobanken planlegges å vare til 24.06.2016. 
 
Komiteen ber om at informasjonsskriv og samtykkeerklæring revideres slik at det fremkommer at det humant biologiske 
materielt skal oppbevares i en forskningsbiobank. Det reviderte skrivet må sendes komiteen til orientering. 
 
Ut fra dette setter komiteen følgende vilkår for prosjektet: 
 
  1. Informasjonsskrivet revideres i tråd med det ovennevnte og sendes        
      komiteen til orientering. 
 
   Vedtak 
Komiteen godkjenner prosjektet i henhold til helseforskningsloven § 9 og § 33 under forutsetning av at ovennevnte vilkår 
oppfylles. 
 
I tillegg til ovennevnte vilkår, er godkjenningen gitt under forutsetning av at prosjektet gjennomføres slik det er beskrevet 
i søknaden. 
 
Tillatelsen gjelder til 24.06.2016. Av dokumentasjonshensyn skal opplysningene likevel bevares inntil 24.06.2021. 
Opplysningene skal lagres avidentifisert, dvs. atskilt i en nøkkel- og en opplysningsfil. Opplysningene skal deretter slettes 
eller anonymiseres, senest innen et halvt år fra denne dato. 
 
Komiteen godkjenner også oppførelsen av en spesifikk forskningsbiobank som beskrevet i søknaden. 
 
Biobankregisteret blir underrettet ved kopi av dette brev. 
 
Hvis forskningsbiobanken opphører, nedlegges eller overtas av andre, skal det søkes REK om tillatelse, jf. 
helseforskningsloven § 30. 
 
Forskningsprosjektets data skal oppbevares forsvarlig, se personopplysningsforskriften kapittel 2, og Helsedirektoratets 
veileder ”Personvern og informasjonssikkerhet i forskningsprosjekter innenfor helse- og omsorgssektoren” 
 
   Sluttmelding og søknad om prosjektendring 
Dersom det skal gjøres endringer i prosjektet i forhold til de opplysninger som er gitt i søknaden, må prosjektleder sende 
endringsmelding til REK. Prosjektet skal sende sluttmelding på eget skjema, se helseforskningsloven § 12, senest et halvt 
år etter prosjektslutt. 
 
    Klageadgang 
Du kan klage på komiteens vedtak, jf. forvaltningslovens § 28 flg. Klagen sendes til REK sør-øst B. Klagefristen er tre 
uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK sør-øst B, sendes klagen videre til Den nasjonale 
forskningsetiske komité for medisin og helsefag for endelig vurdering. 
 
Komiteens avgjørelse var enstemmig. 
Med vennlig hilsen 
Geir Olav Hjortland 
nestleder REK sør-øst B 
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ESPEN 2016 Abstract Submission 
Topic: Liver and gastrointestinal tract 
Abstract Submission Identifier: ESPEN16-ABS-1496 
PREVALENCE OF DYSBIOSIS AND EFFECT OF LOW FODMAP DIET IN CELIAC DISEASE PATIENTS WITH 
IBS-LIKE SYMPTOMS 
Ida Strindmo 1, Kamilla Nuland1, Gudrun Elise Kahrs2, Jan Gunnar Hatlebakk3 
1Department of Clinical Medicine, University of Bergen, 2Department of Occupational Medicine, and Section of 
Clinical Nutrition, 3Section of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, 
Norway 
 
If you think another topic than the one selected at first would suit your abstract, please choose below: 
Nutrition and chronic diseases 
Presentation Method: Oral or Poster presentation 
Please indicate your professional occupation: Dietitian 
The presenting author fulfills the above conditions and wants to apply for a travel award: Yes 
I confirm that the presenting author is under the age of 35: Yes 
Rationale: A subgroup of celiac disease patients have IBS (irritable bowel syndrome)-like symtoms despite 
following a gluten free diet (GFD). We wanted to compare the microbiota in these patients with an IBS- and a 
healthy population, and look at changes during a low FODMAP (fermentable oligo-, di-, monosaccharides and 
polyols) diet vs. a more strict GFD. 
Methods: 40 celiac disease patients with IBS-like symptoms confirmed by the Rome III-criteria and IBS-SSS 
(symptom severity scale) were compared to Norwegian IBS and healthy cohorts, and randomized: Group A 
followed a more strict GFD for 6 weeks, whilst patients in group B reduced FODMAPs in their GFD. Faecal 
samples at baseline (BL) and 6 weeks. IBS-SSS at BL, 3 and 6 weeks. The faecal samples were analysed by 
Genetic Analysis for bacteria and Dysbiosis Index (DI) 1-5, where DI>2 is clinically relevant. Statistics: T-test, 
Mann-Whitney U, Fisher’s linear discriminant analysis. 
Results: FODMAPs were reduced from 12 to 2g/day (p=0.0001) in group B and IBS-SSS improved in both 
groups. 45% of the patients had dysbiosis at BL, compared to 73% in IBS (p<0.0091) and 16% in healthy controls 
(p<0.0007), with a mean score of 2.5±1.1 vs. 3.0±1.0 and 1.7±0.7, respectively. Group B had significantly more 
Bacilli and Prevotella than healthy controls. In group A (18F/2M, age 39±15), dysbiosis stayed constant on diet, 
but more patients had severe dysbiosis (DI>3), 15% vs. 25% (p=0.85). In group B (15F/5M, age 44±12), fewer 
patients had dysbiosis after diet, 60% vs. 50% (p=0.79). Responders to low FODMAP diet had less Lactobacilli 
and Firmicutes (Clostridia), and more Atopobium at BL. 
Conclusion: Celiac disease patients with IBS-like symptoms had less severe dysbiosis than an IBS-population, 
but more than healthy controls. We found that the level of Lactobacilli, Firmicutes (Clostridia) and Atopobium 
predicted response to the lowFODMAP diet. 
Disclosure of Interest: None Declared 
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PREVALENCE OF DYSBIOSIS AND EFFECT OF LOW FODMAP DIET IN 
CELIAC DISEASE PATIENTS WITH IBS-LIKE SYMPTOMS  
I. Strindmo1, K. Nuland1, G. E. Kahrs2,3 and J.G. Hatlebakk4 
1Clinical Institute 1, University of Bergen, 2Department of Occupational Medicine, and Sections of 3Clinical Nutrition and 
4Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway3. 
 
Rationale: A subgroup of celiac disease patients have IBS (irritable bowel syndrome)-like 
symtoms despite following a gluten free diet (GFD). We wanted to compare the microbiota in 
these patients with an IBS- and a healthy population, and look at changes during a low 
FODMAP (fermentable oligo-, di-, monosaccharides and polyols) diet vs. a more strict GFD. 
Methods: 40 celiac disease patients with IBS-like symptoms confirmed by the Rome III-
criteria and IBS-SSS (symptom severity scale) were compared to Norwegian IBS and healthy 
cohorts, and randomized: Group A followed a more strict GFD for 6 weeks, whilst patients in 
group B reduced FODMAPs in their GFD. Faecal samples at baseline and 6 weeks. IBS-SSS 
at BL, 3 and 6 weeks. The faecal samples were analysed by Genetic Analysis for bacteria and 
Dysbiosis Index (DI) 1-5, where DI>2 is clinically relevant. Statistics: T-test, Mann-Whitney 
U, Fisher’s linear discriminant analysis.  
Results: FODMAPs were reduced from 12 to 2g/day (p=0.0001) in group B and IBS-SSS 
improved in both groups. 45% of the patients had dysbiosis at baselline, compared to 73% in 
IBS (p<0.0091) and 16% in healthy controls (p<0.0007), with a mean score of 2.5±1.1 vs. 
3.0±1.0 and 1.7±0.7, respectively. The patients had significantly more Bacilli and Prevotella 
than healthy controls. In group A (18F/2M, age 39±15), dysbiosis stayed constant on diet, but 
more patients had severe dysbiosis (DI>3), 15% vs. 25% (p=0.85). In group B (15F/5M, age 
44±12), fewer patients had dysbiosis after diet, 60% vs. 50% (p=0.79). Responders to low 
FODMAP diet had less Lactobacilli and Firmicutes (Clostridia), and more Atopobium at 
baseline. 
Conclusions: Celiac disease patients with IBS-like symptoms had less severe dysbiosis than 
an IBS-population, but more than healthy controls. We found that the level of Lactobacilli, 
Firmicutes (Clostridia) and Atopobium predicted response to the lowFODMAP diet.  
Conflicts of interest: None 
 
 
